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ABSTRACT

3D scaffold-free spherical micro-tissue (spheroids) holds great potential in tissue
engineering as building blocks to fabricate the functional tissues or organs in vitro. To
date, agarose based hydrogel molds have been extensively used to facilitate fusion
process of tissue spheroids. As a molding material, agarose typically requires low
temperature plates for gelation and/or heated dispenser units. Here, we developed an
alginate-based, direct 3D mold-printing technology: 3D printing micro-droplets of
alginate solution into biocompatible, bio-inert alginate hydrogel molds for the fabrication
of scaffold-free tissue engineering constructs. Specifically, we developed a 3D printing
technology to deposit micro-droplets of alginate solution on calcium containing
substrates in a layer-by-layer fashion to prepare ring-shaped 3D agarose hydrogel molds.
Tissue spheroids composed of 50% human endothelial cells and 50% human smooth
muscle cells were robotically dispensed into the 3D printed alginate molds using a 3D
printer, and were found to rapidly fuse into toroid-shaped tissue units. Histological and
immunofluorescence analysis indicated that the cells secreted collagen type I playing a
critical role in promoting cell-cell adhesion, tissue formation and maturation.
The current inability to derive mature cardiomyocytes (CMs) from human
pluripotent stem cells (hiPSC) has been the limiting step for transitioning this powerful
technology into clinical therapies. To address this, scaffold-based tissue engineering
approaches have been utilized to mimic heart development in vitro and promote
maturation of CMs derived from hiPSC. While scaffolds can provide 3D
microenvironments, current scaffolds lack the matched physical/chemical/biological
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properties of native extracellular environments. On the other hand, scaffold-free, 3D
cardiac spheroids prepared by seeding CMs into agarose microwells were shown to
improve cardiac functions. However, CMs within the spheroids could not assemble in a
controlled manner and led to compromised, unsynchronized contractions. Here we show,
for the first time, that incorporation of a trace amount (i.e., ~0.004% w/v) of electrically
conductive silicon nanowires (e-SiNWs) in otherwise scaffold-free cardiac spheroids can
form an electrically conductive network, leading to synchronized and significantly
enhanced contraction (i.e., >55% increase in average contraction amplitude), resulting in
significantly more advanced cellular structural and contractile maturation.
Our previous results showed addition of e-SiNWs effectively enhanced the
functions of the cardiac spheroids and improved the cellular maturation of hiPSC-CMs.
Here, we examined two important factors that can affect functions of the nanowired
hiPSC cardiac spheroids: (1) cell number per spheroid (i.e., size of the spheroids), and (2)
the electrical conductivity of the e-SiNWs. To examine the first factor, we prepared
hiPSC cardiac spheroids with four different sizes by varying cell number per spheroid
(~0.5k, ~1k, ~3k, ~7k cells/spheroid). Spheroids with ~3k cells/spheroid was found to
maximize the beneficial effects of the 3D spheroid microenvironment. This result was
explained with a semi-quantitative theory that considers two competing factors: 1) the
improved 3D cell-cell adhesion, and 2) the reduced oxygen supply to the center of
spheroids with the increase of cell number.

Also, the critical role of electrical

conductivity of silicon nanowires has been confirmed in improving tissue function of
hiPSC cardiac spheroids. These results lay down a solid foundation to develop suitable
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nanowired hiPSC cardiac spheroids as an innovative cell delivery system to treat
cardiovascular diseases.
We reasoned that the presence of e-SiNWs in the injectable spheroids improves
their ability to receive exogenous electromechanical pacing from the host myocardium to
enhance their integration with host tissue post-transplantation. In this study, we examined
the cardiac biocompatibility of the e-SiNWs and cell retention, engraftment and
integration after injection of the nanowired hiPSC cardiac spheroids into adult rat hearts.
Our results showed that the e-SiNWs caused minimal toxicity to rat adult hearts after
intramyocardial injection. Further, the nanowired spheroids were shown to significantly
improve cell retention and engraftment, when compared to dissociated hiPSC-CMs and
unwired spheroids. The 7-days-old nanowired spheroid grafts showed alignment with the
host myocardium and development of sarcomere structures. The 28-days-old nanowired
spheroid grafts showed gap junctions, mechanical junctions and vascular integration with
host myocardium. Together, our results clearly demonstrate the remarkable potential of
the nanowired spheroids as cell delivery vehicles to treat cardiovascular diseases.
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CHAPTER ONE
BACKGROUND AND SIGNIFICANCE
1. Introduction:
1.1. Cardiovascular diseases (CVD) and myocardial infarction (MI)
CVD can be attributed to about 1 in every 4 deaths in the United States and are
regarded as the leading cause of death in the world [1]. The American Heart Association
reports that there were 780,000 patient deaths from CVD in the United States in 2011.
The most common type of CVD is coronary artery disease (CAD), which accounts for
370,000 deaths and costs $109 billion each year in United States, imposing a huge
economic burden on our society [2]. CAD is a chronic process that is characterized by
gradually occurring atherosclerosis in the epicardial coronary arteries of the heart. As
shown in the Fig. 1.1, the progressive accumulation of a waxy substance named plaques
(the hallmark of atherosclerosis) leads to the hardening of the coronary artery and
narrowing of the lumen, impairing blood flow crucial to bring enough oxygen and
nutrients to supply the heart tissue and maintain the normal function of the heart. In
addition, the thrombosis caused by ruptured plaques could block the coronary arteries in
the heart, which is known as MI [3-5].
MI is the irreversible necrosis of heart muscle due to the blocked coronary
arteries, and approximately 1.5 million cases of MI occurred annually in the United
States. Briefly, the first incidence of MI is the blockage of the coronary arteries, as
consequence the blood supply to the myocardium is insufficient which result in
cardiomyocytes death permanently. The pathological development of MI includes
inflammation occurrence, myocardium necrosis (cardiac cells death), fibrosis formation,
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the extension of the infarction area, and the remodeling of the heart (thinning and dilation
of the left ventricular (LV) wall, enhanced roundness of LV cavity). MI causes a
significant amount (around 25%) of irreversible cardiac cells death within the LV
myocardium. The impaired heart function and the pathological development of MI could
lead to some serious complications like atrial fibrillation, ventricular tachycardia,
regurgitation of blood through the mitral valve, and fatal heart failure [4].
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Figure 1.1 Schematics of myocardial infarction. As plaques encroach the coronary artery
lumen, blood flow becomes limited on demand of the heart; alternatively, rupture or
erosion of plaques can result in the formation of blood clot in the coronary artery. And
the complete blockage of coronary artery would lead to a transmural MI. Reproduced
from [5].
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1.2 Current clinical treatments of MI
The regular treatments for MI is aiming of prompting revascularization with
clinical interventions (coronary angioplasty, coronary artery bypass), or antiplatelet
/anticoagulant therapy. While above mentioned strategies are helpful in promoting the
revascularization of injured area to restore the blood supply post MI and prevent
expansion of the infarction, they are limited in restoring impaired heart function resulted
from the significant amount of myocardium death. Alternatively, the whole heart
transplantation, the long-term solution for the treatment of MI, is regarded as the last
resort providing effective treatment for heart failure patients but is greatly restricted by
the severe shortage of donor hearts and tremendous cost burden [6]. On the other hand,
the survival rates of whole heart transplantation is still not very satisfied and greatly
influenced by the conditions of the recipient and donor. 83% of patients post whole heart
transplantation could survive for over 1 year, while 5 years survival rate covers 72%
patients and only 50% could survive over 9.4 years [7]. In addition, heart transplant
recipients have to take immunosuppressive medicines routinely for the rest of their lives
to avoid organ rejection, and the side effects brought by these drugs, can include
tiredness, lack of strength, and nervousness [8, 9].
While above mentioned clinical interventions have shown to slow down the
progression of heart failure, none of them can reverse this deleterious process and
regenerate new myocardium to replace the necrotic regions of the LV [10]. Although the
clinical treatment and understanding of the problem has improved over the last decade,
the impact of MI on public health calls for further scientific exploration into new
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technologies and tools to enable better treatment allowing for myocardium regeneration
to restore the normal function of the heart.
1.3 Pathophysiology of MI
MI is mainly caused by the narrowing or blockage of the coronary arteries due to
atherosclerotic processes and thrombotic incidence.

Ischemic conditions caused by

insufficient blood supply to the heart muscle lead to a significant amount of
cardiomyocyte death, which could form necrotic area in the LV myocardium, causing
heart function to deteriorate. Consequently, the defects of contractile function will initiate
the LV remodeling (wall thinning and dilation of the heart, enhanced roundness of LV
cavity) and fibrotic scar tissue will take over the infarction area over time. Although the
following in situ fiborosis provides a temporary solution to maintain total LV wall
integration, the progression of MI eventually leads to fatal heart failure [11].
2. Cell therapies for MI treatment
Current clinical approaches for the treatment of MI may improve symptoms and
prolong life, but none of them can address the fundamental problem posed by MI:
regeneration or remuscularization of the lost myocardium post MI. Cells therapies have
emerged as a potential alternative strategy aiming heart tissue repair and regeneration.
Since the first time of cell transplantation, the ultimate goal is not to control damage done
to the heart, but to eliminate damage altogether with de novo myocardium replacement.
The translational efforts of cell therapy with various cell types for MI treatment have
proceeded rapidly since the beginning of the 21st century as shown in Fig. 1.2.
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Figure 1.2. Trend of various types of cell therapies in patients with CVDs. Produced
from [12].
During the past two decades, numerous studies and clinical trials have been
conducted to demonstrate that various cell based therapies could improve cardiac
function, reduce fibrosis, promote angiogenesis and attenuate adverse LV remodeling
post MI. Despite this great advance achieved in this field, many fundamental issues
remain in order to achieve a stable and consistent outcome after cell transplantation.
There are five key aspects regarding cell therapy (shown in Fig. 1.3), which will be
discussed in detail as below.
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Figure 1.3. The summarized five key elements of cell therapies for cardiac regeneration.
Produced from [13].
2.1 Resources for cell therapies
The types of cell to be used in cell therapy could be classified as xenogeneic,
allogeneic, or autologous in origin. Nonhuman xenogeneic cells have restrictions in
clinical outcomes due to considerable differences in antigens compared with human,
which could lead to immune rejection after transplantation. Instead, human originated
allogeneic cells are possible to have better outcomes post cell transplantation. However,
these allogeneic cells may still have high possibility for severe immune response and
graft rejection. In order to eliminate the risk of immune rejection post transplantation, the
same individual derived autologous cells have become the best choice for cell therapy.
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This autologous cells includes several types such as skeletal myoblasts, bone marrow
derived cells, resident cardiac stem or progenitor cells, induced pluripotent stem cells and
terminally differentiated cardiac cells.
It remains unknown which cell type is most effective for treatment of MI amongst
the different types of stem/progenitor/terminally differentiated cells. Here we will review
all the cell types of cell therapies for the treatment of MI, and we establish our standard to
choose one cell type for our study as the cell should be 1) autologous: no
immunoresponse after transplantation in vivo; 2) able to mass remuscularization: has
solid evidence to regenerate large amount of myocardium in vivo; 3) capable of mass
expansion in vitro: sufficient number of cells for transplantation to replace large area
damaged myocardium.
2.1.1 Skeletal Myoblasts (SkMs)
The first cell type investigated for cardiac cell therapy is the skeletal myoblasts,
which are defined as muscle progenitor cells that mediate regeneration of skeletal muscle
[14-16]. Interestingly, some studies show that transplanted SkMs in rat MI model result
in some beneficial effects like decreased LV diastolic dimension and MI size, improved
heart function with increased fractional area change and reversed LV remodeling [17].
SkMs also have a lot of advantages for cell therapy including autologous derivation from
muscle biopsies, large scale in vitro expansion and relative ischemia resistance. On the
other hand, SkMs do have some negative aspect limited its efficacy for the treatment of
MI, such as only differentiation into the wrong form of muscle like skeletal rather than
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cardiac and lacking adhesion and gap junction proteins to form functional integration
with host myocardium upon transplantation [18].
In addition, there is a clinical trial named MAGIC shows disappointing outcomes
and an increased risk of arrhythmias in patients who received transplantation of
autologous SkMs obtained via thigh muscle biopsy in patients [19]. Because of above
mentioned discouraging results from clinical trials, studies of SkMs transplantation have
decreased in recent decade.
2.1.2 Bone marrow derived cells (BMCs)
Many cell types have been studied as cell therapy resource for the MI treatment,
but most clinical trials have applied autologous BMCs due to its proven clinical safety
and familiarity in the hematopoietic disorders but it still has some problems such as
heterogeneous results in terms of efficacy [20]. Bone marrow contains multiple types of
cells, including mononuclear cells (MNCs), hematopoietic stem cells (HSCs), endothelial
progenitor cells (EPCs), and mesenchymal stem cells (MSCs), which will be discussed in
details later in this chapter. Transplanted BMCs in the damaged heart could enhance
angiogenisis, reduce LV remodeling progress, and improve heart function in both animals
model and humans clinical trials [21-25].
Bone marrow derived MNCs play an critical role in immune defense,
inflammation suppression, and tissue healing process [26]. In addition, MNCs could
promote angiogenesis post MI which has been proved by recent studies that MNCs
include a population of potent EPCs actively contributed in postnatal vasculogenesis,
although it is unsure if MNCs can become fully functional endothelial cells in vivo. Thus
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transplantation of extracardiac MNCs harvested from bone marrow in patients could have
potential to improve heart repair after MI occurs. However, no solid evidence has been
shown to prove implanted MNCs have the capability to generate large amount of
myocardium for heart repair, instead paracrine effects are the major mechanism
underlying the beneficial effect from MNCs transplantation in both numerous animal
studies and clinical trials in the past decades.
Bone marrow derived HSCs can differentiate into cells of myeloid and lymphoid
lineages [27]. Interestingly, several reports suggest that HSCs has possibility to
transdifferentiate into cardiomyocytes for cardiac repair [21, 28]. These promising results
have prompted several clinical trials to investigate the potential application of HSCs in
the treatment of MI. HSCs are a rare population of cells in bone marrow (1 in 10,000cells
) and (1 in 100,000 cells ) blood. The phenotype of human HSCs is still difficult to well
defined due to the complexity of the specific markers. Generally, human HSCs are
CD59+ CD34+ Lin- CD38- c-kit- cells, but several other cell types could express the LinCD34+, and CD38 is not a well-defined marker [29, 30]. On the other hand, some
research indicates that HSCs readily adopt the hematopoietic phenotype post implantation
into MI heart [31-33].
Bone marrow derived EPCs could migrate to peripheral blood post MI incidence
and promote angiogenisis by differentiating into blood vessel lining cells (endothelial
cells) [34, 35]. Their specific markers are CD34, CD133, and VEGFR-2 (vascular
endothelial growth factor). Several researchers have shown that bone marrow-derived
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EPC transplantation is capable of restoring vasculogenesis, reducing the myocardial
infarcted area and improving cardiac function in MI models [36-39].
Bone marrow derived MSCs are the second most population of stem cells located
in bone marrow as structural component cells without little ability to enter circulation.
Their specific markers are a Lin-, CD34-, c-kit+, Sca-1+, CD45- and they can
differentiate into multiple cell lines including chondrocytes, adipocytes, osteoblasts,
skeletal muscle cells and cardiomyocytes [40, 41]. Although this cardiogenic potential
remains controversial [42], the results of MSCs transplantation in animal models of MI
are still encouraging to improve heart function and reduce fibrosis.
In summary, MNCs, HSCs, EPCs and MSCs are distinct stem/progenitor cell
populations or mixture cells in bone marrow. These autologous cell types differ in size,
surface markers, and the ability to proliferate and differentiate after transplantation in
myocardium. Despite the lack of a significant amount of myocardium regeneration after
transplantation, current research with BMCs based cell administration will be able to
provide further evidence for a nonmyogenic and clinical safe pathway for the MI
treatment.
2.1.3 Cardiac stem cells/ progenitor cells (CPCs)
During the past several decades, tremendous studies have proved that three
fundamental principles for cardiac regeneration have now been established [43]. First, in
the embryonic mammalian heart there is a small population of resident multi-potent
CPCs, which are committed to differentiate into cardiac cells (cardiomyocytes, smooth
muscle cells and endothelial cells) [44-50]; second, a limited number of new
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cardiomyocytes after birth in mammals has been observed [51, 52]; and third, some
vertebrates, such as amphibians [53, 54] and zebrafish [55-57] retain a very robust
capacity for self cardiac regeneration throughout life, while only early stage of mammals,
like neonatal mice, can fully regenerate damaged myocardium following experimental
injury [58]. Actually, some studies have also shown that cardiomyocytes can continue to
proliferate in adult mammals including humans, but with a very low rate (around 1% per
year), and that the rate will decline over time [59, 60].
The obvious question would be: where does the regenerated myocardium come
from? There are two major theories that have occurred over the past decade‟s research to
implicate the cell sources of regenerated cardiomyocytes in adult mammals. First, the
resident CPCs located in the heart possess the capacity to differentiate into
cardiomyocytes, smooth muscle cells, and endothelial cells, which could lead to new
myocardium; second, the mature cardiomyocytes could reenter the mitotic cell cycle to
divide into more new cardiomyocytes for heart repair as shown in Fig 1.4.
In 2003, a special population of cells isolated from the adult rat myocardium that
expressed the tyrosine kinase receptor c-kit (a marker of stemness) is commonly named
CPCs, which may reside in the heart itself, or derive from a circulating bone marrow
stem cell [61]. These cells have been proven to have capabilities as stem cells through
self-renewing properties and multi-potent differentiation into cardiomyocytes, smooth
muscle cells, and endothelial cells both in vitro and in vivo [46, 62]. Thus most
researchers use the presence of the c-kit as a specific marker for identification of CPCs
for cell harvesting and purification [63, 64]. Briefly, these CPCs can be isolated from
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myocardium biopsy during heart surgery and then expanded in culture in vitro for
application in autologous transplantation. However, a single specific marker as c-kit to
harvest CPCs from myocardium has some limitations and the isolated c-kit+ CPCs are
highly susceptible to contamination by non-CPCs, which may lead to compromised and
inconsistent outcome after transplantation in vivo.
In the past decade, the ability of CPCs from both humans and rodents to improve
heart function, promote cardiac regeneration and reduce fibrosis has been repeatedly
demonstrated by several researchers in various animal models (mice, rat, dog and etc) of
MI [62, 65-68]. In addition, there are two prominent clinical trials with CPSs
transplantation in humans, which have reported early results post transplantation. The
phase 1 results of the first clinical trial, SCIPIO, showed a 12.3% improvement in LV
ejection fraction in patients post 1 year with intracoronary injection of autologous c-kit+
CPCs following MI [69]. And the second clinical trial (CADUCEUS) phase 1 trial
recruited randomized patients with 2–4 weeks post MI receiving cardiosphere-derived
autologous CPCs transplantation or regular treatment as control [70]. However, CPCs
transplantation results in no critical benefits to improve heart function but only has
reduced fibrosis and increased viable heart tissue and regional contractility evaluated
MRI post half year [70].
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Figure 1.4 The mechanism of cardiac self –repair in mammals. Produced from [43].
There is another sub-type of CPCs [71, 72]in the adult mouse heart named Sca-1+
CPCs, which are capable to be differentiated into functional cardiomyocytes in vitro. In
addition, in vivo data indicates that transplanted Sca-1+ CPCs into damaged myocardium
in mouse MI model could attenuate LV remodeling due to their committed differentiation
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into cardiac linage cells. However, the lack of homolog of Sca-1in human hinders this
translational application in clinical trials [71, 72].
The side population cells (SPs) were considered as a sub-population of CPCs,
which is first described in 1996 [73] as a way to enrich HSCs from the bone marrow of
adult mice. First identified in mouse bone marrow as HSCs, SPs were subsequently
isolated from both adult and embryonic mouse hearts with specific markers (CD31-, Sca1+, c-kit-, CD34-, and CD45-). In vitro study shows that cardiac SPs have abilities to
differentiate into cardiac cells and animal study indicates their potentials for cardac
regeneration in cryoinjured heart. However, it is necessary to test their effectiveness in
MI models before clinical trials [74-77].
The LIM-homeobox transcription factor islet-1 (Isl-1) is a distinct marker of
undifferentiated CPCs [78]. The Isl-1+ CPCs are able to differentiate into myocardium,
blood vessels and the conduction system in the heart. However, based on my knowledge
there is no research shows that the Isl-1+ CPCs could induce myocardium regeneration in
animal study. On the other hand, these Isl-1+ CPCs do not exist in the adult heart, which
make them less possible in clinical application [79-81].
Initially cardiosphere-derived cells (CDCs) were found in 2004 [82]. The
researchers are able to isolate CDCs from myocardium biopsy of both human and animal
origins. The CDCs could grow into colonies in vitro and be able to differentiate into
cardiac cells. These injected CDCs could improve cardiac function in mouse, rat, pig and
dog MI models due to their cardiac regeneration in vivo [83-86].
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Cardiac stem/progenitor cells cannot considerably repair injured myocardium,
adverse LV remodeling and prevent deterioration in heart function post MI. In fact, the
main mechanism underlying the efficacy of CPCs transplantation in vivo is paracrine
effect, which could induce endogenous resident CSCs for in situ proliferation and
differentiation of cardiac cells resulted in limited myocardium regeneration.
2.1.4 Embryonic Stem Cells
Human embryonic stem cells can proliferate without limit, and maintain the
potential to differentiate into all the cells of the body. This remarkable potential makes
them a useful cell resource for basic research on the function of the human body, drug
screening and testing, and transplantation medicine. In 1998, James Thomson first
successfully isolated embryonic stem cells (ESCs) from the inner cell mass of blastocysts
stage (4–5 days post fertilization of egg) [87]. ESCs have been proven to be able to
differentiate into all the derivatives of the three primary germ layers: ectoderm,
mesoderm and endoderm. ESCs are considered as an unlimited supply of cardiac cells
produced in vitro as the cell resource of cell therapy for heart repair and regeneration [88,
89].
Despite the proved capacity of ESCs for heart repair in vivo, they have restricted
in clinical application for the treatment of MI patients due to both biological and ethical
issues. Specifically, their allogeneic nature could induce graft rejection post
transplantation and their pluripotency has potential of teratoma formation in vivo [90].
However, the recent development of autologous human induced pluripotent stem cells
which have similar pluripotency comparable with ESCs is a more promising clinical cell
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resource that could avoid these two major problems of ESCs (ethical and biological
concerns).
2.1.5 Induced pluripotent stem cells (iPSCs)
In 2006, Yamanaka discovered that differentiated cells such as fibroblasts can be
reprogramed into an undifferentiated state named „iPSCs‟, which have similar
characteristics with ESCs [91]. The beneficial effects in terms of cardiac contractility
have been observed after transplantation of iPSCs into mice MI model [92]. In addition,
a similar outcome involving enhanced regional perfusion and improved cardiac function,
was reported in a porcine MI model [93]. However, the tumorgenetic stemness of iPSCs
is not clinically safe in vivo and may lead to some negative effects such as in situ tumor
incidence after iPSCs transplantation. And a study shows that heterogeneous teratoma
formation in the heart was induced by transplantation of undifferentiated rat iPSCs in a
rat model [94].
Thus terminally differentiated iPSCs cardiac cells (cardiomyocytes, endothelial
cells and smooth muscle cells) have been widely used as cell resources for cell therapy to
avoid the iPSCs tumorgenicity in vivo. The transplanted murine iPSCMs in adult mouse
hearts can survive in long term in vivo and form electrical integration with host
myocardium, which proves their potential application for the cardiac regeneration and
heart repair [95]. The implanted bioengineered myocardium from mouse iPSCs in adult
rat MI model could survive at the epicardial implantation site and result in attenuated LV
remodeling [96]. The above mentioned research indicated iPSCs derived cardiomyocytes
are a new promising cell resource for the treatment of MI.
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hiPSC-CMs emerged as an unlimited supply of autologus cardiomyocytes
produced in vitro as the cell resource of cell therapy for heart repair and regeneration.
The transplanted hiPSC-CMs could engraft, survive and functional integrate with host
myocardium to form electromechanical junctions within the healthy rat heart [97]. The
inherent features of hiPSC-CMs strongly indicate that they are the ideal cell resource of
cell therapy for MI treatment.
2.2 Delivery for cell therapies
2.2.1 Route for delivery
The most effective way to deliver targeted cells into myocardium for maximized
outcomes post transplantation is still on the way to explore. The major applied delivery
routes are intracoronary infusion and direct injection into the injured myocardium
(intramyocardial). Practically in the clinical setting, the cell delivery by intracoronary
infusion is the most favorable route for cell transplantation in MI patients. Compared
with directly intramyocardial injection, intracoronary delivery provides several
advantages: 1) it could induce much more uniformed cells distribution within injured
myocardium, 2) it has minimal invasion to the infarcted myocardium during
transplantation, and 3) it is relatively easier for physician to follow the similar existing
procedure (bone marrow cells transplantation for leukemia) to conduct the operation.
However, this intracoronary route has raised some negative effects compared with
intramyocardial route: 1) the very low immediate retention of transplanted cells (eg,
intracoronary: 2.6±0.3% vs intramyocardial: 11±3%), could be caused of the migration of
major cell population into circulation, 2) the larger cells populations such as CDCs (≈21
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µm in diameter), SkMs (≈20 µm in diameter), MSCs (10–20 µm in diameter) have high
possibility to block the vascular structure to hinder the additional cells infusion into the
injured myocardium once occlusion formation and 3) the blocked coronary arteries
prevent the delivery of cells into myocardium in situ [98-101].
Intramyocardial injection through epicardial route offers direct visualization of
infarcted myocardium but it is restricted by invasive opening chest procedure. On the
other hand, endocardial injection route is a less invasive way to delivery cells by using an
image-guided catheter to enter into the cavity of the heart, which has been widely used in
the clinical settings. There are two advantages of endocardial injection route over
intracoronary ones 1) the application of NOGA system can trace the distribution of the
heart tissue with ischemia and fibrosis, which could enable precisely transplantation of
cells into targeted area of injured myocardium such as border zone or center part of
infarction; 2) in case of the totally blocked coronary artery it is feasible to delivery cells
into infarcted area for targeted in situ cardiac regeneration. However, intramyocardial
route also has some limitations and risks: 1) the distribution of transplanted cells within
myocardium is not homogeneous and bulk transplanted cells could form big engraftment
in situ without vascularization to maintain the long term survival in the heart. 2)direct
delivery itself could invasively disrupt myocardium architecture and cause further
damage to the myocardium in the injection location.
2.2.2 Engineered method for cell delivery
Single cell suspension in medium based injection is the first way to test cell
therapy for the efficacy of the MI treatment, and this simple method achieved some
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promising results in some studies [102, 103]. However, the consequence of very low cell
retention and engraftment underestimates its great potential for better improvement of
heart function post transplantation [104, 105].
In recent decade, new strategy has emerged by focusing on tissue engineering
methods that could mimic native myocardium environment with the biological, physical
and chemical cues to better maintain transplanted cell phenotype and survival. There are
three engineered methods for cell delivery: 1) biomimetic scaffolds; 2) decellularized
extracellular matrix (ECM); 3) scaffold-free engineered tissue. The scaffolding materials
can provide a structural environment that supports cell adhesion, migration,
differentiation, and organization with delivering soluble and insoluble biochemical cues,
which leads to new tissue formation [106]. Engineered method for cell delivery has great
potential to improve the cell engraftment and survival compared with single cell
suspension in medium based injection. In a recent review, five natural materials
(collagen, gelatin, Matrigel, alginate and fibrin) and seven synthetic materials
(polyethylene glycol, polyhydroxyethylmethacrylate, polylactide-glycolic acid, and
poly(N-isopropylacrylamide) and copolymers) have been discussed in application for
cardiac regeneration but none of them seems the optimal scaffolding materials for cell
transplantation for heart repair [107].
Natural biomaterials are biodegradable, biocompatible and less immunogenic than
synthetic materials with better cell adhesion, migration, differentiation, and organization.
Because they are naturally originated as the proteins or polysaccharides with similar
structures to the native component of ECM [108-113]. The disadvantage of using natural
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biomaterials as scaffolds for cell transplantation is their untailored poor mechanical
property. In addition, the degradable byproducts from natural materials may be toxic or
immunogenic in vivo.
While synthetic materials for the application in cardiac tissue engineering are
easily tailored with predictable physical and chemical properties, but their potential
adverse effects (induce inflammatory and immune response) might affect beneficial
outcome post cell transplantation [113-116].
In summary, the optimal materials for cardiac tissue engineering should has no
immunogenicity and should has mechanical stability, electrical conductivity for electrical
signals propagation. Furthermore, it could allow sufficient oxygen and nutrient supply to
cells, and have a appropriate degradation rate with native ECM replacement.
Recent study shows that decellularized ECM based injectable materials are very
promising in the cardiac tissue engineering. In addition, some research indicates the
composites of natural and synthetic materials could take advantage of both components to
maxim the outcome for cell transplantation. However, the field in decellularization of
ECM is developing to fulfill the need as scaffold materials cardiac tissue engineering
[117, 118].
2.2.3 Cell patch
Engineered cardiac patches can be fabricated from stacking scaffold free cell
sheets or by seeding the cells into the scaffolding material designed to mimic the native
ECM. The tissue-engineered cardiac patch provides a better method to deliver cardiac
cells to the injured myocardium to achieve better outcomes such as higher cell retention
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and survival, larger and more controlled infarction area coverage, reduced LV
remodeling post MI [119-122].
Though cardiac patch based cell transplantation leds to better engraftment, longterm survival, and progressive maturation of human cardiomyocytes, the human
engraftment is totally isolated from host tissue by fibrosis and it does not contribute to
functional improvements in MI model [123, 124].
2.2.4 Scaffold free cardiac tissue engineering
The cell density inside the material-engineered cardiac construct is very low
compared with the very dense cell distribution in the natural myocardium. In addition,
inflammatory reaction, immune response and fibrosis formation caused by the
degradation of scaffolding materials led to the reconsideration of engineering tissue
without the use of xenogeneic or allogenious scaffolding materials.
2.2.5 Cell sheet
As intact layers of cells, the scaffold-free two-dimensional (2D) myocardial
sheets can be used to stack them in multiple layers to produce a 3D cardiac construct for
cell transplantation.
The cell culture surface is coated with temperature-responsive hydrogel (poly Nisopropylacrylamide), which is hydrophobic at 37°C and allows for the cell attachment in
the incubator; the surface becomes hydrophilic under 32°C and leads to the detachment
of the cells as an intact layer to preserve the cell-to-cell junction proteins without
digesting the ECM secreted by cells. .When the 2D cell sheets are stacked together, they
can rapidly fuse into scaffold-free cardiac patch due to the presence of the intact ECM
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secreted by cells. The research shows that spontaneously beating cardiac patch with rapid
electrical coupling between the sheets from stacking multiple monolayers of neonatal rat
cardiomyocytes indicate the rapid formation of functional gap junctions within patch
[125, 126].
After transplantation of mono-layer of adipose tissue-derived MSCs in mouse MI
model, angiogenesis, prevention of LV remodeling and improved cardiac function were
observed post four weeks transplantation [127].
Another study shows that transplanted 3D sheets of neonatal rat cardiomyocytes
in MI models in rats could attach to the host tissue with improved heart function, highly
expressed gap junctions and enhanced angiogenesis in situ.[128]
However, application of scaffold-free cell sheets is still facing some problems.
Firstly, the diffusion limitation of avascular tissue limit the thickness of sheets in vivo
(only 80 μm), or three layers; even thicker engineered cardiac sheet resulted in cell death
as necrosis [129]. Secondly, the transplantation of cell sheets in vivo is invasive
procedure requiring opening the check and induce more damage to the mycadium post
operation. Several strategies have been explored to increase the vascular structure within
the cell sheets and thickness of engineered tissue like coculture with endothelial cells and
treatment with VEGF and culture under bioreactor [130].
2.2.6 Spheroid
The survival rate of single cell transplantation for heart repair is very low partially
due to harsh conditions within the damaged myocardium including hypoxia, fibrosis and
inflammatory environment [131]. It is necessary to optimize delivery approach and form
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of cell therapy, which includes intactness of the cell harvesting or specific cell
pretreatment procedures prior to transplantation. Compared with cell sheet, spheroids can
be tailored for suitable size for less invasive cell delivery as direct injection into
myocardium post MI. Regarding cell delivery, spheroids avoid the harsh enzymatic
treatment step in cell harvesting procedure of monolayer cultured single cells and reduce
anoikis by multi-cellular interaction in the hypoxia environment post transplantation. In
addition, spheroids could improve cell retention after transplantation due to their
significantly bigger size compared with single cells.
The 3D spheroids mimic the natural microenvironment of tissue and enhance
cell–cell interactions to better maintain the function and phenotype of cells compared
with traditional 2D monolayer cell cultures. It has been reported that MSCs spheroids
have better survive under ischemia compared with 2D cultured cells [132] And cells in
3D spheroid culture could up-regulate expression levels of hypoxia-inducible factor 1 and
manganese superoxide dismutase, which could improve the resistance to cell apoptosis
induced by oxidative stress [133]. Enhanced survival and engraftment post
transplantation of 3D MSC spheroids transplantation was observed in the rat MI model
[134].
Another study shows human CPCs spheroids transplantation significantly
improve the engraftment capacity compare with single cell injection in both mouse
healthy and injured hearts [135]. After 10 spheroids injection into the healthy
myocardium of mice, human engraftment formed from transplanted CPC spheroids could
be detected for 1 week post transplantation. While, no grafted cells could be observed
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post three days following injection with the same amount of single cells delivery. In
addition, the same level of engraftment capability has been observed with cells
transplantation in spheroids in cardiotoxin-injured heart model [135].
The form of 3D scaffold-free spheroids for cell delivery represents unique
opportunities in the improvement of the therapeutic potential post cell transplantation.
Less invasive procedure, less harsh cell harvesting process, enhanced cell-cell
interactions, and anti-anoikis features of cells in ischemic environment demonstrate this
promising strategy of cell delivery for hiPSC-CMs transplantation aiming cardiac repair
and regeneration in clinical settings.
2.3 Survival for cell therapies
hiPSCs and hESCs can be differentiated into functional cardiomyocytes and have
the potential to repair large scale of injured heart tissue post MI. One of the key
challenges towards clinical application of hiPSC-CMs is to enhance survival, retention
and engraftment of the transplanted cells in hash infarction environment (ischemic,
fibrosis and avascular). Immediately post transplantation, most cardiomyocytes are lost as
a result of combined mechanical, cellular and host factors. In addition, a large portion of
the remained cells in host tissue will undergo apoptosis or necrosis in short term due to
incidence of inflammation and immunological response and the lacking adhesion signals,
oxygen and nutrients supply in the ischemia environment. In order to improve cell
retention and survival post transplantation, many strategies have been applied such as
conditioning cells before transplantation, promoting angiogenesis in infraction regions,
using pro-survival cocktails to delivery cells, blocking the apoptotic signaling pathways,
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immunosuppressing the host myocardium and application of bioengineered methods
[136].
Several studies have shown 10–30% of transplanted cells could remain post a few
days, and only 1–5% of cells could survive post 10–12 weeks [137, 138]. Mechanical
factors could extrude cell out of the host tissue by spontaneous contraction of the hearts
[139]. Studies of radio-labeled cells [140] and microspheres [141] in a porcine MI model
indicated that less than 10% cells remained immediately post transplantation. Here we
summarize current strategies to improve cell retention and survival post transplantation
listed in the Table 1.1-1.2.
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Cell conditioning

Heat shock
Hypoxic pre-conditioning
Hypoxia inducible factor-1
Diazoxide
Isoflurane
Erythropoietin

Anti-apoptotic pathways

Rho-associated kinase inhibition
TGF-β2 treatment
SDF-1 signalling of PI3K/Akt
p38 MAPK inhibition

Pro-survival cocktail

Akt and Bcl overexpression
Pinacidil
Cyclosporine
ZVAD-fmk
Insulin-like growth factor-1

Table 1.1 Cellular protection strategies described to improve transplanted cell survival.
Reproduced from [136]
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Inflammation inhibition

CD4/CD8/C3 inhibition
Prednisone
Cyclosporine

Angiogenic and homing factors

FGF
VGEF
SDF-1a/CXCR4

Co-transplant

Mesenchymal stem cells
Fibroblasts
Endothelial cell progenitors

Hydrogels and bioengineering solutions

Collagen
Hyaluronic acid
Matrigel
Fibrin
Chitosan
Oligopolyethylene
Alginate
Magnetic targeting
Engineered cell sheets
Spheroid

Table 1.2 Optimizing host myocardium strategies described to improve transplanted cell
survival. Reproduced from [136].
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2.4 Function integration for cell therapies
The functional integration of graft with host myocardium is necessarily required
to transmit contractile force and propagate the action potential for pumping out blood
properly. Firstly, the mechanical integration between graft and host requires cell-cell and
cell-ECM junction formation. Interestingly, the electrical integration is more complicated
because of the complex gap junction coupling and ion channel expression required for
action potential propagation [142]. Successful electromechanical integration could
reverse the conduction block, synchronize the graft contraction with the host myocardium
and prevent arrhythmogenicity of the heart [143].
The immature phenotypes of hESC-CMs or hiPSC-CMs pose a potential risk for
arrhythmogenicity in vivo, which could hamper host conducting system and functional
integration of transplanted cardiomyocytes with the host myocardium [43, 144]. In the
past decade, physical stimuli (e.g. electrical and mechanical stimulation) has been applied
to advance the immature cardiomyocytes towards more matured phenotypes with more
organized sarcomere structures (width, length and alignment) and unregulated expression
level of gap junction protein (Connexin-43) [145]. In order to mimic the electrically
conductive properties of native myocardium, conductive nanomaterials (gold nanowires,
carbon tubes) have been used as scaffolding materials to fabricate engineered cardiac
tissue with stronger contractile and electrical properties for promoting cardiomyocyte
maturation in vitro and in vivo [146, 147].
We recently utilized e-SiNWs to facilitate the self-assembly of hiPSC-CMs to
form nanowired hiPSC cardiac spheroids and improve the functions of the microtissues,
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which lead to significantly more advanced cellular structural and contractile maturation
of hiPSC-CMs in nanowired spheroids system [148, 149]. Here, we reasoned that the
presence of the e-SiNWs in the injectable cardiac spheroids improves their ability to
receive exogenous electromechanical pacing from the host myocardium and enhance
their functional integration with host tissues post-transplantation.
2.5 Stability and safety for cell therapies
The hiPSC-CMs or hESC-CMs can be directly differentiated into cardiomyoctes
with high efficiency [150], which have emerged as an unlimited cell source for in vitro
disease modeling for drug discovery and in vivo transplantation for heart repair post MI
[151]. Although the electrophysiology of single hiPSC-CMs or hESC-CMs has been
characterized in several studies [7–13], their risks of arrhythmogenicity in vivo has not
yet been systematically and comprehensively investigated due to unmatched animal
models with human [152]. Given the immature phenotypes of hiPSC-CMs and hESCCMs at the single-cell level, both of them have risks of arrhythmias in vivo post
transplantation. A recent study showed substantial arrhythmia development after injection
of hESC-CMs into the myocardium of nonhuman primates [153]. In addition, hiPSCCMs or hESC-CMs are heterogenous cell populations consisted of a mixture of
ventricular, atrial and pacemaker cardiomyocytes [154]. In order to avoid the arrhythmia
post transplantation, more mature homogenous cardiomyocyte types, like purified
ventricular cardiomyocytes, should be used in vivo for cell transplantation.
The other safety issue associated with cell therapies is tumorgenicity in vivo post
transplantation. Although the host myocardium released cardiotrophic factors guide
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transplanted ESCs toward cardiac differentiation, the noncardiogenic signaling associated
with pluripotency of ESCs for unguided differentiation can overcome the limited
endogenous cardioinstructive signaling to form neoplastic transformation [155]. Thus
transplantation of terminally differentiated cardiomyocytes may avoid this risk of
tumorgenicity in vivo. A recent study shows that no teratomas or tumors were found in a
rat MI model with engineered hESC-CMs patch transplantation at long term monitoring
(110 or 220 days respectively) [123].
2.6 Other consideration regarding cell therapies
2.6.1 Timing for cell transplantation
There is a study aiming to determine the optimal time point for bone marrow
derived MSCs transplantation post MI. The rats underwent MI procedure by LAD
ligation, and received direct intramyocardial injection of MSCs at time points of 1h, 1
week and 2 weeks post MI, respectively. MSCs transplantation was shown to improve
heart function and reduce infarct size in MI model rats with attenuated LV chamber
dilation. Interestingly, the greatest benefit was observed in rats that received MSCs 1
week post MI with more abundant engrafted MSCs survival, in situ angiogenesis and
functional cardiomyocytes than the other two groups. At the time point of one week post
MI, scar formation had not occurred and the acute inflammation and immune response
was reduced and stable, which could facilitate survival, engraftment and integration of
transplanted MSCs with functional recovery [156]. Thus one week post MI is a good time
point to perform the cell transplantation to achieve the better efficacy by avoiding the
acute inflammation reaction, immune response and fibrosis formation.
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2.6.2 Dose for cell therapies
The optimal cell dose of cell therapies aiming the treatment of MI still remains an
open question. Obviously, a higher dose of cell transplantation could have better
outcomes upon cell delivery to the injured myocardium. A study by direct
intramyocardial injection of bone marrow derived MNCs or MSCs in rat MI models
shows the maximum cell number after increasing injected cell number into the
myocardium [157]. However, it is not always safe and feasible to deliver a large number
of cells into the injured myocardium. One study that used the swine MI model while
delivering CDCs isolated from human biopsies found that over 2.5 x 107 intracoronaryadministrated cells infusion could increase the size of engraftment but meanwhile results
in side effects such as partial myocardial damage, as evidenced by the elevating level of
Troponin I (ischemia maker in blood serum) [158]. In addition, more transplanted cells
can be found in other organs such the lungs, liver, kidneys and spleen with increased
number of transplanted cells in short term, but few or no grafted cells were detected in
long term (over six weeks). The long term low survival rate of transplanted cells in the
heart may limit therapeutic efficacy of cell therapies, while the distribution of
transplanted cells to other organs rather than heart must be manipulated to avoid adverse
effects in all cell therapy applications [157].

Interestingly, there is a study using

allogeneic mesenchymal precursor cell (MPCs) isolated from male crossbred sheep for
transplantation in a female sheep transmural MI model. This study investigated the
effects of different doses with injection of 25, 75, 225, or 450 x 106 MPCs respectively
on the heart functional improvement post cell transplantation, and only the low dose cell
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transplantation (25 and 75 x 106 MPCs) significantly attenuated infarct expansion and
increased both LV end diastole and systole volumes [159]. The researchers concluded
that the high cell doses lead to intense competition for limited oxygen and nutrient supply
in the ischemia environment of injured heart, which could result in the limited cell
survival and functional improvement. In addition, the large number of transplanted cells
may initiate a more profound inflammation reaction and immune response that
accelerates cell apoptosis and clearance [159]. The alternative strategy using multiple
small doses for transplantation over an extended period (e.g. days to weeks) may
represent a promising direction for optimizing the dose of cell therapies to achieve the
better outcomes for the MI treatment.
Though cell therapies are promising approaches to heart regeneration post MI, the
outcomes of the most current clinical trials show inconsistent, modest, borderline, or
undetectable benefits (most of them applied only one dose of cells) [12, 160-162].
Roberto Bolli raised a good point, asserting that most pharmacological drugs are
ineffective when only given one dose but can be highly effective when given repeatedly,
so one time cell therapy may have no effect, or only be modestly effective, but multiple
transplantations may turn out to be very effective due to the accumulated improvement.
His studies in rodents have shown that repeated cell therapy is much more effective than
single-dose therapy. When the rats with chronic ischemic cardiomyopathy (old MI) were
given three doses of c-kit+ CPCs 35 days respectively, each dose generated a similar
increase in LV function, so the total cumulative improvement was approximately triple
than that observed with one dose administered . In a following study in mice with chronic
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ischemic cardiomyopathy, they found that three doses of cardiac mesenchymal cells
(CMCs), given 14 days separately, generated a significantly greater outcomes as the
bigger improvement in LV function and led to less myocardial fibrosis in the
noninfarcted region compared with single dose [163, 164].
2.7 Cell therapy based future strategies for the treatment of MI
Recent researches on MI treatment are focused on reversing heart remodeling and
reducing scar formation with stem/ progenitor/ terminally differentiated cells injection or
replacing scar tissue with a functional engineered myocardium.
Among all the cell types for cell therapies for the MI treatment, hiPSCs have
emerged as a more promising cell resource for heart repair due to their proven capacity to
produce patient-specific functional cardiomyocytes (hiPSC-CMs) [165-169]. In addition,
recent progress in cardiac differentiation of hiPSCs allows for the derivation of a large
number of hiPSC-CMs (>109 cells/patient) needed for cardiac repair [124, 170-172]. To
realize the therapeutic potential of hiPSC-CMs or hESC-CMs (cardiomyocytes derived
from human embryonic stem cells), significant efforts have been made, transplanting
hiPSC-CMs or hESC-CMs into animal MI models to improve cardiac function, with
limited myocardium regeneration [97, 104, 124, 170, 173-178].
While most of research utilizes direct injection of the dissociated hiPSC-CMs or
hESC-CMs into healthy/injured myocardium, the success of this cell delivery approach is
limited by low cell retention and survival after cell transplantation. Dissociated hiPSCCMs are rapidly redistributed to other organs (e.g., lung) after injection due to
mechanical dispersion of beating hearts [140]. Additionally, lack of cell-to-cell adhesion

34

amongst single cells leads to cell death caused by anoikis and/or ischemia [179]. To
improve the efficiency of cell delivery, significant efforts have been devoted to the
development of tissue-engineered epicardial patches [175, 180-182]. In addition to the
invasive surgical procedure to transplant the patches, recent research has shown there is
limited electrical integration between the transplanted patches and host myocardium,
largely attributed to the chronic fibrotic response that occurs after transplantation [180182]. This highlights an urgent need to develop an innovative platform to improve the
retention, engraftment and integration of the injected hiPSC-CMs with the adult
myocardium after transplantation.
hiPSC cardiac spheroids have been proposed as an attractive cell delivery system
for heart repair, given the recent literature showing spheroid/aggregate delivery improves
cellular retention and post transplantation survival [183-189]. To this end, we recently
utilized electrically conductive silicon nanowires (e-SiNWs) to facilitate the selfassembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids and improve the
functions of the microtissues, resulting in significantly more advanced cellular structural
and contractile maturation of hiPSC-CMs [148]. Here we reasoned that the presence of
the e-SiNWs in the injectable spheroids improves their ability to receive exogenous
electromechanical pacing from the host myocardium and enhances their integration with
host tissues post-transplantation. This theory was inspired by our recent finding that the
addition of e-SiNWs in hiPSC-CM spheroids are essential for exogenous electrical
stimulation/pacing to promote hiPSC-CM development and maturation [190].
Furthermore, recent reports showed the presence of electrical nanomaterials (e.g., gold
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nanowires) in cardiac tissue engineering constructs synergizes with exogenous electrical
pacing to improve the function of the constructs [147, 191]. Compared to other electrical
nanomaterials (e.g. gold nanowires, carbon nanotubes), e-SiNWs have distinct
advantages, including their controllable electrical conductivity, tunable dimensions, and
convenient surface tailorability [192, 193]. Additionally, both in vitro and in vivo
biocompatibility studies have shown no significant cytotoxic effects for either undoped or
n-type e-SiNWs [194-196]. Notably, the absence of a pre-aligned structure within the
nanowired hiPSC cardiac spheroids has raised concerns over their suitability for
transplantation. The ability of hiPSC-CMs from hiPSC cardiac spheroids to align and
functionally engraft/integrate with the host tissue after transplantation remains an open
question that needs to be investigated.
In our study, we plan to inject nanowired hiPSC cardiac spheroids into adult rat
hearts and examine cell retention, engraftment and integration with host myocardium. In
addition, we will examine the cardiac biocompatibility of e-SiNWs in the adult rat hearts
to verify the safety of the application of nanowired cardiac spheroids in vivo.
3. Study objectives
3.1 Significance
The current inability to derive mature cardiomyocytes from hiPSCs has been the
limiting step for transitioning this powerful technology into clinical therapies. To address
this, scaffold-based tissue engineering approaches have been utilized to mimic heart
development in vitro and promote maturation of cardiomyocytes derived from human
pluripotent stem cells. While scaffolds can provide 3D microenvironments, current
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scaffolds lack the matched physical/chemical/biological properties of native extracellular
environments. On the other hand, scaffold-free, 3D cardiac spheroids (i.e., sphericalshaped microtissues) prepared by seeding cardiomyocytes into agarose microwells were
shown to improve cardiac functions. However, cardiomyocytes within the spheroids
could not assemble in a controlled manner and led to compromised, unsynchronized
contractions.
To realize the enormous potential of hiPSC-CMs for heart repair and
regeneration, significant efforts have been devoted during the last decade to the
transplantation of hiPSC-CMs into damaged animal hearts to restore their. However, low
cell retention and limited cell survival have been found regardless of cell delivery
methods. For example, several researchers demonstrated that less than 10% cells stay in
the hearts immediately after injection in the rat, porcine or monkey infarct models, and
even lower cell retention was found for intracoronary and intravenous injection. For the
cells retained in the hearts, most of them were found to undertake apoptotic and necrotic
pathways. Murry and coworkers showed that as high as 90% retained cardiomyocytes
died within the first few days after transplantation. This high cell death after injection has
mainly been attributed to three major pathways: anoikis, due to the lack of matrix support
after harvesting cells from culture substrates; ischemia, due to the lack of oxygen and
nutrient supply within the avascular infarct regions; and inflammation as attributed to
cytokines and free radicals. The low cell retention and engraftment after transplantation
are major limiting factors to develop clinically applicable hiPSC-CM based therapies to
treat cardiovascular diseases. Notably, both low retention and low survival of hiPSC-
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CMs after transplantation can be attributed to the current utilization of dissociated single
hiPSC-CM for cell transplantation. After injection, single cells can be rapidly
redistributed to the other organs due to the mechanical dispersion of beating hearts and its
small size going through circulation system. Further, the lack of cell-cell adhesion of
single cell can lead to anoikis mediated cell death and/or low expression of pro-survival
factors in a hypoxia environment and result in low cell survival after transplantation.
We propose that application of nanowired spheroids as cell delivery system could
improve cell retention and survival after transplantation. The underlying hypotheses are:
1) spheroids can improve cell retention after transplantation due to their size, 2) the
spheroid grafting can avoid the harsh enzymatic treatment step in cell harvesting
procedure and reduce anoikis by multi-cellular interaction, 3) spheroids improve cell
survival in a hypoxia environment due to their 3D microtissue configuration, and 4) the
addition of electrically conductive e-SiNWs into spheroids effectively enhance electrical
integration of transplanted cardiac spheroids with host myocardium and reduce the risk of
arrhythmia.
3.2 Specific aims
To collectively address these challenges, we plan to use e-SiNWs to facilitate the
self-assembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids aiming to
accelerate structural and contractile maturation of hiPSC-CMs in vitro. Our central goal
is to utilize nanowired human cardiac spheroids as a cell delivery system to improve cell
retention, survival and integration after transplantation through intramyocardium
delivery.
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Aim #1: Accelerate structural and contractile maturation of hiPSC-CMs by using
electrically conductive e-SiNWs in scaffold-free 3D spheroids system. We hypothesize
that incorporation of e-SiNWs into hiPSC cardiac spheroids can create an electrically
conductive microenvironment, leading to synchronized and enhanced contractions of
hiPSC-CMs and resulting in hiPSC-CM maturation.
Aim #2: Optimize cell number per spheroid (i.e, spheroid size) to improve the
functional maturation of hiPSC-CMs and examine the effects of electrical conductivity of
e-SiNWs on the function of cardiac spheroids. We hypothesize that the optimal cell
number per spheroid is determined by two competing factors: 1) the improved 3D cellcell interaction with the increase of cell number, and 2) the reduced oxygen supply to the
center of spheroids with the increase of cell number. In addition, we hypothesize that
electrical conductivity of e-SiNWs plays a critical role in improving the function of
cardiac spheroids, which leads to structural and contractile maturation of hiPSC-CMs.
Aim #3: Investigate the cardiac compatibility of e-SiNWs and validate the
concept that cell delivery with nanowired spheroids can improve cell retention, survival
and functional integration with host myocardium post transplantation in rat adult health
hearts. We hypothesize that the e-SiNWs are biocompatible in vivo and would be
degraded in the heart tissue over time with limited inflammatory and toxic effects. We
also hypothesize that nanowired spheroids are not prone to leak out or migrate to other
organ through blood circulation after transplantation, when compared with dissociated
single cells due to their size. In addition, spheroids can avoid the harsh enzymatic
treatment step in cell harvesting procedure of monolayer cultured single cells and reduce
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anoikis by multi-cellular interaction in the hypoxia environment post transplantation.
Most importantly, the presence of e-SiNWs within spheroids could improve their ability
to receive exogenous electromechanical pacing from the host myocardium and enhances
their integration with host tissues post-transplantation.
4. Organization of Dissertation
The following manuscript is arranged in chapters that highlight individual studies
that relate to the overall aims of my project studying cardiac regenerative medicine.
Chapter 2 focuses on application of 3D printing technology to facilitate scaffoldfree vascular tissue unit fabrication for engineered blood vessels construction. Briefly, we
proposed and developed a 3D mold-printing technology to produce biocompatible, bioinert alginate hydrogel molds, which can facilitate the fusion process of tissue spheroids
to form scaffold-free tissue-engineered constructs with defined 3D structures.
Specifically, we developed a 3D printing technology to print micro-droplets of alginate
solution on calcium-containing substrates in a layer-by-layer manner to fabricate a
variety of 3D structures. Further, we utilized this technology to fabricate ring-shaped 3D
hydrogel molds for toroid-shaped tissue unit fabrication. Tissue spheroids composed of
50% endothelial cells and 50% smooth muscle cells were robotically placed into the 3D
printed alginate molds, and they were found to rapidly fuse together into toroid-shaped
tissue units. Histological and immunofluorescence analyses indicated the critical role of
cell-secreted collagen I in tissue formation and maturation. These scaffold-free toroidshaped tissue units could be used to stack together to fabricate a blood vessel-like tube
for further clinical research and application.
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In Chapter 3, we will present my core research on the application of trace
amounts of electrically conductive silicon nanowires to induce maturation of
cardiomyocytes derived from human induced pluripotent stem cells. Briefly, we
incorporated a trace amount of e-SiNWs into rat-neonatal and hiPSC cardiac spheroids to
create electrically conductive microenvironments and induce synchronized and enhanced
contraction, which was shown to promote structural and contractile maturation. Although
powerful, the addition of e-SiNWs into the human cardiac spheroids alone may not be
able to derive fully matured hiPSC-derived cardiomyocytes. A longer term experiment
(i.e., 3 weeks) was explored, and the improvements in hiPSC-WC spheroids in
contraction amplitude and sarcomere structure seen at Day 7 were maintained through
Day 21. However, the extended culture did not indicate further improvements in the
maturation of hiPSC-derived cardiomyocytes. The sarcomere structure and nuclear shape
in hiPSC-WC spheroids and hiPSC-NC spheroids at Day 21 resembled that of the Day 7
spheroids. Our future research will combine additional chemical/physical stimuli (e.g.,
growth factors, miRNA) with e-SiNW-reinforced human cardiac spheroids to produce
fully matured hiPSC-cardiomyocytes.
In Chapter 4, we have experimentally identified the optimal cell number in the
spheroids and developed a semi-quantitative theory to explain the finding. Briefly, the
existence of the two competing factors (reduced oxygen supply vs. enhanced 3D cell
adhesion with the increase of cell number per spheroid) indicates there could be an
optimal cell number for spheroid fabrication, and our experimental data indicates that
spheroids contain ~3k cells per spheroid maximizes the benefits of the 3D environment
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of nanowired spheroids. In our previous report, we showed the addition of e-SiNWs in
the human cardiac spheroids improved cellular maturation and tissue function. However,
the role of electrical conductivity of the e-SiNWs has not been examined. In the second
part of the chapter, we prepared three types of the spheroids: spheroids without the
addition of nanowires (NC), spheroids with the addition of phosphorus doped silicon
nanowires (WCD), and undoped silicon nanowires (WCN). We studied the functions of
these three different types of spheroids and confirmed the critical role of electrical
conductivity of e-SiNWs in improving tissue function for the hiPSC cardiac spheroids.
In Chapter 5, we examined the cardiac biocompatibility of the e-SiNWs and cell
retention, engraftment and integration after injection of the nanowired hiPSC cardiac
spheroids into adult rat hearts. Our results showed that the e-SiNWs caused minimal
toxicity to rat adult hearts after intramyocardial injection. Further, the nanowired
spheroids were shown to significantly improve cell retention and engraftment, when
compared to dissociated hiPSC-CMs and unwired spheroids. The 7-days-old nanowired
spheroid grafts showed alignment with the host myocardium and development of
sarcomere structures. The 28-days-old nanowired spheroid grafts showed gap junctions,
mechanical junctions and vascular integration with host myocardium. Together, our
results clearly demonstrate the remarkable potential of the nanowired spheroids as cell
delivery vehicles to treat cardiovascular diseases.
In Chapter 6, we will summarize overall conclusions drawn from the body of our
research, discuss challenges and limitations involved in nanowired spheroids system
regarding therapeutic efficacy and potential risks, establish research directions in the
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future to apply our nanowired spheroids system in MI rat models aiming heart functional
improvement, and suggest some potential applications of nanowired spheroids system in
brain tissue regeneration.
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CHAPTER TWO
3D PRINTING FACILITATED SCAFFOLD-FREE TISSUE UNIT
FABRICATION
1. Abstract:
3D scaffold-free spherical microtissue (spheroids) holds great potential in tissue
engineering as building blocks to fabricate the functional tissues or organs in vitro. To
date, agarose based hydrogel molds have been extensively used to facilitate fusion
process of tissue spheroids. As a molding material, agarose typically requires low
temperature plates for gelation and/or heated dispenser units. Here, we proposed and
developed an alginate-based, direct 3D mold-printing technology: 3D printing microdroplets of alginate solution into biocompatible, bio-inert alginate hydrogel molds for the
fabrication of scaffold-free tissue engineering constructs. Specifically, we developed a
3D printing technology to deposit micro-droplets of alginate solution on calcium
containing substrates in a layer-by-layer fashion to prepare ring-shaped 3D hydrogel
molds. Tissue spheroids composed of 50% endothelial cells and 50% smooth muscle
cells were robotically placed into the 3D printed alginate molds using a 3D printer, and
were found to rapidly fuse into toroid-shaped tissue units. Histological and
immunofluorescence analysis indicated that the cells secreted collagen type I playing a
critical role in promoting cell-cell adhesion, tissue formation and maturation.
2. Introduction:
Tissue engineering holds remarkable promise for providing architecturally and
functionally competent replacements for tissues damaged by injury, disease and aging
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[197-203]. During the last decades, both scaffold and scaffold-free tissue engineering
strategies have been explored [184, 188, 204-207]. As the central portion of scaffoldbased tissue engineering, biomaterials can provide molecular and mechanical signals to
promote cell adhesion and proliferation, and enhance extracellular matrix (i.e., ECM)
protein deposition and tissue formation [208, 209]. Although it retains a high potential for
application, the scaffold-based approach faces numerous challenges. One of the key
problems is that the ideal material to satisfy all the requirements for tissue engineering
applications remains elusive.

In addition, scaffold materials and their degradation

products can introduce a variety of adverse effects [210]. As an alternative, bioprintingbased, scaffold-free tissue fabrication methods (i.e., organ printing) have been explored
[210, 211].

For example, Cyrille Norotte and coworkers developed a 3D printing

technology to fabricate scaffold-free, vascular tissue engineered constructs. This
approach has several distinct advantages. In particular, it can allow for the creation of
tissues with a high cell density. In addition, it can facilitate rapid tissue formation and
accelerate tissue maturation [210, 212].
One core concept of organ printing is the use of tissue spheroids as building
blocks to assemble functional tissues [210, 211]. Tissue spheroids are sphere-shaped
micro-tissues formed by spontaneous self-assembly of cell suspensions in the absence of
cell-adhesive substrates (e.g., inside agarose microwells). They hold great promise as a
bioink for organ printing because they could potentially accelerate tissue formation and
maturation [210, 211]. Notably, we have developed a robotic technology for rapid and
scalable fabrication of a large number of tissue spheroids needed for organ printing [213].

45

To date, agarose molds have been extensively used to facilitate the assembly of
tissue spheroids. The agarose molds can be fabricated by both direct (i.e., 3D printing)
and indirect (i.e., casting) methods. In the case of indirect mold fabrication, the current
technology typically involves microfabrication, including 3D printing, of the master mold
(e.g., wax mold) for the subsequent agarose mold fabrication [214]. For direct mold
fabrication, agarose has been printed into a mold to fabricate a small diameter vessel
tissue engineering construct [212]. Here, we describe a proof-of-concept method to
directly print a customized alginate mold for tissue fabrication. This has a distinct
advantage in that printing alginate does not require low temperature plates for gelation
nor heated dispenser units, as may be the case for printing agarose [212, 215, 216].
Similar to agarose, alginate is essentially a non-biodegradable, bio-inert, and
biocompatible material. These are all highly desirable characteristics for printing a mold
structure because it would maintain its shape fidelity to direct tissue morphology and not
interact with the forming tissue. Also, it allows for the fabrication of customized molds
for specific applications.
In this study, we proposed and developed a 3D mold-printing technology to
produce biocompatible, bio-inert alginate hydrogel molds, which can facilitate the fusion
process of tissue spheroids to form scaffold-free tissue-engineered constructs with
defined 3D structures. Specifically, we have developed a 3D printing technology to print
micro-droplets of alginate solution on calcium-containing substrates in a layer-by-layer
manner to fabricate a variety of 3D structures. Further, we utilized this technology to
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fabricate ring-shaped 3D hydrogel molds for toroid-shaped tissue unit fabrication. Tissue
spheroids composed of 50% endothelial cells and 50% smooth muscle cells were
robotically placed into the 3D printed alginate molds, and they were found to rapidly fuse
together into toroid-shaped tissue units. Histological and immunofluorescence analyses
indicated the critical role of cell-secreted collagen I in tissue formation and maturation.
These scaffold-free toroid-shaped tissue units could be used to stack together to fabricate
blood vessel-like tube for further clinical research and application.
3. Materials and methods:
3.1 Configuration of the Palmetto 3D bioprinter
The Palmetto 3D Printer (Fig. 2.1), is a fully automated 3D printer developed by
the Medical University of South Carolina and Clemson University, and assembled by
Izumi International (Greenville, SC). The core devices for 3D printing include a threeaxis motion control stage (Janome R2300N, Mahwah, NJ), a linear liquid dispensing
system (Fishman, Hopkinton, MA) and a digital microscope (Dino Lite, Torrance, CA) to
record the printing process. The printing hardware is housed in a sterile chamber, and the
control and monitoring systems are set outside of the chamber. This 3D printer is capable
of accurately dispensing micro-droplets of 1 µl volume per second at a resolution of 10
-flow tips with
a range of 250-840 µm inner diameters (Fishman, Hopkinton, MA) as printing nozzles. In
this application, 250 µm inner diameter tips were used as a printing nozzle for alginate
and Pasteur pipettes (diameter ~1000 µm) were used to deposit tissue spheroids.
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Figure 2.1. A picture of the Palmetto 3D Printer.
3.2 Alginate solution for 3D printing
3% sodium alginate solution (w/v) (FMC BioPolymer Co., Philadelphia, PA,
USA) was selected as ink for 3D bioprinting because: 1) it can rapidly form hydrogels at
the physiological condition by reacting with calcium ions and 2) it has suitable viscosity
for robotic liquid dispensing, while maintaining the droplet shape after dispensing (i.e., a
high contact angle). To rapidly crosslink micro-droplets of alginate solution into
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hydrogel, 100 mM CaCl2 in 2% gelatin solution were utilized to prepare printing
substrates according to the report of Brugger and coworkers [217].
3.3 Cell culture and spheroids fabrication
Human aortic smooth muscle cells (hSMCs) and human umbilical vein
endothelial cells (HUVECs) (passage 3) were purchased from Lonza (Catalogue number:
CC-2571 and C2517A respectively; Lonza, Basel, Switzerland). They were cultivated in
media as suggested by the manufacturer (cell culture media: Lonza CC-3162 and CC3182, respectively). At passage 5, the two cell types were mixed at a 1:1 ratio and then
seeded into non-adhesive agarose hydrogels molds containing 35 concave recesses with
hemispheric bottoms (400 µm diameter, 800 µm deep) to facilitate the formation of tissue
cell spheroids.
The agarose hydrogel molds were prepared using commercial master micro-molds
from Microtissues, Inc (Providence, RI) as negative replicates. 330 µl 1% sterile agarose
solution was pipetted into the master micro-molds to form an agarose hydrogel mold,
which was then carefully detached from the master mold and transferred into one well of
a 24 well tissue culture plate.
The schematic presentation of cell spheroids fabrication is shown in the Fig. 2.
3M hSMCs (Passage 5) and 3M HUVECs (Passage 5) were suspended in 2ml media
composed of 50% hSMC media and 50% HUVEC media. 75 µl of the cell suspension
was pipetted into each agarose mold. After the cells had settled down into the recesses of
the mold (10 min), additional media was added (1.0ml/well for a 24 well plate) and

49

exchanged as needed. In this way, 840 cell spheroids with diameter 300 µm can be
routinely prepared using a 24 well plate containing 24 agarose hydrogel molds.

Figure 2.2: A: Schematic presentation of the protocol for spheroid fabrication by seeding
the cells suspension into non-adhesive agarose model; B: bright field images of a 3-dayold tissue spheroids in low and high magnification. Scale bar is 200μm.

3.4 Histological and immunofluorescence analysis of tissue units
The printed tissue units were fixed for 30 minutes in 4% paraformaldehyde
solution. After dehydration, tissues were processed for paraffin infiltration and
embedding and sectioned. The paraffin sections were stained with hematoxylin–eosin and
the images were captured using light microscope (Olympus BX40 equipped with a DP25
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digital camera). For immunofluorescence staining, primary antibodies were rabbit antihuman collagen I (Cedarlane USA, Burlington, NC), mouse anti human α-smooth muscle
actin (Sigma Aldrich, St. Louis, MO), and secondary antibodies were Alexa Fluor 546
and Alexa Fluor 647 (Invitrogen, Carlsbad, CA). First, a heat-induced epitope retrieval
step was performed by 5 minutes pressure-cooking of the deparaffinized sections in 1.6 L
PBS and 15ml antigen unmasking solution (H-3300, Vector Laboratories, Burlingame,
CA). The sections were then permeabilized in a 0.1% Triton X-100 in PBS for 15 min at
ambient temperature. After washing in PBS (3x), the tissues were incubated in
Background Buster (Innovex Biosciences, Richmond, CA) for 30 minutes at ambient
temperature. After washing in PBS (3 × 5 min), sections were incubated with primary
antibodies diluted in 1.0% BSA in PBSA (PBS + 0.01% sodium azide) overnight in
refrigerator. After washing in PBS (3 × 5 min), tissues were incubated with coordinate
secondary antibodies diluted in 1.0% BSA in PBSA for 1h at ambient temperature. After
copious washing in PBS, nuclei were counterstained with DAPI (Molecular
Probes/Invitrogen, Eugene, OR) diluted in PBSA for 15 min at ambient temperature.
Following the final wash procedure, individual slides were mounted under cover glass
using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA). A TCS SP5 AOBS laser
scanning confocal microscope (Leica Microsystems, Inc., Exton, PA) was used to obtain
fluorescent images.
4. Results and discussion
4.1 Optimization of printing parameters and printing algorithm
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Alginate has been extensively used in the 3D bioprinting because it can robustly
form cell compatible hydrogels in physiological conditions [218, 219]. Notably, native
alginate is not adhesive for cells and is also not broken down enzymatically in mammals
[220, 221]. These are all highly desirable characteristics as molding materials to facilitate
tissue formation. As a bio-inert material, alginate does not compete with cell-cell
adhesion and therefore promote fusion process of tissue spheroids. In addition, it has
limited biodegradability and sufficient mechanical property for molding [222].
In this work, we have developed a technology to robotically deposit microdroplets of alginate solution onto calcium-containing gelatin substrates to construct 3D
hydrogels (Fig. 2.4) [218]. A substrate of 100 mM CaCl2 in 2% gelatin solution were
prepare to serve as a reservoir for calcium ion. A lower concentration of calcium ions in
the gelatin solution can lead to slow gelation process and undefined shape of
microdroplets. It is important to note that some cell types may be sensitive to the free
calcium ion that slowly diffuses from the physically crosslinked alginate mold [223, 224].
However, auxiliary tests confirmed high viability (>90%) post-printing using Ca2+sensitive porcine chondrocytes with an atypical calcium concentration (100mM) (Fig.
2.3) [225, 226]. By using a layer-by-layer approach, we can fabricate hydrogels with a
number of defined 3D structures. This has been attributed to the upward diffusion of
calcium ion from the gelatin substrates (Fig. 2.4) [217].
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Figure 2.3: Live dead staining indicated high viability (>90%) post-printing using
Ca2+sensitive porcine chondrocytes suspended in an alginate solution printed on a high
calcium concentration-containing gelatin substrate (100mM).
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Figure 2.4: Schematic presentation of 3D alginate hydrogel printing on calciumcontaining gelatin substrate. Adapted from the reference [217].
To ensure a high consistency among the alginate hydrogel micro-droplet formed
on calcium-containing substrates, we have optimized both concentration of alginate
solution and the volume of each droplet. A 3% sodium alginate solution (w/v) was found
suitable for 3D printing because 1) it can rapidly form hydrogel micro-droplets on the
calcium ion-containing gelatin substrates, and 2) it has proper viscosity for robotic liquid
dispensing while maintaining the droplet shape after dispensing. The dispensing volume
for 3% (w/v) alginate solution was set as 1 µl in this study because a smaller volume (0.5
µl) can give rise to larger variation among printed droplets (Fig. 2.5). To prevent the
coalescence of newly printed droplets with their neighbors (Fig. 2.6a), we developed a
printing algorithm to ensure that no printed droplet lands next to an un-gelled droplet and
the final printed product maintained a defined structure as designed (Fig. 2.6b) [217].
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Figure 2.5: The different size of alginate microdroplets (A=0.5, B=1.0, and C=1.5µl)
printed on calcium containing gelatin substrates. D: The averaged diameter of alginate
microdroplets with different volume.
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Figure 2.6: (a) Printing algorithm before optimization: printing microdroplets of alginate
solution next to each other can lead to the coalescence of newly printed droplets. (b)
Printing algorithm after optimization: printing microdroplets of alginate solution in 4
steps to to ensure that no printed droplet lands next to an un-gelled droplet and the final
printed product can maintain a defined structure as designed.

To prove the feasibility of 3D hydrogel printing, we designed and printed
hydrogels with different 3D geometries (cube, square frame, and pyramid). Both the
printing scheme and the printed alginate hydrogel structures are shown in Fig. 2.7. This
demonstrates the 3D hydrogel printing we developed here can allow for a proof-ofconcept for the fabrication of alginate hydrogels with defined 3D structures. To quantify
the printing accuracy, we measured the dimensions of a 3D printed cube structure and
compared them to the design. As shown in Figure 2.7D, the cube structure was designed
to have dimensions of 9.6 x 9.6 x 1.75 mm (X, Y, Z), which is a result of a printing
design with dimensions of 9 mm x 9 mm (based on the center of dot) and a Z dimension
defined by 5 layers. Typically, the first layer of alginate, which is printed onto the gelatin
surface, has a height of ~0.7-0.8 mm, while the second and above layers of alginate,
which is printed onto alginate surface, have heights of ~0.2-0.3 mm. The actual printed
cube structure has dimensions of 9.6 x 9.8 x 1.8 mm, and it thus can be defined as an
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accurate printed structure [227]. Using the cube structure as a model, overnight culture in
PBS resulted in an average increase in dimension (X, Y) of 1.8%, thus maintaining the
designed parameters. This demonstrates the 3D hydrogel printing we developed here can
allow for a proof-of-concept for the fabrication of alginate hydrogels with defined 3D
structures. Given the quickly advancing field in biofabrication, improved parameters and
limitations to bioprinting must be further optimized to achieve the highest needed control.

Figure 2.7: Microdroplets facilitated 3D printing alginate hydrogels with different
geometries (cube (a), square frame (b) and pyramid (c)). : the left is the schematic
presentation of 3D printing algorithm used to print 3D structures shown in the right. Each
layer was printed using an multi-step algorithm similar to the one shown in Figure 3. The
optimal expected dimensions of 9.6 x 9.6 x 1.75 mm were based on a design of 9 mm x 9
mm in the X and Y dimension (measured from the dot center) and a Z dimension defined
by 5 layers (d). The scale bar for (a),(b), and (c) is 1 mm. The scale bar for (d) is 2 mm.
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The blue, green, yellow, grey and red represent the 1st, 2nd, 3rd, 4th, and 5th layer of
bioprinted alginate microdroplets, respectively.

4.2 3D Printing alginate molds and robotically seeded spheroids
To utilize the 3D printed alginate hydrogel molds to facilitate fusion processes of
tissue spheroids, we have designed ring-shaped alginate molds to fabricate toroid-shaped
tissue units, which can be utilized to produce tissue engineering constructs (Fig 2.8)
[228]. To prepare the mold, 24 layers of alginate hydrogel was printed in a layer-by-layer
fashion to generate ring-shaped molds with inner diameter 5 mm, outer diameter 7 mm
and height 3 mm over a time span of approximately 30 min (~30 secs/layer with ~1 min
gelation time between layers). Subsequently, 840 spheroids (average diameter ~300 µm)
composed of 50% hSMCs and 50% HUVECs was robotically seeded into the mold to
achieve a connected tissue [229, 230]. Tissue spheroids were selected as bioink for 3D
bioprinting in this study because they have the potential to accelerate tissue formation
and maturation [210, 211].
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Figure 2.8: Schematic presentation (a) and actual product (b) of 3D alginate hydrogel
printing for tissue unit fabrication using vascular spheroids (i.e., containing smooth
muscle cells and endothelial cells). Scale bar is 1mm

To utilize the Palmetto 3D Printer to robotically seed the cell spheroids, a variety
of dispensing nozzles have been examined. Interestingly, Pasteur pipettes have been
found most suitable for robotic dispensing of cell spheroid due to the smooth transition
from upper portion of the pipette to the tip of the pipette (i.e., dispensing nozzle) and the
diameter of pipette tip (~1000 µm) (Fig. 2.9). Customized Pasteur pipettes with a smaller
tip diameter (~750 µm) were found difficult to seed cell spheroids since spheroids often
blocked the dispensing nozzle.
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Figure 2.9: A picture showing the pasture pipette printing tip loaded with tissue
spheroids for dispensing.

4.3 Fabrication of toroid-shaped tissue units
After seeding into ring-shaped molds, the construct was moved to an incubator for
15 min to melt the calcium-containing gelatin. The melted gelatin solution was
immediately replaced with fresh cell culture media to minimize exposure to high calcium
concentration environment. The cell spheroids quickly began fusing into toroid-shaped
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tissue units after 3 days culture in a reliable manner, which is in agreement with previous
research [210, 212]. Notably, the quality of the 3D printed mold can effectively affect
the shape of the formed tissue units. These tissue units were cultivated for an additional
13 days to facilitate their maturation. To examine the fusion and maturation process,
histological and immunofluorescence analysis were conducted. At day 4, the boundaries
of many individual spheroids were clearly visible (Fig. 2.10a, b, j, and k) with many open
spaces between spheroids (white arrow in Fig 2.10k). Notably, collagen I was often found
between the boundaries of two adjacent spheroids (Fig. 2.10k and l).

As a structural

ECM protein with cell adhesion motifs (e.g., RGD peptide sequence), collagen I was
thought to function as adhesive to facilitate the fusion process of the spheroids. At day 8,
most spheroids were found to be closely associated to each other, while gaps between
some spheroids were still found (white arrows in Fig. 2.10d and e). At day 16, the
spheroids had fused into a complete tissue with abundant, newly synthesized collagen I
(Fig. 2.10m). In addition, the collage I had filled all the gaps between spheroids (white
arrows in Fig. 2.10o). This data indicates collagen I plays a critical role in promoting cellcell adhesion, tissue formation and maturation. This is consistent with the previous
report that cell-adhesive ECM proteins can crosslink adjacent cells together by binding to
their cell surface receptor (e.g., integrin) and promote tissue cohesion [231]. In addition,
the day 16-tissue units were stained for smooth muscle cells and endothelial cells (Fig
2.10p-r). The high expression of specific molecular markers for both cell types (i.e.,
smooth muscle actin and VWF) indicates high cell viability and normal cell behavior
after 16-day cell culture.

61

a

b

c

d

e

f

g

h

i

j

k

l

m

n

o

p

q

r

SMA
CollagenⅠ
DAPI

SMA
CollagenⅠ
DAPI

SMA
Anti VWF
DAPI

62

Figure 2.10: Histological and immunofluorescence analysis of the tissue units cultured
for 4, 8 and 16 days. (a,b,c) H&E staining for tissue units cultured for 4 days at 10x, 20x
and 40x magnification, respectively. (d,e,f) H&E staining for tissue units cultured for 8
days at 10x, 20x and 40x magnification, respectively. (g,h,i) H&E staining for tissue
units cultured for 16 days at 10x, 20x and 40x magnification, respectively. (j,k,l)
immunofluorescence analysis of tissue units cultured for 4 days at 20x, 40x and 63 x
magnification. (m,n,o) immunofluorescence analysis of tissue units cultured for 16 days
at 20x, 40x and 63 x magnification. (p,q,r) immunofluorescence analysis of tissue units
cultured for 16 days at 40x magnification for smooth muscle actin, anti VWF and merge
picture. Scale bar is 100μm

5. Conclusion
3D printing holds great promise for rapid, scalable fabrication of tissue
engineering constructs. Here, we have developed a robust technology to robotically 3D
print alginate hydrogel molds to facilitate fusion process of tissue-cell spheroids for the
fabrication of scaffold-free tissue units. To this end, we have optimized both printing
parameters and printing algorithm for constructions of alginate hydrogels with defined
3D architectures. In addition, we also utilized the Palmetto 3D Printer to robotically place
tissues spheroids into the alginate molds to rapidly fuse into toroid-shaped tissue units.
Our system has displayed the proof-of-concept for using alginate as a 3D printable,
molding material to facilitate scaffold-free tissue unit fabrication. The approach
developed in this manuscript could be used to fabricate various open-structured molds
(e.g., honeycomb-shaped molds) for the construction of complex structures [214]. Further
calibrations and improvements to the system are needed for the fabrication of non-openstructured molds to prepare tissues with more complex shapes, such as small diameter
blood vessels, which require printing spheroids and alginate in a more controlled manner.
Given the rapid development in printing technology, we expect that the technology

63

developed here can be used to fabricate tissues with complex structures for tissue
engineering and drug testing applications.
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CHAPTER THREE
SILICON NANOWIRE-INDUCED MATURATION OF CARDIOMYOCYTES
DERIVED FROM HUMAN INDUCED PLURIPOTENT STEM CELLS
1. Abstract:
The current inability to derive mature cardiomyocytes from human pluripotent
stem cells has been the limiting step for transitioning this powerful technology into
clinical therapies. To address this, scaffold-based tissue engineering approaches have
been utilized to mimic heart development in vitro and promote maturation of
cardiomyocytes derived from human pluripotent stem cells. While scaffolds can provide
3D microenvironments, current scaffolds lack the matched physical/chemical/biological
properties of native extracellular environments. On the other hand, scaffold-free, 3D
cardiac

spheroids

(i.e.,

spherical-shaped

microtissues)

prepared

by

seeding

cardiomyocytes into agarose microwells were shown to improve cardiac functions.
However, cardiomyocytes within the spheroids could not assemble in a controlled
manner and led to compromised, unsynchronized contractions. Here we show, for the
first time, that incorporation of a trace amount (i.e., ~0.004% w/v) of electrically
conductive silicon nanowires (e-SiNWs) in otherwise scaffold-free cardiac spheroids can
form an electrically conductive network, leading to synchronized and significantly
enhanced contraction (i.e., >55% increase in average contraction amplitude), resulting in
significantly more advanced cellular structural and contractile maturation.
2. Introduction:
Cardiovascular disease is the leading cause of death worldwide [232]. Due to the
limited regenerative capacity of adult hearts, human embryonic stem cell (hESC)- and
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human induced pluripotent stem cell (hiPSC)-based therapy has been the focus of a
significant amount of research [4, 233]. This is due to their proven capacity to produce
de novo cardiomyocytes. However, the current cardiomyocytes derived from hESCs and
hiPSCs retain an immature phenotype, including poorly organized sarcomere structures
(i.e., functional units of the contractile machinery) [234-236]. Thus, these cells lack the
ability to generate sufficient, anisotropic forces as adult cardiomyocytes. This has led to
difficulties for electrical and mechanical integration with human adult myocardium [153,
174], which has limited the applications of hESC and hiPSC technology for cardiac
repair.
During embryonic development, environmental factors (e.g., extracellular matrix,
growth factors, mechanical and electrical stimulation) have major effects on the
maturation of cardiomyocytes. To mimic the maturation process in vitro, hESC- and
hiPSC-derived cardiomyocytes have been mixed with scaffolding materials (e.g.,
Matrigel and collagen type I gel) to prepare cardiac tissue-engineered constructs and then
conditioned with electrical and/or mechanical stimulation [234, 237-239]. While these
scaffolds can provide tissue-like 3D microenvironments, current scaffolding materials
lack the matched physical/chemical/biological properties with the native extracellular
environments during heart development. On the other hand, scaffold-free, 3D cardiac
spheroids have emerged as promising model systems to mimic cardiac tissues [184, 187].
Unlike in the myocardium, cardiomyocytes in the spheroids do not organize in a
controlled manner and led to compromised, unsynchronized contractions. To improve
this, we reasoned the incorporation of e-SiNWs in cardiac spheroids can facilitate the
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formation of an electrically conductive network, and provide synchronized and improved
electrical/mechanical signals to advance structural and contractile maturation of the
cardiomyocytes (Fig. 3.1 and Fig. 3.2).

100µm

Figure 3.1. DIC image of the e-SiNW-reinforced human cardiac spheroids shows the
uniform distribution of e-SiNWs within the spheroids at a 1:1 ratio (number of
cells/number of e-SiNWs).
3. Materials and Methods:
3.1 Electrically conductive silicon nanowire fabrication and harvesting.
Single-crystalline SiNWs were synthesized using the nanocluster-catalyzed
vapor-liquid-solid method described previously in a quartz tube connected to a gas
manifold and vacuum pump and heated by a temperature controlled tube furnace.1
Monodisperse gold nanoparticles (100 nm, Ted Pella) were dispersed on SiO2/silicon
substrates, which were placed within the central region of the quartz tube reactor. The
SiNWs were synthesized at 470-485 oC using silane (SiH4) as the silicon reactant source,
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20µm

H2 as the carrier gas, and phosphine (PH3, 1000 ppm in H2) as the n-type dopants. In a
typical synthesis of uniform n-type, 100 nm SiNWs, the flow rates of SiH4, PH3 and H2
were 1-2, 2-4 and 60 standard cubic centimetres per minute, respectively, and the total
pressure 40 torr. The nanowires were collected from the oxidized silicon substrates by
sonication in isopropanol for 1 min followed by centrifugation to obtain SiNWs with an
average dimension of 100 nm diameter and 10 µm length. The electrical conductivity of
the SiNWs were measured by using four-probe transport measurement.
3.2 Cell harvest and culture.
Rat-neonatal cardiac cells were isolated from 2-day-old Sprague-Dawley rats by
using the neonatal isolation kit (Worthington Biochemical Corporation, Lakewood, NJ).
Rat-neonatal cardiac cells and spheroids were cultured in Dulbecco's Modified Eagle
Medium (DMEM, 4500 mg/L glucose) (Thermo Scientific, Pittsburgh, PA) containing
10% heat inactivated fetal bovine serum (HI FBS) (Life Technologies, Carlsbad, CA),
1% penicillin-streptomycin (Life Technologies, Carlsbad, CA), and 1% non-essential
amino acids (Life Technologies, Carlsbad, CA). hiPSC-derived cardiomyocytes (iCell
Cardiomyocytes, Cellular Dynamics International, Madison, WI, USA) were cultured
according to the manufacturer's protocol. Briefly, hiPSC-derived cardiomyocytes were
plated on 0.1% gelatin coated 6-well plates in iCell Cardiomyocyte Plating Medium
(Cellular Dynamics International) at a density of about 3 × 105 to 4.0 × 105 cells/well
and incubated at 37 °C in 5% CO2 for 4 days. Two days after plating, the plating medium
was removed and replaced with 4 mL of iCell Cardiomyocytes Maintenance Medium
(Cellular Dynamics International). After 4 days of monolayer pre-culture, cells were
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detached using trypLE Express (Gibco Life Technologies, Grand Island, NY) and
prepared for spheroid fabrication.
3.3 Spheroid fabrication and electrical stimulation.
The agarose hydrogel molds were prepared using commercial master micro-molds
from Microtissues, Inc (Providence, RI) as negative replicates to create non-adhesive
agarose hydrogels molds containing 35 concave recesses with hemispheric bottoms (800
µm diameter, 800 µm deep) to facilitate the formation of tissue cell spheroids. 330 µL
1% sterile agarose solution was pipetted into the master micro-molds and was then
carefully detached after gelation from the master mold and transferred into one well of a
24-well tissue culture plate. The schematic presentation of cell spheroids fabrication is
shown in the Fig. 2C. A suspension of rat-neonatal cardiac cells and e-SiNWs in media
was prepared at a 1:1 ratio (number of cells/number of SiNWs) with a concentration of
5.0 x 106 cells/mL. Similarly, hiPSC-derived cardiomyocytes were mixed with e-SiNWs
in the Maintenance media at a 1:1 ratio (number of cells/number of SiNWs) with a
concentration of 3.0 x 106 cells/mL. Approximately 75 µl of the cell/e-SiNW suspension
(rat-neonatal cardiac cells, 5.0 x 106 cells/mL; hiPSC-CMs, 3.0 x 106 cells/mL) was
pipetted into each agarose mold. After the cells had settled down into the recesses of the
mold (10 min), additional media was added (5 mL) and exchanged every 2 days for the
length of the experiment. After 4 days of spheroid culture, an electrical stimulation
treatment (C-Pace unit, Ion Optix, Milton, MA 02186) was started for designated groups
for 7 days (15 V, 1 Hz, 2 ms). For the long term culture experiment of hiPSC cardiac
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spheroids, the electrical stimulation treatment was performed for 21 days for the
designated groups after the initial 4 days of spheroid culture.
3.4 Video and image analysis of beating spheroids.
Videos of 6 spheroids from each group were recorded starting after the initial 4
days of spheroid culture using Zen 2011 software (Zeiss, Göttingen, Germany) with
capture rate of 14 frames per second. Then the videos were converted to a series of TIFF
format pictures by Adobe Premiere (Adobe, San Jose, CA). Threshold edge-detecting in
ImageJ software (National Institutes of Health) was used on high contrast spheroid
pictures and graphed to realize contraction profiles, from which other quantifiers were
calculated (i.e., fractional area change and beats per minute).
3.5 Histological and immunofluorescent analysis of spheroids and cells.
Freshly collected spheroids (~30-35) were placed onto a pre-labeled tissue base
mold and the entire tissue block was covered with OCT. Immediately, the base mold
containing spheroids was transferred into pre-cooled ethanol with dry ice to ensure that
the spheroids were frozen completely. By using the cryotome, the frozen spheroids block
were sectioned into 7 µm thickness layers onto glass slides for immunohistochemistry.
The sections were fixed with pre-cooled acetone (-20 °C) for 10 min. The fixative was
poured off and the acetone was allowed to evaporate from the sections for 20 min at room
temperature. After washing (3 times at 5 min) in PBS with 0.1% Triton X-100 (PBST),
100 µl blocking buffer was added (10% goat serum in PBS) onto the sections of the
slides and incubated in a humidified chamber at room temperature for 1 h. Sections were
incubated with appropriately diluted primary antibody: alpha sarcomeric actinin (Abcam,
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Cambridge, UK), troponin I (Santa Cruz, Dallas, TX), connexin-43 (Sigma Aldrich, St.
Louis, MO) and beta myosin heavy chain (Millipore, Billerica, MA) overnight at 4 °C.
After washing in PBST (3 times at 5 min), tissues were incubated with coordinate
secondary antibodies diluted in PBST for 1h at ambient temperature. After washing in
PBST (3 times at 5 min), nuclei were counterstained with DAPI (Molecular
Probes/Invitrogen, Eugene, OR) diluted in PBST for 15 min at ambient temperature.
Following the final wash procedure (PBST, 3 times at 5 min), glass cover slips were
added to the slides using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA).
Finally, TCS SP5 AOBS laser scanning confocal microscope (Leica Microsystems, Inc.,
Exton, PA) was used to get fluorescent images. Fluorescent protein expression was
calculated as the fluorescence area coverage divided by the number of nuclei.
3.6 TUNEL staining for the frozen section of spheroids.
In Situ Cell Death Detection Kit (Roche, Penzberg, Germany) was used to
determine the viability of the cell in the frozen section of spheroids based on the protocol
from website of Roche. Briefly, the frozen sections of spheroids were fixed with 4%
paraformaldehyde in PBS for half hour at room temperature. Following washing in PBS
for 30 minutes, samples were incubated in a permeabilization solution (0.1% Triton X100 and 0.1% sodium citrate in PBS) for 2 minutes on ice. Then 50ul of the TUNEL
reaction mixture were added to samples and incubated in 37 °C for 1 hour. After washing
in PBST (3 times at 5 min), nuclei were counterstained with DAPI (Molecular
Probes/Invitrogen, Eugene, OR) diluted in PBS for 15 min at ambient temperature.
Following the final wash procedure (PBS, 3 times at 5 min), glass cover slips were added
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to the slides using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA). Finally,
TCS SP5 AOBS laser scanning confocal microscope (Leica Microsystems, Inc., Exton,
PA) was used to get fluorescent images.
3.7 Western blotting analysis.
Following 7 days of cell culture with or without electrical stimulation, 30-35
spheroids from each rat-neonatal group were harvested from agarose molds. After
centrifugation and washing by PBS once, 30 µl lysis buffer with 1% protease and
phosphatase inhibitor cocktails (Pierce Biotechnology, Rockford, IL) was added into the
vials containing pellet of spheroids. Thereafter, the mixture was homogenized by the
FastPrep24 instrument (MP Biomedicals, Santa Ana, CA ) to break down spheroids into
single cells. After 30 minutes to lyse cells on ice, then tubes were centrifuged for 10 min
at 10 000g at 4 °C and the supernatant was collected as protein solution. After
quantifying the protein concentration by using the bicinchoninic acid methods, the
protein solution was mixed with 4x LDS sample loading buffer (Pierce Biotechnology)
and boiled for 5 min. Protein samples of equal amount were separated in a 4%–12% Bis
Tris NuPAGE gel (Life Technologies, Carlsbad, CA). Proteins were transferred to a
PVDF membrane (Life Technologies) and blocked with 5% nonfat milk for one hour,
followed by incubation with the following primary antibodies: alpha sarcomeric actinin
(Abcam, Cambridge, UK), connexin-43 (Sigma Aldrich, St. Louis, MO), beta myosin
heavy chain (Millipore, Billerica, MA), and GAPDH (Sigma Aldrich) overnight at 4°C.
Blots were then probed with horseradish peroxidase-labeled secondary antibodies (Cell
Signal, Danvers, MA) and visualized by an enhanced chemiluminescence detection kit
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(Amersham Pharmacia Biotech (GE Healthcare), Pittsburgh, PA). The intensity of each
signal was analyzed by using ImageJ software.
3.8 Spheroid spreading assay.
Spheroids were seeded onto 0.1% gelatin-coated glass cover slips and incubated
at 37 °C, 5% CO2, 20% O2. Cell culture medium was changed every other day. After 12
days culture, the spheroids spread into a monolayer structure, which was suitable for
immunofluorescent staining for high resolution, single cell, sarcomere structure analysis.
3.9 Single cell cardiomyocyte analysis.
The average sarcomere length was defined as spacing between α-SA striations
and was measured using black and white renderings of confocal α-SA-stained
cardiomyocyte images, according to previous methods.2 Using ImageJ, fluorescence
profiles along lines passing perpendicular through 3 different striated regions of at least 9
cells, containing at least 6 consecutive sarcomere structures, were measured and divided
by the number of sarcomeres (space between profile peaks). Z-line width, as previously
explored,3 was measured directly on α-SA-stained cardiomyocyte images in 12 cells with
15 measurements per cell. Z-line alignment was defined to establish a sensitive method
for sarcomere alignment to reflect the enhanced contraction and synchronization.
Calculations were made using an ImageJ plug-in, OrientationJ, which creates an
orientation distribution output.4 The area under the curve at ±20° the peak orientation
degree divided by the total area under the curve was established as the fraction Z-line
alignment.
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3.10 Calcium transient imaging of cardiac spheroids.
Fluo-4 Direct Calcium Assay Kits (Life Technologies, Carlsbad, CA) was used to
label calcium ion in the whole spheroids based on the protocol from Life Technologies.
Briefly, spheroids were seeded onto 0.1% gelatin-coated glass cover slips and incubated
at 37 °C, 5% CO2, 20% O2. Cell culture medium was changed every other day. After 4
days culture, the spheroids were rooted on the cover slips. Then cover slips with the
spheroids were put into 12 wells plates with 2 ml calcium dye solution per well and
incubated at 37 °C, 5% CO2, 20% O2 for 1h. TCS SP5 AOBS laser scanning confocal
microscope (Leica Microsystems, Inc., Exton, PA) was used to collect the videos of the
calcium transient of whole spheroids with a capture rate of 14 frames per second. Finally,
we used the software of LAS AF from Leica to conduct the quantification of videos
collected by confocal.
3.11 qRT-PCR analysis.
Total RNA was isolated according to the kit and protocol of an RNeasy Micro Kit
(Qiagen, Vinlo, Netherlands) with the addition of the QIAShredder (Qiagen) during the
homogenization step for spheroids. For each group, 20-35 spheroids were used for RNA
isolation. At least 25 ng of total RNA for each group was subjected to cDNA synthesis
using the Bio-Rad (Hercules, USA) iScript cDNA synthesis kit. qRT-PCR step was
performed using “best coverage” validated Taqman primers (Life Technologies,
Carlsbad, USA) in 10 μl reactions for the following genes: CACNA1C, CACNA1G,
GAPDH, GJA1, MYL2, ACTB. Data was normalized as the change in cycle threshold
(Ct) to GAPDH and ACTB (dCt) and analyzed using, mRNA expression = 2^(-(dCt)).
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3.12 Transmission Electron Microscopy.
SiNWs were gently sonicated in isopropyl alcohol (IPA) and dispersed onto lacey
carbon grids (Ted Pella Inc.). TEM imaging was conducted using a 300kv FEI Tecnai G2
F30 Super Twin Transmission Electron Microscope.
Spheroids were fixed with 2.5% glutaraldehyde, postfixed in PBS buffered 1%
osmium tetroxide with 1.5% K+ ferricyanide, dehydrated in graded ethanol and
Acetonitrile, and embedded in PolyBed 812 (Polysciences). 70-nm thick spheroid
sections were prepared by using a Leica UltraCut R and a diamond knife, stained with
Hanaichi Pb citrate and uranyl acetate, and imagined using a JOEL 200 CX transmission
electron microscope.
3.13 Statistics Analysis
Differences between experimental groups were analyzed using a independent
Student T-tests and one-way ANOVA followed by Tukey‟s post-hoc test. P< 0.05 was
considered significantly difference for all statistical tests.
4. Results and Discussion:
This approach has the distinct advantage in that only a trace amount of e-SiNWs
is utilized, minimizing the adverse effects of traditional scaffolds, such as unmatched
physical/chemical/biological properties with the native extracellular environments during
heart development. e-SiNWs were selected because of their controllable electrical
conductivity, tunable dimensions, and convenient surface tailorability [240, 241].
Although SiNWs might not be well known as biocompatible materials, in vitro
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biocompatibility studies have shown no significant cytotoxic effects for both undoped
and n-type SiNWs [242]. Further, the recent research showed SiNWs are biodegradable,
and their degradation products are found mainly in the form of Si(OH)4 and are
metabolically tolerant in vivo [195, 243-246]. This makes them advantageous over other
non-biodegradable, electrically conductive nanomaterials (e.g., gold nanowires, carbon
nanotubes and nanofibers), especially for potential in vivo applications.

A

B

cardiac spheroids
without e-SiNWs

e-SiNW-reinforced
cardiac spheroids
Figure 3.2. Schematic overview of e-SiNWs reinforced cardiac spheroids. (A)
Structure of cardiac spheroids without (top) or with (bottom) e-SiNWs: cardiac cells
(red), nuclei (blue) and e-SiNWs (black). e-SiNWs (bottom) can act as bridges to
electrically connect cardiac cells and create electrically conductive microenvironments
throughout the spheroids. (B) Cardiomyocytes in the cardiac spheroids without e-SiNWs
(top) form electrically isolated small beating clusters with random contractions, while
cardiomyocytes in the e-SiNWs-reinforced cardiac spheroids can produce synchronized
and enhanced contractions (bottom). Arrows represent the directions of contractile forces.
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In this study, n-type SiNWs (Diameter ≈ 100 nm; length ≈ 10 m;
Silane/Phosphane = 500) were prepared according to the previously established protocol
[247] (Fig. 3.3A, B). The doping ratio and diameter of the e-SiNWs were chosen to
obtain a high conductivity (150 - 500 S/m) compared to cell culture medium (~1.75
S/m) and myocardium (~0.1 S/m) to create highly electrically conductive
microenvironments within spheroids[191, 248]. The length of the SiNWs was selected to
inhibit cell internalization. As shown in the Fig. 3.3C-E, both rat neonatal cardiac cells
and cardiomyocytes derived from human induced pluripotent stem cells have been used
to prepare e-SiNWed-reinforced cardiac spheroids. The rat left-ventricle neonatal cardiac
cells were utilized in the initial study due to their ready availability. They were mixed
with e-SiNWs at a ratio of around 1:1 (number of cells/number of e-SiNWs) and seeded
into agarose microwells to prepare e-SiNW-reinforced rat-neonatal cardiac spheroids
(Fig. 3.3C, D and Fig. 1). The ratio between e-SiNWs and cardiac cells was selected to
minimize the interference of e-SiNWs on the self-assembly process of cardiac cells due
to their high density and high stiffness (Fig. 3.4). Notably, TEM images of e-SiNWreinforced cardiac spheroid indicated the e-SiNWs located in the extracellular space in
the spheroids, which supported our selection of dimensions of e-SiNWs (Fig. 3.3E).
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Rat-neonatal cardiac
cells / hiPSC-derived
cardiomyocytes

Ratio

1

e-SiNWs

:

1

Mix

E
B
Seed into agarose
molds to form
spheroids
4 days pre-culture

+
Rat-neonatal cardiac
cells : electrical
stimulation
(15 V/ 1 Hz/ 2 ms)

hiPSC-derived
cardiomyocytes:
no electrical
stimulation

Figure 3.3. Electrically conductive silicon nanowires (e-SiNWs) introduced to
cardiac spheroids. (A) Transmission electron microscopy (TEM) image of an e-SiNW
(diameter ≈ 100 nm; length ≈ 10 µm) and (B) high-resolution TEM image of the e-SiNW.
(C) Schematic representation of spheroid fabrication using rat-neonatal cardiac cells or
human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes at a ratio 1:1
(number of cells/number of e-SiNWs) with or without electrical stimulation. (D) Bright
field image of hiPSC spheroid with e-SiNWs. (E) TEM image of hiPSC spheroid with eSiNWs, black arrow indicates the e-SiNWs located in the extracellular area. Scale bars:
(A) = 0.2 µm; (B) = 5 nm; (D) = 100 µm; (E) = 500nm.

Although few spontaneous contractions have been found in many rat-neonatal
cardiac spheroids after 4 days in culture, both contraction frequency and amplitude can be
significantly enhanced by electrical stimulation (Fig. 3.5A-D). To recapitulate the
electrical pulses of native myocardium, the spheroids were stimulated at 15 V at 1 Hz, 2
ms[249]. To independently investigate the effects of e-SiNWs and electrical stimulation,
four samples have been prepared and examined: rat-neonatal cardiac spheroids without e-
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SiNWs and without electrical stimulation (i.e., r-NC spheroids), rat-neonatal cardiac
spheroids with e-SiNWs but without electrical stimulation (i.e., r-WC spheroids), ratneonatal cardiac spheroids without e-SiNWs but with electrical stimulation (i.e., r-NS
spheroids), and rat-neonatal cardiac spheroids with e-SiNWs and with electrical
stimulation (i.e., r-WS spheroids).

Figure 3.4. Changes in diameter of rat-neonatal cardiac spheroids using different ratios
of cells to e-SiNWs on Day 0; n = 6 spheroids per condition. Asterisks (*) represent
statistical significance with p<0.05; error bar represents standard deviation.

Video analysis revealed that the chronically stimulated spheroids (i.e., r-NS and rWS spheroids) contract regularly and periodically, while the non-stimulated spheroids
(i.e., r-NC and r-WC spheroids) did not contract consistently. As shown in Fig. 3.5A-D,
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the average contraction amplitude gradually increased over time for the chronically
stimulated spheroids (i.e., r-NS and r-WS) and was several-fold higher than the nonstimulated spheroids (i.e., r-NC and r-WC) with/without stimulation during measurement,
which is consistent with the previous report [249]. When comparing r-NS spheroids with
r-WS

spheroids,

significant

improvement

in

the

contraction

amplitude

and

synchronization were found in the r-WS spheroids (Fig. 3.5 B, D), which indicate eSiNWs can facilitate synchronized electrical signal propagation throughout the spheroids.
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Figure 3.5. Functional and structural analysis of rat-neonatal cardiac spheroids. (A)
Averaged fractional area change (i.e., contraction amplitude) over 3 days for r-NS
spheroids and (B) a characteristic beating profile on day 3 for r-NC, r-NC under
stimulation during measurement, and r-NS spheroids. (C) Averaged fractional area
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change over 3 days for r-WS spheroids and (D) a characteristic beating profile on day 3
for r-WC, r-WC under stimulation during measurement, and r-WS spheroids. (E) Western
blot analysis (averaged data of three separate experiments) of protein expression levels
relative to GAPDH expression after 7 days with or without electrical stimulation
normalized to the r-NC group. (F, G) Immunofluorescent staining of cardiac-specific
contractile and conductive proteins for all groups after 7 days. r-NC= rat-neonatal cardiac
spheroids, no e-SiNWs, no stimulation; r-NS= rat-neonatal cardiac spheroids, no eSiNWs, with stimulation; r-WC= rat-neonatal cardiac spheroids, with e-SiNWs, no
stimulation; r-WS= rat-neonatal cardiac spheroids, with e-SiNWs, with stimulation. n = 6
spheroids per condition (A-D). Asterisks (*) represent statistical significance with
p<0.05; error bars represent standard deviation. Scale bars: (F) = 100 µm; (G) = 20 µm.

To understand the effects of e-SiNWs and chronic stimulation, the expressions of
several key cardiac-specific proteins in all four different spheroids were examined using
western blotting and immunofluorescence staining (Fig. 3.5E-G and Fig. 3.6A, B).
Among them, connexin-43 (i.e., Cx-43) forms gap junction channels that regulate
electrical signal propagation between cardiomyocytes[250, 251]. Cardiac -sarcomeric
actinin (-SA) and cardiac troponin I (cTnI) are cardiac-specific contractile proteins, and
-myosin heavy chain (-MHC) is neonatal isoform of myosin heavy chain in rat
cardiomyocytes[249]. As shown in the Fig. 3.5E, F and Fig. 3.6A, B, chronic stimulation
can significantly increase the expressions and assembly of contractile proteins (e.g., SA and cTnI), in agreement with the previous report [249]. On the other hand, the
incorporation of e-SiNWs led to enhanced expression and clustering of Cx-43 (Fig. 3.5E,
G), also consistent with the previous literature [146, 147, 252, 253]. The combination of
SiNWs and chronic stimulation can result in the reduced expression of -MHC, which
indicates a transition from the neonatal isoform of myosin protein to the adult
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isoform[249]. This could be attributed to the up-regulated Cx-43 expression (Fig. 3.6 E,
G) and/or the increased contraction amplitude (Fig. 3.5 D).
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Figure 3.6. Protein expression analysis of rat-neonatal cardiac spheroids after 7 days of
treatment. (A) Western blot of cardiac-specific proteins after 7 days for all 4 groups. (B)
Protein expression levels based on fluorescent signal-covered area per nuclei normalized
over r-NC expression; n = 3 picture regions; 50 µm x 80 µm picture regions, at least
containing >24 nuclei. r-NC= rat-neonatal cardiac spheroids, no e-SiNWs, no
stimulation; r-NS= rat-neonatal cardiac spheroids, no e-SiNWs, with stimulation; r-WC=
rat-neonatal cardiac spheroids, with e-SiNWs, no stimulation; r-WS= rat-neonatal cardiac
spheroids, with e-SiNWs, with stimulation. Asterisks (*) represent statistical significance
with p<0.05; error bar represents standard deviation.
The results from rat-neonatal cardiac spheroids led to the development of hiPSC
cardiac spheroids (i.e., cardiac spheroids prepared from hiPSC-derived cardiomyocytes,
Fig. 3.3C). Unlike the rat-neonatal cardiac spheroids, strong spontaneous contractions
with consistent contraction frequency were found for the non-stimulated hiPSC cardiac
spheroids. Notably, a significant decrease in contraction amplitude was found for
electrically stimulated hiPSC-derived cardiac spheroids (i.e., hiPSC-NS and hiPSC-WS
spheroids) (Fig. 3.7A). TUNEL staining (marker of early apoptosis) of the spheroid
sections revealed significant increase in cell death at the center of hiPSC-NS and hiPSCWS spheroids, while not in the r-NS and r-WS spheroids (Fig. 3.8). Given the similar
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sizes of the rat-neonatal and hiPSC cardiac spheroids, the increased cell death at the
center of stimulated hiPSC-derived cardiomyocytes was attributed to the increased
metabolic demands of the hiPSC-derived cardiomyocytes compared to rat-neonatal
cardiac cells [254-256]. Accordingly, strong expression of the assembled cardiac
contractile proteins (e.g., -SA and c-TnI) can only be found on the periphery of the
hiPSC-NS and hiPSC-WS spheroids (Fig. 3.9A, B).
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Figure 3.7. Functional analysis of hiPSC-derived cardiomyocyte spheroids. (A)
Average contraction amplitude from Day 1 to Day 7 of each group. Double asterisk (**)
represents statistical difference between all groups. (B, C) Representative fractional area
change (i.e., contraction amplitude) of spontaneously beating spheroids with and without
e-SiNWs at time points Day 0 and Day 6; n = 6 spheroids per condition. (D, E)
Representative calcium transient imaging of 7 regions of interest (colored circles) per
spheroid for each group. Fluorescence amplitude, F/F0, refers to measured fluorescence
intensity normalized to background fluorescence intensity. (F) Comparison of the peak
value of F/F0 for each group. (n=3) (G) Comparison of calcium release duration for each
group. (n=3) hiPSC-NC= human induced pluripotent stem cell cardiac spheroids, no eSiNWs, no stimulation; hiPSC-WC= human induced pluripotent stem cell cardiac
spheroids, with e-SiNWs, no stimulation. Asterisks (*) represent statistical significance
with p<0.05; error bar represents standard deviation. Scale bars = 100 µm.
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3.0

Figure 3.8. TUNEL staining for the frozen sections of spheroids. Blue color is DAPI
staining for nuclei, which indicates the viable cells in spheroids. Green color is TUNEL
staining for fragments of DNA, which indicates the apoptosis of cells in spheroids. Scale
bars: 50µm.

On the other hand, the addition of e-SiNWs into hiPSC cardiac spheroids without
electrical stimulation (i.e., hiPSC-WC spheroids) can lead to significant improvement in
contraction amplitude and synchronization. As shown in the Fig. 3.7 A, the contraction
amplitude of the hiPSC-WC spheroids averaged more than 55% higher than the hiPSCNC spheroids from Day 1 to Day 7. The sharper peaks of fractional area change of the
hiPSC-WC spheroids over the hiPSC-NC spheroids strongly indicated the enhanced
contraction synchronization (Fig. 3.7B, C). This is further supported by calcium transient
imaging of whole spheroids (Fig. 3.7D, E). The quantification of calcium imaging of
spheroids revealed the hiPSC-WC spheroids have the increased overall amplitude (F/F0)

85

of calcium levels and the accelerated time to peak of the calcium transient (Fig. 3.7 F, G),
which supported the enhanced synchrony during spontaneous contraction. The significant
improvement in contraction amplitude and synchronization of hiPSC-WC spheroids is
remarkable, considering only a trace amount of e-SiNWs (i.e., 0.004% w/v) was utilized
to create e-SiNW-reinforced cardiac spheroids.
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Figure 3.9. Cellular organization of hiPSC-derived cardiomyocyte spheroid crosssections after 7 days of treatment. (A) Low and (B) high magnification confocal images
(green, α-sarcomeric actinin (α-SA); red, troponin I; blue, DAPI nuclear stain) that
display the difference in the sarcomere expression and organization within spheroids. (C)
Protein expression analysis based on fluorescent signal-covered area per nuclei
normalized over hiPSC-NC expression; n = 3 picture regions; 75 µm x 130 µm picture
regions, at least containing >50 nuclei. (D) Characteristic images of hiPSC-NC and
hiPSC-WC treatments to reveal differences in sarcomere alignment of each whole
spheroid (dotted line = spheroid border). hiPSC-NC= human induced pluripotent stem
cell cardiac spheroids, no e-SiNWs, no stimulation; hiPSC-NS= human induced
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pluripotent stem cell cardiac spheroids, no e-SiNWs, with stimulation; hiPSC-WC=
human induced pluripotent stem cell cardiac spheroids, with e-SiNWs, no stimulation;
hiPSC-WS= human induced pluripotent stem cell cardiac spheroids, with e-SiNWs, with
stimulation. Error bars represent standard deviation. Scale bars: (A) = 100 µm; (B) = 20
µm; (D) = 5 µm.

The enhanced contraction amplitude and synchronization of the hiPSC-WC
spheroids resulted in improved functional maturation. As shown in the Fig. 3.10A-C and
supplementary Fig. 3.10C, D, the immunofluorescence staining indicated the significant
increase in expression level and assembly of both conductive and contractile proteins
(e.g., Cx-43, α-SA, and cTnI) in the hiPSC-WC spheroids, which was further supported
by the increased expression of conductive gene GJA1 (Cx-43) and contractile gene
MYL2 (ventricle isoform of myosin light chain) (Fig. 3.11). In addition, the Fig. 3.7 D-G
showed the improved peak calcium amplitude and the speed of calcium release, which
suggest the improved calcium handling channels and indicates increased maturation. This
is further supported by the increased ratio of gene expression of the calcium channel Ltype/T-type subunits (CACNA1C/CACNA1G) (Fig. 3.11). The improved calcium
handling properties can be attributed to the enhanced organization of the sarcomere
structures in the hiPSC-WC spheroids[257].
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Figure 3.10. Structural analysis of hiPSC-derived cardiomyocyte spheroids. (A)
Immunofluorescent staining of alpha sarcomeric actinin (α-SA) and troponin I (cTn I).
(B) Immunofluorescent staining of connexin-43 (Cx-43) and beta myosin heavy chain (βMHC). (C) Protein expression analysis based on fluorescent signal-covered area per
nuclei normalized over hiPSC-NC expression (n = 3; 75 µm x 130 µm picture regions, at
least containing >50 nuclei) based on (A, B). hiPSC-NC= human induced pluripotent
stem cell cardiac spheroids, no e-SiNWs, no stimulation; hiPSC-WC= human induced
pluripotent stem cell cardiac spheroids, with e-SiNWs, no stimulation. Asterisks (*)
represent statistical significance with p<0.05; error bar represents standard deviation.
Scale bars = 20 µm.
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Figure 3.11. qPCR analysis of mRNA expression of conductive and contractile genes in
hiPSC-NC and hiPSC-WC spheroids. GJA1 – connexin-43; MYL2 – myosin light chain
ventricular isoform; CACANA1C – calcium L-type channel; CACNA1G – calcium Ttype channel. Asterisks (*) represent statistical significance with p<0.05; error bar
represents standard deviation, n = 3.

To confirm the effects of e-SiNW-reinforced 3D cell culture on the structural and
contractile maturation of hiPSC-derived cardiomyocytes, monolayer cells were obtained
from hiPSC cardiac spheroids by seeding them onto gelatin-coated substrates, which was
thought to minimize dramatic stress usually associated with mechanical/enzymatic
spheroid dissociation processes. Sarcomere length and Z-band width were measured as
they were known as effective indicators of twitch force generated by cardiomyocytes[258,
259] (Fig. 3.12). As shown in Fig. 6A-C and G, cardiomyocytes harvested from both
hiPSC-NC and hiPSC-WC spheroids showed significant improvement in Z-band width
when compared to pre-spheroid hiPSC-derived cardiomyocytes. This indicates that 3D
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culture can provide supportive microenvironments for the maturation of hiPSC-derived
cardiomyocytes. Moreover, the hiPSC-WC cardiomyocytes showed significant
improvement in both sarcomere length and Z-band width when compared to the hiPSCNC cardiomyocytes (Fig. 3.12F, G).

These improvements were attributed to the

enhanced contraction of the hiPSC-WC spheroids. Notably, the alignment of Z-band in
hiPSC-WC

cardiomyocytes

showed

remarkable

resemblance

with

adult

rat

cardiomyocytes (Fig. 3.12C-E, H). The increased sarcomere alignment in the hiPSC-WC
spheroids was attributed to the e-SiNW-induced synchronized contractions (Fig. 3.7 B,
C), which was hypothesized to provide an anisotropic mechanical environment to direct
the assembly of contractile machinery of hiPSC-WC cardiomyocytes.
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Figure 3.12. Single cell analysis of hiPSC-derived cardiomyocytes before and after
spheroids, and rat-neonatal and adult cardiomyocytes. (A) Fluorescent confocal
images (green, α-sarcomeric actinin (α-SA); red, troponin I; blue, DAPI nuclear stain) of
single cells harvested before hiPSC spheroid fabrication, (B) after 7 days from hiPSC-NC
spheroids, (C) and after 7 days from hiPSC-WC spheroids. (D) Rat-neonatal
cardiomyocyte and (E) adult left ventricular cardiomyocyte for morphological
comparison. (F) Sarcomere length measured as distance between α-SA-stained Z-line
structures from cardiomyocytes with visible sarcomere structures; n = 9 cells per
condition. (G) Z-line width measurements based on α-SA-stained Z-line structures in
comparison to neonatal and adult rat cardiomyocyte references; n = 10 cells per
condition. (H) Z-line alignment calculations were based on a fraction (±20° of the peak
orientation degree) of aligned α-SA-stained structures; n = 12 cells (hiPSC), 4 cells (rat)
per condition. hiPSC-NC= human induced pluripotent stem cell cardiac spheroids, no eSiNWs, no stimulation; hiPSC-WC= human induced pluripotent stem cell cardiac
spheroids, with e-SiNWs, no stimulation. Asterisks (*) represent statistical significance
with p<0.05; error bars represent standard deviation. Scale bars = 25 µm.
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5. Conclusion:
For the first time, we incorporated a trace amount of e-SiNWs into rat-neonatal
and hiPSC cardiac spheroids to create electrically conducting microenvironments and
induce synchronized and enhanced contraction, which was shown to promote structural
and contractile maturation. Although powerful, the addition of e-SiNWs into the human
cardiac spheroids alone may not be able to derive fully matured hiPSC-derived
cardiomyocytes. A longer term experiment (i.e., 3 weeks) was explored, and the
improvements in hiPSC-WC spheroids in contraction amplitude and sarcomere structure
seen at Day 7 were maintained through Day 21 (Fig. 3.13). However, the extended
culture did not indicate further improvements in the maturation of hiPSC-derived
cardiomyocytes. The sarcomere structure and nuclear shape in hiPSC-WC spheroids and
hiPSC-NC spheroids at Day 21 resembled that of the Day 7 spheroids (Fig. 3.9 and Fig.
3.13). Our future research will combine additional chemical/physical stimuli (e.g., growth
factors, miRNA) with e-SiNW-reinforced human cardiac spheroids to produce fully
matured hiPSC-cardiomyocytes.[145, 257]
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Figure 3.13. Analysis of hiPSC-derived cardiomyocyte spheroids after 3 weeks culture.
(A) Low and (B) high magnification confocal images (green, α-sarcomeric actinin (αSA); red, troponin I; blue, DAPI nuclear stain) that display the difference in the
sarcomere expression and organization within spheroids after 21 days in culture. (C)
Average contraction amplitude (i.e., fractional area change) of spontaneously beating
spheroids with and without e-SiNWs and/or electrical stimulation after 21 days in culture;
n=6 spheroids per condition. (D) Protein expression analysis based on fluorescent signalcovered area per nuclei normalized over hiPSC-NC expression; n = 3 picture regions; 40
µm x 40 µm picture regions. hiPSC-NC= human induced pluripotent stem cell cardiac
spheroids, no e-SiNWs, no stimulation; hiPSC-NS= hiPSC cardiac spheroids, no eSiNWs, with stimulation; hiPSC-WC= hiPSC cardiac spheroids, with e-SiNWs, no
stimulation; hiPSC-WS= hiPSC cardiac spheroids, with e-SiNWs, with stimulation.
Asterisk (*) represents statistical difference between groups with p<0.05; error bar
represents standard deviation. Scale bars: (A) = 50 µm; (B) = 20 µm.
Recently, nanocomposite scaffolds composed of electrically conductive
nanomaterials and hydrogels have been developed for cardiac tissue engineering
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applications[146, 147, 191, 253]. The research reported here is the first demonstration of
using nanoscale semiconductors to promote cardiac tissue formation and cardiomyocyte
maturation without involving conventional scaffolding materials (e.g., polymers and
hydrogels). Also, this research is the first example to directly utilize silicon-based
nanomaterials for tissue engineering applications. Our results suggest that silicon-based
nanomaterials can have major impacts in tissue engineering. Notably, e-SiNW induced
synchronized contraction could have major implications in cell-based cardiac therapy,
considering that arrhythmia caused by unsynchronized contraction is a major concern in
cardiac surgery [170, 174]. Our future research will also include the transplantation of eSiNW-reinforced hiPSC cardiac spheroids into infarcted hearts to examine their electrical
integration with the host myocardium.
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CHAPTER FOUR
CELL NUMBER PER SPHEROID AND ELECTRICAL CONDUCTIVITY OF
NANOWIRES INFLUENCE THE FUNCTION OF SILICON NANOWIRED
HUMAN CARDIAC SPHEROIDS
1. Abstract:
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs)
provide an unlimited cell source to treat cardiovascular diseases, the leading cause of
death worldwide. However, current hiPSC-CMs retain an immature phenotype that leads
to difficulties for integration with adult myocardium after transplantation. To address this,
we recently utilized electrically conductive silicon nanowires (e-SiNWs) to facilitate selfassembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids. Our previous
results showed addition of e-SiNWs effectively enhanced the functions of the cardiac
spheroids and improved the cellular maturation of hiPSC-CMs. Here, we examined two
important factors that can affect functions of the nanowired hiPSC cardiac spheroids: (1)
cell number per spheroid (i.e., size of the spheroids), and (2) the electrical conductivity of
the e-SiNWs. To examine the first factor, we prepared hiPSC cardiac spheroids with four
different sizes by varying cell number per spheroid (~0.5k, ~1k, ~3k, ~7k cells/spheroid).
Spheroids with ~3k cells/spheroid was found to maximize the beneficial effects of the 3D
spheroid microenvironment. This result was explained with a semi-quantitative theory
that considers two competing factors: 1) the improved 3D cell-cell adhesion, and 2) the
reduced oxygen supply to the center of spheroids with the increase of cell number. Also,
the critical role of electrical conductivity of silicon nanowires has been confirmed in
improving tissue function of hiPSC cardiac spheroids. These results lay down a solid
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foundation to develop suitable nanowired hiPSC cardiac spheroids as an innovative cell
delivery system to treat cardiovascular diseases.
2. Introduction:
Cardiovascular diseases are the leading cause of death and disability worldwide
[232, 260]. Due to limited regeneration capacity of adult human hearts, human embryonic
stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) have emerged as
a powerful cell source for cardiac repair due to their proven capacity to produce
functional human cardiomyocytes [124, 153, 165-169, 172, 261]. To this end, significant
efforts have been devoted to transplanting hESC/hiPSC-derived cardiomyocytes
(hESC/hiPSC-CMs) into damaged hearts to improve their functions in animal models [97,
104, 124, 153, 174-178, 262]. In particular, Murry and coworkers have demonstrated the
injection of hESCs-CMs into the injured myocardium led to cardiac muscle regeneration
in a non-human primate model [153]. Despite the progress, the current hESC/hiPSC-CMs
retain an immature phenotype, including poorly organized sarcomere structures (i.e.,
functional units of the contractile machinery). This leads to difficulties for electrical and
mechanical integration with human adult myocardium after transplantation and poses an
arrhythmic risk [145, 153, 263, 264]. To address this challenge, we recently utilized
electrically conductive silicon nanowires (e-SiNWs) to facilitate self-assembly of hiPSCCMs to form nanowired human cardiac spheroids for heart repair [148]. We
demonstrated that addition of e-SiNWs into the human cardiac spheroids creates an
electrically conductive microenvironment and improves tissue function and cellular
maturation of hiPSC cardiac spheroids. In addition, recent research has shown that
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cellular spheroids/aggregates improve cell retention and survival after transplantation due
to their 3D microtissue configuration [177, 183, 265]. In this manuscript, we aim to
examine two major factors that can affect the functions of the nanowired human cardiac
spheroids: (1) the number of cells per spheroid (i.e., size of the spheroids), and (2) the
role of the electrical conductivity of the e-SiNWs in improving tissue functions of the
spheroids.
The optimal cell number in the spheroids is affected by two competing factors: 1)
the improved 3D cell-cell adhesion, and 2) the reduced oxygen supply to the center of
spheroids with the increase of cell number. In the first part of the study, we
experimentally identified the optimal cell number in the spheroids and developed a semiquantitative theory to explain the finding. In our previous report, we showed the addition
of e-SiNWs in the human cardiac spheroids improved cellular maturation and tissue
function [148]. However, the role of electrical conductivity of the e-SiNWs has not been
examined. In the second part of the manuscript, we prepared three types of the spheroids:
spheroids without the addition of nanowires (NC), spheroids with the addition of
phosphorus doped silicon nanowires (WCD), and undoped silicon nanowires (WCN). We
studied the functions of these three different types of spheroids and confirmed the critical
role of electrical conductivity of e-SiNWs in improving tissue functions of the hiPSC
cardiac spheroids.
3. Materials and methods:
3.1 Cell culture
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The hiPSC-CMs (Cellular Dynamics International, Madison, WI, USA) were
cultured according to the manufacturer's protocol. Briefly, hiPSC-CMs were seeded on
0.1% gelatin coated 6-wells plate with plating medium (Cellular Dynamics International)
at a density of about 3 × 105 to 4.0 × 105 cells per well and incubated at 37 °C / 5% CO2
for two days. Two days after plating, the plating medium was removed and replaced with
4 ml of maintenance medium (Cellular Dynamics International) for another 2 days. After
4 days of monolayer pre-culture, cells were detached using trypLE Express (Gibco Life
Technologies, Grand Island, NY) and harvested for spheroid fabrication.
3.2 Spheroid fabrication
The agarose hydrogel molds were prepared using commercial master micro-molds
from Microtissues, Inc (Providence, RI, USA) as negative replicates to create nonadhesive agarose hydrogels molds containing 35 concave recesses with hemispheric
bottoms (800 μm diameter, 800 μm deep) to facilitate the formation of tissue cell
spheroids. 330 μl 2% sterile agarose solution were pipetted into the master micro-molds
and then carefully detached after gelation from the master mold and transferred into one
well of an 8-well tissue culture plate. 75 μl of the cell suspension with different
concentrations were pipetted into each agarose mold. After the cells had settled down into
the recesses of the mold (10 min), additional media was added (5 ml) and exchanged
every 2 days for the length of the experiment.
3.3 Video and image analysis of beating spheroids
Videos of 6 spheroids from each group were recorded using Zen 2011 software
(Zeiss, Göttingen, Germany) with capture rate of 14 frames per second. Then the videos
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were converted to a series of TIFF formatted pictures by Adobe Premiere (Adobe, San
Jose, CA). Threshold edge-detecting in ImageJ software (National Institutes of Health)
was used on high contrast spheroid pictures and graphed to realize contraction profiles,
from which other quantifiers were calculated (e.g., fractional area change of single
spheroids).
3.4 Histological and immunofluorescent analysis of spheroids
Freshly collected spheroids (~30-35) were placed onto a pre-labeled tissue base
mold, and the entire tissue block was covered with OCT. Immediately, the base mold
containing spheroids were transferred into pre-cooled ethanol with dry ice to ensure that
the spheroids were frozen quickly and completely. Frozen spheroids were cryosectioned
into 7 μm thick layers onto glass slides for immunohistochemistry. The sections were
fixed with pre-cooled acetone (-20 °C) for 10 min. After washing (3 times at 5 min) in
PBS with 0.1% Triton X-100 (PBST), 100 μl blocking buffer were added (10% goat
serum in PBST) onto the sections of the slides and incubated in a humidified chamber at
room temperature for 1 h. Sections were incubated with appropriately diluted primary
antibody: alpha sarcomeric actinin (Abcam, Cambridge, UK), troponin I (Santa Cruz,
Dallas, TX), connexin-43 (Sigma Aldrich, St. Louis,MO), and COX IV (Abcam)
overnight at 4 °C. After washing in PBST (3 times at 5 min), tissues were incubated with
coordinate secondary antibodies diluted in PBST for 1 h at ambient temperature. After
washing in PBST (3 times at 5 min), nuclei were stained with DAPI (Molecular
Probes/Invitrogen, Eugene, OR) diluted in PBST for 15 min at ambient temperature.
Following the final wash procedure (PBST, 3 times at 5 min), cover slips were added to
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the slides using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA). Finally, TCS
SP5 AOBS laser scanning confocal microscope (Leica Microsystems, Inc., Exton, PA)
was for fluorescent imaging.
3.5 TUNEL staining for the frozen section of spheroids
In Situ Cell Death Detection Kit (Roche, Penzberg, Germany) was used to
determine the viability of the cell in the frozen section of spheroids based on the Roche
protocol. Briefly, the frozen sections of spheroids were fixed with 4% paraformaldehyde
in PBS for half hour at room temperature. Following washing in PBS for 30 minutes,
samples were incubated in a permeabilization solution (0.1% Triton X-100 and 0.1%
sodium citrate in PBS) for 2 minutes on ice. Then 50 µl of the TUNEL reaction mixture
were added to samples and incubated in 37 °C for 1 h. After washing in PBST (3 times at
5 min), nuclei were stained with DAPI (Molecular Probes/Invitrogen, Eugene, OR)
diluted in PBS for 15 min at ambient temperature. Following the final wash procedure
(PBS, 3 times at 5 min), glass cover slips were added to the slides using Fluoro-Gel
(Electron Microscopy Sciences, Hatfield, PA). Finally, a TCS SP5 AOBS laser scanning
confocal microscope (Leica Microsystems, Inc., Exton, PA) was used to obtain
fluorescent images.
3.6 Calcium transient imaging of cardiac spheroids
Fluo-4 Direct Calcium Assay Kits (Life Technologies, Carlsbad, CA) was used to
label calcium ion in the whole spheroids based on the protocol from Life Technologies.
Briefly, spheroids were seeded onto 0.1% gelatin-coated glass cover slips and incubated
at 37 °C, 5% CO2, 20% O2. Cell culture medium was changed every other day. After
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four days culture, the spheroids were rooted on the cover slips. Then cover slips with the
spheroids were put into 12-well plates with 2 ml calcium dye solution per well and
incubated at 37 °C, 5% CO2, 20% O2 for 1 h. TCS SP5 AOBS laser scanning confocal
microscope (Leica Microsystems, Inc., Exton, PA) was used to collect the videos of the
calcium transient of whole spheroids at room temperature with a capture rate of 14
frames per second. Notably, temperature influences the calcium transient dynamics,
indicated by changes in the beat rate of cardiac spheroids with temperature (Figure 4.1).
Finally, we used the LAS AF software (Leica) to conduct quantification of videos
collected by confocal imaging.
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Figure 4.1. The beat rate of the spheroid’s spontaneous contraction is dependent on
the temperature. The relationship between beat rate (BPM – beats per minute) and
medium temperature.

3.7 Transmission Electron Microscopy

102

Spheroids were fixed with 2.5% glutaraldehyde, postfixed in PBS buffered 1%
osmium tetroxide with 1.5% K+ ferricyanide, dehydrated in graded ethanol and
Acetonitrile, and embedded in PolyBed 812 (Polysciences). 70 nm thick spheroid
sections were prepared using a Leica UltraCut R and a diamond knife, stained with
Hanaichi Pb citrate and uranyl acetate, and imagined using a JOEL 200 CX transmission
electron microscope.
3.8 Numerical modeling of oxygen transport in cardiac spheroids
The oxygen transport within spheroids under static culture conditions mainly
depends on diffusion [266]. A finite element model of oxygen diffusion within cardiac
spheroids was developed based on Fick‟s second law. In a spherical coordinate system,
the oxygen concentration profile in cardiac spheroids is governed by:

where C is oxygen concentration, r is radial distance from spheroid center, D is
oxygen diffusivity, and R is oxygen consumption rate. The oxygen diffusivity through
cells is significantly less than that through water. As used in previous studies [267, 268],
D=3.0×10-6 cm2/s for cardiomyocytes in suspension was adopted in the model. The
concentration-dependent oxygen consumption rate (OCR) of cardiomyocytes can be
modeled by the Michaelis-Menten equation:

where ρ_c is spheroid cell density, V_max is the maximum OCR, and K_m is the
Michaelis-Menten constant. As the oxygen consumption rates of hiPSC-CMs or human
cardiomyocytes are not readily availablein the previous literatures, the oxygen
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consumption rate (V_max=5.44×10-8) nmol/cell/s and K_m=3.79 nmol/mL) of rat
neonatal cardiomyocytes in a quiescent condition was used in the model [255]. The
boundary condition is that on the spheroid surface, the oxygen concentration maintains
constant at 20% O2 (185 nmol/mL) [267]. The oxygen transport finite element model was
numerically solved by the software COMSOL Multiphysics (COMSOL Inc, Burlington,
MA). The oxygen concentration profiles were determined in spheroids with radius of ~70,
~100, ~150, and ~200 µm, corresponding to ~0.5k, ~1k, ~3k, and ~7k cells/spheroid.
3.9 Oxygen Consumption Rate Measurement
OCR of spheroids was measured according to the previous report [269]. Briefly,
30-60 spheroids of each group were placed in the OCR chamber equipped with fiber
optic sensors (Instech Laboratories, Plymouth Meeting, PA), which could measure the
declining oxygen partial pressure (pO2) over time. OCR measurements were conducted
in high glucose DMEM medium without FBS at 37°C. The liquid volume in chamber
was known as 175 μl, so the OCR (mol O2 per unit time) of spheroids could be
calculated from the linear slope of the measured pO2. Each measurement usually took 90
minutes. Since the cell number of spheroids is known, the OCR value was normalized
with cell number for each measurement with unit (pmol/hour/cell).
3.10 Statistics Analysis
Differences between experimental groups were analyzed using an independent
Student T-test, one-way or two-way ANOVA followed by Tukey‟s post-hoc test. P<0.05
was considered significantly different for all statistical tests.
4. Results and Discussion
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The scaffold-free 3D spheroids provide a conductive microenvironment to
promote cell-cell interactions and electrical coupling, leading to enhanced maturation of
hiPSC-CMs [270]. The number of cells in a spheroid plays a key role in its function.
When a spheroid contains too many cells, the supply of nutrient and oxygen to the cells
in the spheroid center will be limited or insufficient to maintain cellular viability and/or
normal function. When a spheroid contains a too small number of cells, the benefit of the
improved 3D cell-cell adhesion over 2D culture will diminish. In this study, we
fabricated hiPSC-CM spheroids with four different cell numbers per spheroid (i.e., ~0.5k,
~1k, ~3k, ~7k cells/spheroid) with and without the addition of 1:1 e-SiNWs (number of
cells : number of e-SiNWs) using our previously established method [148]. Spheroids
without and with e-SiNWs were designated as “NC” and “WCD”, respectively. As in the
previous study, n-type SiNWs (Diameter ≈ 100 nm; length ≈ 10 µm; Silane/Phosphane =
500) were used to prepare WCD spheroids (Figure 4.2 A-C). The length of the SiNWs
was selected to inhibit cell internalization, and the doping ratio and diameter of the eSiNWs were chosen to obtain a high conductivity (150 - 500 µS/µm) to create highly
electrically conductive microenvironments within spheroids [191, 248]. The addition of
the e-SiNWs into the cardiac spheroids did not significantly influence the sizes of the
spheroids at all four cell number/spheroid (Figure 4.3 A-B). This indicates the addition of
e-SiNWs should not significantly affect the nutrient and oxygen supply to the cells in the
spheroid center.
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Figure 4.2. Fabrication of silicon nanowired human cardiac spheroids. (A) Bright field
image of silicon nanowires (diameter ≈ 100 nm; length ≈ 10 µm). (B) Bright field images
of silicon nanowired human cardiac spheroids in agarose molds. (C) Confocal image of
frozen section of silicon nanowired human cardiac spheroids at Day 0 (Blue – DAPI;
Green – α-SA: alpha sarcomeric actinin; Yellow-silicon nanowires). Scale bars: (A) = 10
µm; (B) = 100 µm; (C) = 10 µm.

Previous studies have shown that spheroids with a radius over 250 µm became
apoptotic or necrotic over the time [271]. In addition, Radisic and coworkers have shown
the diffusion of oxygen in the cardiac tissue engineering constructs is limited to 150~200
µm [256]. Thus, the ~7k cells per spheroid (~200 µm radius) was chosen to be the upper
limit in this study. On the other hand, our data showed the lowest contraction amplitude
(i.e., fractional area change) in spheroids with ~0.5k cells/spheroid (Figure 4.3 C), which
is in agreement with previous research that indicates the beneficial impact of the 3D cellcell adhesion is limited for smaller spheroids [272]. In addition, it is difficult to process
and section these smaller spheroids. Therefore, this study mainly focused on the three
larger sizes of spheroids (i.e., 1k, 3k and 7k cells/spheroid). As seen in Figure 4.4 A-B,
TUNEL staining of the spheroid sections revealed a high level viability of hiPSC-CMs
(>90%) for all three sizes after 7 days culture [205]. These results support our selection of
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the range of cell numbers in the spheroids. In addition, the high cell viability of the WCD
spheroids supports the high biocompatibility of e-SiNWs, which is consistent with the
previous reports [195, 273, 274].

Figure 4.3. Human cardiac spheroids with controlled size and functional analysis. (A)
Bright field images of spheroids with different cell number (0.5k, 1k, 3k, 7k) per spheroid.
(B) Averaged radius of spheroid based on statistics (n=14). (C) Average fractional area
change from Day 1 to Day 7 of each group (n=7). NC – without e-SiNWs; WCD – with
e-SiNWs. Scale bars: (A) = 100 µm. Asterisks (*) represent statistical significance with
p<0.05; error bars represent standard deviation.
As in our previous report, contraction amplitude (i.e., fractional area change) of
the spontaneous, rhythmic beating of hiPSC-CM spheroids was used to examine the
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functions of the spheroids [148]. Figure 4.3 C shows that the presence of e-SiNWs in
WCD spheroids significantly increased the average contraction amplitude of 1k, 3k and
7k spheroids when compared with that of NC spheroids. This shows that the beneficial
effects of adding e-SiNWs into human cardiac spheroids is not limited to a specific
spheroid size, and this further supports our hypothesis that the addition of e-SiNWs into
hiPSC cardiac spheroids creates an electrically conductive microenvironment and
improves cardiac tissue function. In addition, the Figure 2C shows the WCD-3k
spheroids, the WCD spheroids with ~3k cells/spheroid, have the highest fractional area
change among all the groups.

Figure 4.4. Viability analysis of spheroids using TUNEL staining. (A) TUNEL staining
of the frozen sections of NC and WCD spheroids at day 7. Blue – DAPI; Green-TUNEL
(apoptosis marker). (B) Quantification of viability from TUNEL staining (viability: blue
colored area is divided by total colored area). NC – without e-SiNWs; WCD – with eSiNWs. Error bars represent standard deviation. Scale bars: (A) = 100 µm.

The results from contraction amplitude analysis are further supported by the
immunohistochemistry (IHC) analysis of cardiac contractile (α-SA : α-sarcomeric actinin)
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and conductive (Cx-43: Connexin-43) proteins of the spheroids sections (Figure 4.5). αSA was selected as it is a key component of the cardiac sarcomere structure, and
connexin-43 (i.e., Cx-43) was selected as it forms gap junction channels that regulate
electrical signal propagation between cardiomyocytes [250, 251].

Notably, the

specificity of the Cx-43 antibody was confirmed by the staining of hiPSC-CMs in 2D
culture, where cell-cell borders were more clearly visible than in 3D spheroid crosssections (Figure 4.6). Consistent with functional analysis, structural analysis showed
more organized structure and higher expression of contractile proteins (α-SA) (Figure 4.5
A-B) and cell-cell gap junction protein (Cx-43) (Figure 4.5 C-D) in the WCD spheroids,
when compared with the NC spheroids. Notably, hallmarks of structural maturation (i.e.,
Cx-43 and α-SA structures) did not show a strong correlation with nanowires location
(Figure 4.8). In addition, WCD-3k spheroids showed a highly organized sarcomere
structure and highest expression level of α-SA and Cx-43 (Figure 4.5 A-D). To
additionally support the functionality of Cx-43, the co-staining of spheroid cross sections
with Cx-43 and N-cadherin (N-cad), a membrane junction protein, as shown in the Figure
S4, in which the co-localization of N-cad and Cx43 indicates the formation of functional
cellular junctions [275]. These results indicate the WCD-3k spheroids can maximize
synergistic effects of the appropriate cell number per spheroid and the presence of eSiNWs. It is also important to note that all the spheroids after 7 days culture (Figure 4.5
A) showed significantly improved sarcomere structure, when compared with that of the
newly form spheroids (Figure 4.2 C). This result shows spheroids provide a supportive
3D microenvironment for the development of hiPSC-CMs.
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Figure 4.5. Histological analysis of spheroids. (A-B) Immunofluorescent staining and
quantification of cardiac-specific contractile proteins (α-SA) for all groups after 7 days
cell culture. Blue – DAPI; Green – α-SA; NC – without e-SiNWs; WCD – with e-SiNWs.
(C-D) Immunofluorescent staining and quantification of conductive proteins (Cx-43) for
all groups after 7 days cell culture. Blue – DAPI; Red – Cx-43. NC – without e-SiNWs;
WCD – with e-SiNWs. Fluorescent signal area per nuclei on cross section are normalized
to the NC-1k condition (n=3; 75 μm × 130 μm picture regions, at least containing >50
nuclei). Error bars represent standard deviation. Scale bars: (A)= 20 µm; (C)= 20 µm.
Asterisks (*) represent statistical significance between WCD3k and other groups with
p<0.05
Changing the number of cells per spheroids (i.e., size of spheroid) can alter the
oxygen supply throughout the spheroid, which can have direct effects on the metabolic
activity of the hiPSC-CMs within the spheroids. As an indicator for metabolic activity, a
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COX IV stain was used to show differences in mitochondrial expression between
different spheroid size groups (Figure 4.4 and Figure 4.7). IHC analysis showed the
presence of significantly more COX IV-positive structure in WCD-3k spheroids
compared to WCD-7k and WCD-1k spheroids (Figure 4.7 A,B). To support the IHC
analysis, oxygen consumption rate (OCR) measurements have been conducted for the
WCD spheroids with different sizes. Consistent with the IHC analysis, the hiPSC-CMs in
WCD-3k spheroids have highest OCR, demonstrating a high level of metabolic activity
(Figure 4.7 C and Figure 4.10). Notably, the measured OCRs are 0.34, 0.51 and 0.21
pmol/h/cell for the hiPSC-CMs in the WCD-1k, WCD-3k and WCD-7k spheroids
respectively, which is similar to the reported OCR for hiPSC-CMs in 2D monolayer
culture (0.71pmol/h/cell) [276]. While the size of 7k spheroids (i.e., radius: ~200 μm)
approaches the diffusion limit of oxygen [256], the lower COX IV-stained structure and
lower contraction amplitude of the WCD-1k spheroids suggests a functional limitation
due to an insufficient amount of cells per spheroid.

Figure 4.6 Specificity of immunofluorescent staining of Cx-43 and COX IV. (A) Cx43 (red) shows specific labeling at the cell junction of α-SA (green) stained 2D
monolayer hiPSC-CMs. (B) Mitochondria staining of COX IV (green) for 2D monolayer
hiPSC-CMs on gelatin-coated cover slips. Blue – DAPI.
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Figure 4.7 Metabolic analysis of nanowired spheroids with different cell numbers per
spheroid. (A) Confocal images of cross-sections of WCD spheroids with different cell
numbers per spheroid (Blue – DAPI; Green – COX IV). (B) COX IV positive area per
nuclei of WCD spheroid sections are normalized to the WCD-1k (n=3; 75 μm × 130 μm
picture regions, at least containing >50 nuclei). 7k (i.e., 7000), 3k, and 1k indicate
number of cells per spheroid. WCD – with e-SiNWs. (C) Quantification of oxygen
consumption rate of WCD spheroids with different cell numbers per spheroid. Asterisks
(*) represent statistical significance with p<0.05; error bars represent standard deviation.
Scale bars: (A)=100μm
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Figure 4.8 Immunofluorescent staining of α-SA/Cx-43 of the WCD-3k spheroid
sections. Confocal imaging shows locations of α-SA (green) and Cx-43 (red) and eSiNWs (yellow) in the WCD-3k spheroid sections. The α-SA and Cx-43 structures are
not localized to regions close to e-SiNWs.
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Figure 4.9. Immunofluorescent staining of N-Cad/Cx-43 of the WCD-3k spheroid
sections. The white circles show the co-localization of Cx-43 (red) and N-Cad (green)
surrounded in nuclei in the WC-D3k spheroids. Blue – DAPI.

114

Figure 4.10 Metabolic analysis of the WCD spheroids with different cell numbers
per spheroid. Oxygen consumption rate for WCD-1k, -3k and -7k spheroids were
measured using Instech Oxygen Consumption Chamber. WCD1k_30: 30 x WCD-1k
spheroids, WCD1k_60: 60 x WCD-1k spheroids, WCD3k_30: 30 x WCD3k spheroids,
WCD3k_60: 60 x WCD-3k spheroids, WCD7k_30: 30 x WCD7k spheroids.

The size of the spheroid (i.e., cell number per spheroid) influences both oxygen
diffusion and 3D cell-cell interactions. As oxygen consumption rates of hiPSC-CMs at
different oxygen concentrations are not readily available, we used the existing data of the
oxygen consumption rate of rat neonatal cardiomyocytes to model oxygen concentration
within spheroids with radii of ~50, ~100, ~150 and ~200 μm [255]. A finite element
model of oxygen diffusion within the cardiac spheroids was developed based on Fick‟s
second law. As shown in the Figure 4.11A, the amount of available oxygen is rapidly
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reduced from the edge of the spheroids to the center of the spheroids, and larger
spheroids have lower oxygen supply for the cells in the center of the spheroids. On the
other hand, the volume to surface area ratio increases with cell number, equaling 33.8,
47.5, and 66.0 for 1k, 3k, and 7k spheroids, respectively (Figure 4.11 B) [277]. This
indicates an enhanced 3D cell-cell adhesion with the increase of cell number per spheroid.
The existence of the two competing factors (reduced oxygen supply vs. enhanced 3D cell
adhesion with the increase of cell number per spheroid) indicates there could be an
optimal cell number for spheroid fabrication, and our experimental data indicates that
spheroids contain ~3k cells maximizes the benefits of the 3D environment of nanowired
spheroids (Figure 4.11 C).
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Figure 4.11 Functionally optimized range of cell number per spheroid. (A) A
mathematical model of oxygen percentage using rat neonatal cardiomyocyte data for
oxygen consumption (ref. 29), showing the range of oxygen concentration throughout
theoretical spheroids of different sizes. (B) The volume to surface area ratio of different
sized spheroids represents the amount of 3D cell-cell interaction, as a larger volume to
surface ratio indicates more cells inside the spheroid with higher chance of multidimensional cell-cell interaction. (C) Data points from oxygen percentage and spheroid
volume to surface area ratio at the 1k, 3k, and 7k cells per spheroid can be combined to
summarize our findings on the size with maximized benefits centered around 3k cells per
spheroid.
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Using the newly established spheroid size (i.e., 3k cells per spheroid), we
explored the role of the e-SiNWs in improving function and structural organization of
hiPSC-CMs in spheroids, we fabricated three groups of human cardiac spheroids:
spheroids without the addition of nanowires (NC), spheroids with the addition of doped
silicon nanowire (WCD), and undoped silicon nanowires (WCN). Compared to the
conductivity of the doped silicon nanowires (150 - 500 µS/µm), the undoped silicon
nanowires have a conductivity of 0.001-0.1 µS/µm that is lower than culture medium
(∼1.75 μS/μm) and myocardium (∼0.1 μS/μm) [191, 248]. This allowed for the
examination of both the necessity of the electrical conductivity of nanowires and the
effects of the mere presence of a silicon nanowire structure within the spheroid.
Contraction amplitude analysis showed that the average fractional area change of WCD3k group was significantly higher than that of NC-3k, while the average fractional area
change of WCN-3k spheroids is significantly lower than that of NC-3k (Figure 4.12 A).
These results confirmed the beneficial effects of electrically conductive silicon nanowires
on function of spheroids. This was further supported by calcium transient imaging of
whole spheroids (Figure 4.12 B-D). The WCD-3k spheroids showed a significantly
increased overall amplitude of calcium transient levels during contraction and an
accelerated time to peak of the calcium transient when compared with NC-3k, while
WCN-3k showed a lower peak amplitude of calcium transient level than that of NC-3k.
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Figure 4.12. The effects of electrically conductivity of silicon nanowires on the function
of 3k spheroids. (A) Average fractional area change of NC-3k, WCD-3k and WCN-3k
spheroids at Day 0, 2, 4, 6 and their averages (n=7). (B) Calcium transient of 7 regions of
interest per spheroid for each group. Fluorescence amplitude, F/F0, refers to measured
fluorescence intensity normalized to background fluorescence intensity. (C) Comparison
of the peak value of F/F0 for each group (n=3). (D) Comparison of calcium release
duration for each group (n=3). NC – without e-SiNWs; WCD – with doped SiNWs;
WCN – with undoped SiNWs. Asterisks (*) represent statistical significance with p<0.05;
error bar represents standard deviation.

Consistent with the functional analysis, structural analysis showed that the WCD3k spheroids had higher organization of αSA-stained sarcomere structures as well as an
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increase in Cx-43-positive stained area (Figure 4.13 and Figure 4.14). Also, the
ultrastructural analysis conducted by using electron microscopic imaging revealed a
significantly higher presence of I bands per Z disc, H zones per sarcomere and more
desmosomes per area in WCD-3k spheroids (Figure 4.15). Notably, the WCD-3k
spheroids showed a visible organization of mitochondria around sarcomere structures
similar to that of adult cardiomyocyte phenotype, as shown in Figure 8A-middle [165].
This supported our previous report that the presence of electrically conductive silicon
nanowires in the hiPSC cardiac spheroids promotes cellular maturation of hiPSC-CMs.
Collectively, these data showed the critical role of the electrical conductivity of the
silicon nanowires in improving the tissue functions of hiPSC cardiac spheroids.

Figure 4.13 Immunofluorescent analysis of NC, WCD, and WCN-3k spheroids. (AB) Quantified expression of α-SA and Cx-43 of NC-3k, WCD-3k and WCN-3k
spheroids, respectively. Fluorescent signal area per nuclei on cross section are normalized
to the NC-3k condition (n=3; 75 μm × 130 μm picture regions, at least containing >50
nuclei). NC – without e-SiNWs; WCD – with doped SiNWs; WCN – with undoped
SiNWs. Asterisks (*) represent statistical significance with p<0.05; error bar represents
standard deviation.
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Figure 4.14 Immunofluorescent staining of NC, WCD, and WCN-3k spheroids.
Contractile protein (α-SA) and conductive protein (Cx-43) staining were performed after
7 days cell culture in spheroids without e-SiNWs (NC), with doped e-SiNWs (WCD),
and undoped SiNWs (WCN).
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5. Conclusion
The silicon nanowired hiPSC cardiac spheroids hold remarkable promise as an
effective cell delivery system to treat heart failure [185, 278, 279]. Using our previously
established silicon nanowired hiPSC-CM spheroid system, we identified a cell numberdefined size of spheroids that advances the function and organization of hiPSC-CMs. The
functional analysis of contraction amplitude, IHC analysis of contractile and conductive
proteins, and metabolic investigation demonstrated that 3k spheroids maximize the
beneficial effects of the 3D spheroid microenvironment. Additionally, the electrical
conductivity of silicon nanowires was confirmed to play a critical role in accelerating
structural and functional development of hiPSC-CMs in spheroids.
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Figure 4.15 Ultrastructural analysis of NC, WCD, and WCN-3k spheroids. (A)
Representative TEM images of NC-3k, WCD-3k and WCN-3k spheroids showing
sarcomere structure (sarcomere, white bar; Z disks, Red arrows; H zones, white arrows;
M, mitochondria; N, nucleus) and presence of desmosomes (D, desmosomes). Scale bar,
1 μm. (B) Morphometric analysis (average ± s.d.; n =3-8 per group) showing ratio of I
bands to Z disk, ratio of H zones to sarcomeres and number of desmosomes per 103 um2.
NC – without e-SiNWs; WCD – with doped e-SiNWs; WCN – with undoped SiNWs.
Asterisks (*) represent statistical significance with p<0.05.

While hiPSC-CMs hold remarkable promise to treat injured hearts, the current
hiPSC-CMs retain an immature phenotype, which makes them difficult to integrate with
adult myocardium and pose an arrhythmic risk. Further, the current utilization of
dissociated single cells for cell transplantation leads to low cell retention and survival
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[136]. To collectively address this challenge, we utilized e-SiNWs to facilitate selfassembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids. We demonstrated
the e-SiNWs improved the spheroid functions and cellular maturity of hiPSC-CMs. In
addition, recent research has shown improved cell retention and survival when using 3D
cellular spheroids/aggregates. In this study, we identified an optimal cell number-defined
spheroid size (~3k/spheroid) and confirmed the critical role of electrical conductivity of
e-SiNWs. As the hiPSC-CMs in the WCD-3k spheroids lack characteristics of adult
cardiomyocytes (e.g., sarcomere M lines, T tubules) [145], our future research will focus
on using additional physical/chemical stimuli (e.g., electrical stimulation and/or
microRNA) to further improve the tissue functions and cellular maturity of the nanowired
hiPSC cardiac spheroids. In addition, we will explore the addition of vascular cells (e.g.,
endothelial cells) to the nanowired spheroids to prepare pre-vascularized spheroids for
the improved integration with host vasculature after transplantation. Results from these
studies will allow for the development of suitable nanowired spheroids to repair damaged
hearts and advance the field of cell-based cardiac regenerative medicine.
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CHAPTER FIVE
NANOWIRED HIPSC CARDIAC SPHEROIDS IMPROVE CELL RETENTION,
ENGRAFTMENT AND INTEGRATION AFTER TRANSPLANTATION INTO
ADULT RAT HEARTS

1. Abstract
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) hold
remarkable potential as a powerful cell source to repair injured hearts. After significant
efforts of injecting hiPSC-CMs into animal hearts, it has become clear that current cell
delivery strategies are limited by low cell retention and low engraftment/integration. To
address this, we recently pioneered the use of electrically conductive silicon nanowires
(e-SiNWs) to facilitate the self-assembly of hiPSC-CMs to form nanowired spheroids as
injectable microtissues to deliver hiPSC-CMs. Our previous data showed that the
incorporation of e-SiNWs into the spheroids improved cell/tissue level function and
maturation. Here, we reasoned that the presence of e-SiNWs in the injectable spheroids
improves their ability to receive exogenous electromechanical pacing from the host
myocardium to enhance their integration with host tissue post-transplantation. In this
study, we examined the cardiac biocompatibility of the e-SiNWs and cell retention,
engraftment and integration after injection of the nanowired hiPSC cardiac spheroids into
adult rat hearts. Our results showed that the e-SiNWs caused minimal toxicity to rat adult
hearts after intramyocardial injection. Further, the nanowired spheroids were shown to
significantly improve cell retention and engraftment, when compared to dissociated
hiPSC-CMs and unwired spheroids. The 7-days-old nanowired spheroid grafts showed
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alignment with the host myocardium and development of sarcomere structures. The 28days-old nanowired spheroid grafts showed gap junctions, mechanical junctions and
vascular integration with host myocardium. Together, our results clearly demonstrate the
remarkable potential of the nanowired spheroids as cell delivery vehicles to treat
cardiovascular diseases.
2. Introduction
Cardiovascular disease is the leading cause of death and disability worldwide
[260]. Ischemic heart disease (IHD) and myocardial infarction (MI) are major
contributors to cardiovascular morbidity and mortality and are associated with death of
cardiomyocytes and permanent loss of heart function [232]. Due to the limited
regeneration capacity of adult hearts, human induced pluripotent stem cell (hiPSC) has
emerged as a powerful cell source for cardiac repair due to its proven capacity to produce
patient-specific functional cardiomyocytes (hiPSC-CMs) [165-169]. In addition, recent
progress in cardiac differentiation of hiPSCs allows for the derivation of the large number
of hiPSC-CMs (>109 cells/patient) needed for cardiac repair [124, 170-172]. To realize
the therapeutic potential of hiPSC-CMs or hESCs-CMs (cardiomyocytes derived from
human embryonic stem cells), significant efforts have been devoted to transplanting
hiPSC-CMs or hESCs-CMs into damaged animal hearts to improve their functions [97,
104, 124, 170, 173-178]. While significant efforts have been used to directly inject
dissociated hESC-CMs into healthy/injured hearts, this approach is limited by low cell
retention and survival after cell transplantation. Dissociated hiPSC-CMs are rapidly
redistributed to other organs (e.g., lung) after injection due to mechanical dispersion of
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beating hearts [140]. In addition, lack of cell-cell adhesion of single cells leads to cell
death caused by anoikis and/or ischemia [179]. To improve the efficiency of cell
delivery, significant efforts have been devoted to the development of tissue-engineered
epicardial patches [175, 180-182]. In addition to the invasive surgical procedure to
transplant the patches, recent research has shown the limited electrical integration
between the transplanted patches and host myocardium, largely attributed to the chronic
fibrotic response that occurs after transplantation [180-182]. This highlights an urgent
need to develop an innovative platform to improve the retention, engraftment and
integration of the injected hiPSC-CMs with adult myocardium.
hiPSC cardiac spheroids have been proposed as an attractive cell delivery system
for heart repair, given the recent literature showing spheroid/aggregate delivery improved
cellular retention and survival after transplantation [183-189]. To this end, we recently
utilized electrically conductive silicon nanowires (e-SiNWs) to facilitate the selfassembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids and improve the
functions of the microtissues [148, 280]. Here, we reasoned that the presence of the eSiNWs in the injectable spheroids improves their ability to receive exogenous
electromechanical pacing from the host myocardium and enhance their integration with
host tissues post-transplantation. This was inspired by our recent finding that the addition
of e-SiNWs in hiPSC-CM spheroids are essential for exogenous electrical
stimulation/pacing to promote hiPSC-CM development and maturation [190]. Further,
the recent reports showed the presence of electrical nanomaterials (e.g., gold nanowires)
in the cardiac tissue engineering constructs synergizes with exogenous electrical pacing
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to improve the functions of the constructs [147, 191]. Compared to other electrical
nanomaterials (e.g. gold nanowires, carbon nanotubes), e-SiNWs have distinct
advantages, including their controllable electrical conductivity, tunable dimensions, and
convenient surface tailorability [192, 193]. Further, both in vitro and in vivo
biocompatibility studies have shown no significant cytotoxic effects for either undoped or
n-type SiNWs [194-196]. Notably, the absence of a pre-aligned structure within the
nanowired hiPSC cardiac spheroids has raised concerns over their suitability for
transplantation. The ability of hiPSC-CMs from hiPSC cardiac spheroids to align and
functionally engraft/integrate with the host tissue after transplantation is an open question
that needs to be investigated.
In this study, we injected nanowired hiPSC cardiac spheroids into adult rat hearts
and examined cell retention, engraftment and integration. In addition, we examined the
cardiac biocompatibility of e-SiNWs in the adult rat hearts. For the first time, we
demonstrated that the nanowired spheroids significantly improve hiPSC-CM retention
and engraftment after intramyocardial injection, when compared to the dissociated single
hiPSC-CMs and unwired hiPSC cardiac spheroids. 7 days post-injection, the transplanted
nanowired spheroids showed alignment with the local myocardium and improved the
development of cellular contractile structures. By 28 days post-injection, the nanowired
spheroid

grafts formed electrical/mechanical/vascular junctions with the host

myocardium, supporting functional integration with host myocardium.
3. Materials and methods
3.1 Cell culture
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The hiPSC-CMs (Cellular Dynamics International, Madison, USA) were cultured
according to the manufacturer's protocol. Briefly, hiPSC-CMs were plated on 0.1%
gelatin coated 6-well plates in plating medium and incubated at 37 °C in 5% CO2 for 4
days. Two days after plating, plating medium was removed and replaced with 4 mL of
maintenance medium. After 4 days of monolayer pre-culture, cells were detached using
trypLE (Life Technologies, Grand Island, NY) and prepared for spheroid fabrication.
3.2 Fabrication of nanowired hiPSC cardiac spheroids
The details of the fabrication process can be found in our recent publication (32).
Briefly, the n-type SiNWs (Diameter ≈ 100 nm; length ≈ 10 µm; Si/P = 500) were
prepared according to the previously established protocol (32). The length and diameter
of the e-SiNWs were selected to inhibit cell internalization. The doping ratio was chosen
to obtain a high conductivity (150 - 500 µS/µm) compared to cell culture medium (~1.75
µS/µm) and myocardium (~0.1 µS/µm) to create highly electrically conductive
microenvironments within the spheroids.
3.3 Video and image analysis of beating spheroids
Videos of 6 spheroids from each group were recorded using Zen 2011 software
(Zeiss, Göttingen, Germany) with capture rate of 14 frames per second. Then the videos
were converted to a series of TIFF format pictures by Adobe Premiere (Adobe, San Jose,
CA). Threshold edge-detecting in ImageJ software (National Institutes of Health) was
used on high contrast spheroid pictures and graphed to realize contraction profiles, from
which the fractional area change was calculated.
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3.4 Injection of e-SiNWs and nanowired cardiac spheroids into rat hearts
To evaluate the cardiac biocompatibility of e-SiNWs, young male Sprague–
Dawley rats (8-10 weeks old) were prepared for surgery, anesthetized, given analgesia,
intubated, and a left thoracotomy was performed to expose the heart. The pericardium
was opened and 5 million silicon nanowires in 50 µl PBS were injected to the 3 different
sites in left ventricular region using syringes with a 31-gauge needle. For nanowired
hiPSC cardiac spheroid injection, athymic young male rats (8-10 weeks old) were
prepared for surgery, anesthetized, given analgesia, intubated, and left thoracotomy were
performed to expose the heart. The pericardium was opened and a total of ~30 nanowired
hiPSC cardiac spheroids per rat (i.e., 30,000 hiPSC-CMs per rat) or 30,000 single hiPSCCMs in Matrigel were injected to three different sites (50 µl at each site) in the left
ventricular region using 29-gauge needles. After injection, the thoracotomy incision was
sutured and the animal was allowed to recover for 1 day, 7 days and 28 days before heart
harvest for histological analysis. The influences of the injected e-SiNWs and cellular
therapies on the rat cardiac function were examined on day -1, 1, 7 and 28 post-injection
by using electrocardiogram and echocardiogram as described below. All the surgical
procedures and pre-/post-operative care were performed following NIH guidelines for the
care and use of laboratory animal (NIH publication No. 86-23, revised 1996), and they
were under the supervision of the Institutional Animal Care and Use Committee
(IACUC) of the Medical University of South Carolina (MUSC).
3.5 Cardiac function measurement
To examine rat echocardiography, the Vevo2100 imaging system (VisualSonics,
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Toronto, Canada) was used with 22–55 MHz linear transducer probe (MS400 or MS250)
for 2-D B-mode and M-mode analysis. During the measurement, heart rate was
maintained at 300–400 bpm via isoflurane anesthesia. Left ventricular (LV) volume was
calculated from Simpson‟s method of disks, the ejection fraction (EF) was determined
from the equation: EF= (LV end diastolic volume – LV end systolic volume)/ (LV end
diastolic volume) and the fractional shortening was calculated by the equation: FS = (LV
end diastolic dimension - LV end systolic dimension)/ LV end diastolic dimension.
Offline image analyses were performed using the dedicated VisualSonics Vevo2100 1.2.0
software. Electrocardiogram (ECG) and rectal temperature (RT) were recorded by
MouseMonitor S (Indus Instruments, Webster, TX). Briefly, the rats were anesthetized
using 3% isoflurane and placed on the heated pad (37°C). The ECG (leads I, II, and III)
and RT were obtained from four needle electrodes subcutaneously inserted into the four
paws and one temperature probe placed in rectal location while the rat was in supine
position.
3.6 Histological analysis for in vitro cultured nanowired cardiac spheroids
The freshly collected spheroids (~30-35) were flash frozen in Tissue-Tek OCT
compound (Sakura, Torrance, CA) and cryo-sectioned into 7μm thickness layers onto
glass slides for immunohistochemistry. The frozen sections were fixed with pre-cooled
acetone (-20 °C) for 10 min. The fixative was poured off and the acetone was allowed to
evaporate from the sections for 20 min at room temperature. After washing (3 times at 5
min) in PBS with 0.1% Triton X-100 (PBST), 100 μl blocking buffer (10% goat serum
(Sigma) in PBST) was added onto the sections of the slides and incubated in a humidified
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chamber at room temperature for 1 h. The sections were incubated with appropriately
diluted primary antibody overnight at 4 °C. After washing in PBST (3 times at 5 min),
tissues were incubated with coordinate secondary antibodies diluted in PBST for 1h at
ambient temperature. After washing in PBST (3 times at 5 min), nuclei were
counterstained with DAPI (Molecular Probes/Invitrogen, Eugene, OR) diluted in PBST
for 15 min at ambient temperature. Following the final wash procedure (PBST, 3 times at
5 min), glass cover slips were added to the slides using Fluoro-Gel (Electron Microscopy
Sciences, Hatfield, PA). Finally, TCS SP5 AOBS laser scanning confocal microscope
(Leica Microsystems, Inc., Exton, PA) was used to get fluorescent images. The detailed
information of the antibodies used in this study was listed in the Table 5.1.
Antigen
Vimentin
CD68
pan Troponin I
connexin 43
alpha sacomeric actin
alpha sacomeric actin
N cadherin
Laminin
Collagen I
Human Nuclear
Isolectin B4 Alexa488 Conjugate
DAPI
Live/dead staining kit
TUNEL staining kit

Antibody
Rabbit
Mouse
Rabbit
Rabbit
Rabbit
Mouse
Mouse
Mouse
Rabbit
Mouse

type
Company
polyclonal
Abcam
monoclonal AbD Serotec
polyclonal
santa cruz
polyclonal
sigma
polyclonal
abcam
monoclonal Gene Tech
monoclonal
BD
monoclonal
Sigma
polyclonal
abcam
monoclonal
abcam
life Tech
life Tech
life Tech
Roche

Catalog number
ab92547
MCA341GA
SC-15368
C6129
ab9465
GTX29465
610921
L9393
ab34710
ab191181
I21411
R37606
L3224
11684795910

Dilution
1:200
1:200
1:200
1:200
1:200
1:200
1:200
1:200
1:200
1:200
1:50
1:10
EthD-1 (1:500) / calcein (1:2000)
enzyme solution: label solution=1:9

Table 5.1: The details (vendor source, catalogue number and dilution ratio) of the
antibodies used in this study.

3.7 Histological analysis for the harvested cardiac tissues
The fresh rat hearts were fixed overnight in 4% paraformaldehyde solution and
embedded in a paraffin block. Using an automated microtome (LeicaRM2255, Leica,
Exton, PA), paraffin embedded hearts were sectioned into 8 μm thickness ribbon with
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~1000 sections per heart in total. Three sections were picked up with every 25 sections
gap for mounting on the glass slide and 40 slides (~120 total sections per heart) were
processed and stained for each rat heart in order to avoid missing the human spheroids in
rat myocardium for staining. Paraffin-embedded hearts were sectioned (8 μm) dewaxed
and processed with antigen retrieval solution (Vector Laboratories, Burlingame, CA) in
pressure cooker for 10 min before staining. Sections were incubated with appropriately
diluted primary antibody overnight at 4 °C. After washing in PBST (3 times at 5 min),
tissues were incubated with coordinate secondary antibodies diluted in PBST for 1h at
ambient temperature. After washing in PBST (3 times at 5 min), nuclei were
counterstained with DAPI (Molecular Probes/Invitrogen, Eugene, OR) diluted in PBST
for 15 min at ambient temperature. Following the final wash procedure (PBST, 3 times at
5 min), glass cover slips were added to the slides using Fluoro-Gel (Electron Microscopy
Sciences, Hatfield, PA). Finally, TCS SP5 AOBS laser scanning confocal microscope
(Leica Microsystems, Inc., Exton, PA) was used to get fluorescent images. The average
grafts per heart for spheroid transplantation was calculated as the number of slides per
heart (out of ~30-40 total slides per heart) with visible grafts (N=5 rats, total of ~150
observed slides per treatment). The detailed information of the antibodies used in this
study was listed in the Table 5.1.
3.8 TUNEL staining
In Situ Cell Death Detection Kit (Roche, Penzberg, Germany) was used to
determine the viability of the cells in the paraffin section of rat hearts and frozen sections
of spheroids. Briefly, the paraffin sections of spheroids were dewaxed and processed with
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antigen retrieval solution (Vector Laboratories, Burlingame, CA) in pressure cooker for
10 min , then washed in PBS for 30 minutes. For frozen section spheroids, sections were
fixed in 4% paraformaldehyde solution for 10 min, then washed in PBS for 30 min. After
PBS washes, sections were incubated in permeabilisation solution (0.1% Triton X-100
and 0.1% sodium citrate in PBS) for 2 minutes on ice. Then 50 µl TUNEL reaction
mixture samples was added and incubated in 37 °C for 1 hour. After washing in PBST (3
times at 5 min), nuclei was counterstained with DAPI (Molecular Probes/Invitrogen,
Eugene, OR) for 15 min at ambient temperature. Following the final wash procedure
(PBS, 3 times at 5 min), glass cover slips were added to the slides using Fluoro-Gel
(Electron Microscopy Sciences, Hatfield, PA).
3.9 Transmission Electron Microscopy
e-SiNWs were gently sonicated in isopropyl alcohol (IPA) and dispersed onto
lacey carbon grids (Ted Pella Inc.). TEM imaging was conducted using a 300kv FEI
Tecnai G2 F30 Super Twin Transmission Electron Microscope (Fig. 5.1).
4. Results
4.1 Cardiac compatibility of e-SiNWs
Our previous in vitro research showed the minimal cytotoxicity of e-SiNWs (ntype SiNWs: Diameter ≈ 100 nm; length ≈ 10 m; Silane/Phosphane = 500, Figure 5.1)
when co-cultured with hiPSC-CMs [148, 190]. To use e-SiNW nanowired hiPSC cardiac
spheroids for heart repair, in vivo cardiac biocompatibility of e-SiNWs must be
established. In addition to cellular compatibility, functional compatibility in the heart
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must be considered due to the possible electrical interference of the conductive e-SiNWs
with the innate cardiac electrical signal conduction system. To examine these concerns, 5
million e-SiNWs were injected into the healthy adult rat myocardium. The cardiac
function of the rats injected with e-SiNWs and PBS (control) was examined using
electrocardiogram (ECG) and echocardiography on day -1, 1, 7 and 28 post-injection
(Fig. 5.2A-D). As shown in the Figure 2A, ECG results revealed no detectable
arrhythmia of the rat hearts after e-SiNW injection. This indicates the injected e-SiNWs
do not significantly affect the electrical conduction system of adult rat myocardium. In
addition, left ventricle ejection fraction (EF) (~70%) and fractional shortening (FS)
(~35%) of the rat hearts did not show significant differences between before and after eSiNW injection (Figure 5.2B-D). In addition, the left ventricle EF and FS of the e-SiNW
injected rats were found to be very similar to that of the PBS injected control rats. These
data strongly indicated the e-SiNWs do not alter the cardiac function after a high dose
injection into adult rat myocardium.
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Figure 5.1: Transmission electron micrograph of an e-SiNW. TEM image of a typical ntype e-SiNW used in this study on a carbon grid.
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Figure 5.2: Cardiac functional compatibility analysis after e-SiNWs injection into adult
rat myocardium. (A) Representative ECG profiles of rats with 5 million e-SiNWs
injection in the left ventricular myocardium at time points of before injection (D-1) and
after injection (D1, D7 and D28). (B) Representative echocardiogram images in short
axis of rat hearts with 5 million e-SiNWs injection in the left ventricular myocardium at
time points of D-1 and D28. (C) Ejection fraction and (D) fractional shortening were used
for quantitative analysis of cardiac function after e-SiNWs and PBS injection. Error bars
represent standard deviation (N=4).

In addition to evaluating the cardiac function, the blood samples of the rats
injected with e-SiNWs and the control rats were collected on day -1, 1, 7, 14 and 28 postinjection. As shown in Figure 5.3 and Table 5.2, the total white blood cell counts from
the e-SiNW injected rats are in the normal physiological range without statistically
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D28

differences between the rats with the e-SiNW injections and the control rats. This showed
that the intramyocardial injection of e-SiNWs did not significantly affect the
hematological characteristics of the rats. Supported by a normal growth curve, heart beat
rate and body temperature (Figure 5.4-5.5), our data indicated the intramyocardial
injection of e-SiNWs resulted in a minimal global inflammatory response.

Total White Blood Cells (k/ul)_ Normal range: 2.9~20.9
Pre-surgery

Post surgery

Group

5m e-SiNWs
(n=5)

PBS
(n=3)

Day -1

Day 1

Day 7

Day 14

Day 28

15.80

16.82

16.06

15.76

14.60

23.48

13.38

19.88

17.84

11.74

7.76

12.98

18.66

12.18

11.36

8.86

11.76

18.52

19.76

19.74

16.10

11.90

19.74

13.96

13.32

13.04

12.14

17.22

20.32

19.66

16.46

17.24

12.32

22.78

19.20

17.86

19.86

12.86

18.46

17.58

Table 5.2: Total white blood cells counts for nanowires biocompatibility test.
Hematology profiles of rats blood samples with 5 million e-SiNWs or PBS (control)
intramyocardial injection at time points of before injection (D-1) and after injection (D1,
D7 and D28) indicate minimal inflammation response post surgery. n=5 rats for e-SiNWs
injection group and n=3 rat for PBS injection group.

138

Figure 5.3: Representative blood test result. The hematology profile of rat blood sample
collected from tail vein was performed by Drew Scientific HemaVet 950FS Auto Blood
Analyzer. The red boxed value is used to construct Table 1.
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Figure 5.4: The rats followed a normal weight curve after e-SiNW injection. The rats
with 5 million e-SiNWs or PBS (control) intramyocardial injection were weighed at time
points of before injection (D-1) and after injection (D1, D7 and D28) to monitor the body
growth. Error bars represent standard deviation. n=5 rats for e-SiNWs injection group and
n=3 rat for PBS injection group.
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Figure 5.5: The rats followed a normal physiological condition after receiving NWs
injection. Heart beat rate and rectal temperature were recorded for the rats with 5 million
e-SiNWs or PBS (control) intramyocardial injection at time points of before injection (D1) and after injection (D1, D7 and D28) to monitor the physiological condition. Error bars
represent standard deviation. n=5 rats for e-SiNWs injection group and n=3 rat for PBS
injection group.
Histological analysis was conducted to examine e-SiNW retention and
degradation, as well as the effects of the injected e-SiNWs on myocardium inflammation
and fibrosis. As shown in the Figure 5.7 A-B, a significant decrease in the amount of eSiNWs was found in myocardium 7 days post-injection when compared to 1 day postinjection. After 28 days, few e-SiNWs were found in the injected myocardium, which
was attributed to biodegradation and redistribution [195, 246]. In addition, H&E staining
showed a minor inflammation 7 days post-injection in the myocardium and no sign of
inflammation 28 days post-injection. Naphthol AS-D chloroacetate esterase staining
(Figure 5.7 C) and CD68 staining (Figure 5.7 D) showed neutrophil and macrophage
infiltration

in

the

myocardium

1

day

post-injection,

and

the

infiltrated

neutrophils/macrophages decreased by day 7 and disappeared on the day 28 post-
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injection. Notably, CD68-positive macrophages at day 7 also showed colocalization with
e-SiNWs, which supports the reported phagocytosis mechanism of internalization and
biodegradation of the e-SiNWs (Figure 5.6) [196, 246]. These results clearly showed the
injected e-SiNWs did not induce chronic inflammation or chronic foreign body response
in the myocardium. In addition to inflammation, fibrosis after e-SiNW injection in the
myocardium was examined. Vimentin staining (Figure 5.7 E) showed a minor fibroblast
infiltration 7 days post-injection that disappeared by day 28 after e-SINW injection,
which indicated the injected e-SiNWs did not induce a chronic fibrotic response.
Collectively, our results showed the e-SiNW showed minimal toxicity to the adult
myocardium after intramyocardial injection and lays down the foundation for the use of
nanowired spheroids for heart repair.
A

B

DAPI

e-SiNW (scattered light)

CD68

Merge

e-SiNWs
CD68
DAPI

Figure 5.6: Injected nanowires colocalize with macrophages at D7 post-transplantation.
(A) Colocalization of e-SiNWs with CD68-positive (green) macrophages supports
reported phagocytosis mechanism of internalization and degradation. (B) Large
nanowires (arrow) were often found outside the macrophages in line with size-limited
internalization. Scale bars= 10 µm.
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Figure 5.7: Histological analysis after e-SiNW injection into adult rat myocardium. (A)
H&E staining shows location and density of e-SiNWs that decrease and disappear over
28 days after injection. (B) Confocal images of light scattering signal of e-SiNWs show
similar results with H&E staining. (C) Neutrophils infiltration identified by naphthol ASD chloroacetate staining (dark brown) shows short-term increase in inflammatory
response that diminished by day 28. (D) Macrophages infiltration identified by CD68
staining shows short-term increase in inflammatory response that diminished by day 28.
(E) Non-cardiomyocytes identified by vimentin staining in adult rat heart for 5 million eSiNWs injection at day 1, day 7 and day 28 to indicate fibroblast infiltration. Vimentinpositive cells disappear by day 28 indicating no chronic fibrotic response. Scale bars: (AE)= 200 µm

4.2 Fabrication and characterization of nanowired hiPSC cardiac spheroids
for transplantation
To prepare spheroids suitable for injection, we fabricated nanowired hiPSC
cardiac spheroids containing ~1,000 cells/spheroid using our previosuly established
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method (Figure 5.8 A-B) [148]. After 7 days of spheroid formation, the diameter of the
nanowired spheroids decreased to ~180 µm, an injectable size (i.e., less than inner
diameter of 29 gauge needle) for rat myocardium (Figure 5.8 C). Further extended culture
did not significantly reduce the size of the spheroids. Consistent with the changes in
spheroid size, the amplitude of the spontaneous contraction of the nanowired spheroids
gradually decreased over the time and stabilized after 7-9 days spheroid culture (Figure 8
D). The reduced size and contraction amplitude of the nanowired spheroids indicates the
formation and stabilization/maturation of the human cardiac microtissues.
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Figure 5.8: Fabrication and characterization of nanowired hiPSC cardiac spheroids for
transplantation. (A) Bright field image images of nanowired hiPSC cardiac spheroids
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after 7 days spheroid culture. (B) Transmission electron micrograph of nanowired
spheroid section shows nanowire locates in extracellular space. Asterisk - nanowire
location. (C) Diameter and (D) fractional area change of nanowired hiPSC cardiac
spheroids from spheroid culture D0-D14. Error bars represent standard deviation (N=6).
(E-I) Frozen sections of D0 and D7 spheroids characterize microtissue development
according to cell junctions proteins (E: Cx-43; F: N-cadherin), ECM protein (G: laminin)
and contractile proteins (H: alpha sacomeric actinin; I: troponin I). Scale bars: (A) =200
µm, (B) =500 nm, (E-I) =100 µm.
To validate the cardiac tissue formation and maturation, frozen sections of day 0
and day 7 spheroids were immunofluorescently stained to examine the formation of
cellular junctions, extracellular matrix (ECM) protein production and contractile protein
development. Consistent with our previous work, day 7 spheroids showed significant
increase of cellular junction formation, including electrically conductive channel
proteins, Connexin-43 (Cx-43) (Figure 5.8 E), and mechanical junction proteins, Ncadherin (N-cad), when compared to day 0 spheroids (Figure 5.8 F) [148]. In addition to
cell-cell junctions, the cell-matrix interactions can facilitate cardiac tissue formation and
development. Figure 5.8 F showed the abundant presence of basement membrane protein
(laminin) in the nanowired spheroids (Figure 5.8 G). The formation and maturation of
nanowired spheroids was also supported by significant development in the contractile
protein such as alpha sarcomere actinin (Figure 5.8 H) and troponin I (Figure 5.8 I) in day
7 spheroids, when compared to day 0 spheroids. In addition, we observed that day 7
spheroids are mechanically stable for technical manipulations and intramyocardial
injection protocols. Compared to dissociated hiPSC-CMs in Matrigel, the nanowired
spheroids showed no significant difference in cell apoptosis (i.e., TUNEL) after a 29gauge needle extrusion into a petri dish (Figure 5.9). Together, these results clearly
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showed the nanowired spheroids provided a supportive microenvironment to form
injectable 3D hiPSC cardiac microtissues for transplantation.

Figure 5.9: Viability of hiPSC-CMs in Matrigel and spheroids before and after needle
extrusion. (A) Confocal images of Live/Dead staining of single hiPSC-CMs in Matrigel
before and after extrusion through a 29 gauge syringe needle. Green- live cells; red- dead
cells. (B) Quantification of the cell viability based on the Live/Dead staining. n=3. (C)
Confocal images of TUNEL staining of spheroid sections before and after extrusion
through a 29 gauge syringe needle. Green- apoptosis cells; blue- DAPI. (D)
Quantification of the cell viability based on the TUNEL. n=3. Scale bars: (A, C)=50 µm.
Asterisks (*) represent statistical significance with p<0.05; error bars represent standard
deviation.
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4.3 Nanowired hiPSC cardiac spheroid transplantation improve cell
retention, engraftment and integration
To examine the capacity of the nanowired hiPSC cardiac spheroids to improve
cell retention and engraftment, we injected nanowired hiPSC cardiac spheroids into
healthy Athymic rat hearts. Healthy rats were selected due to their effectiveness to study
hiPSC-CM engraftment and integration without the confounding factors presented in the
injured animal models (e.g., variation among different injured animals) [182]. In this
study, we injected a small number of nanowired hiPSC cardiac spheroids into each
animal (~30 spheroids/rat; ~30k hiPSC-CMs/rat) to examine individual hiPSC cardiac
spheroids‟ integration with the host myocardium. In addition, we conducted ECG and
echocardiography measurement for the rat hearts before and after the injection of the
nanowired spheroids to examine the effects of the injected nanowired spheroids. As
shown in Figure 10 A-C, the injection of the nanowired spheroids did not interfere with
the electrical conduction system as well as the normal function of the rat hearts.
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Figure 5.10: Nanowired spheroids transplantation improves cell retention and
engraftment in adult rat myocardium. (A) Representative ECG profiles of rats with
nanowired cardiac spheroids injection in the left ventricular myocardium at time points of
before injection (D-1) and after injection (D1, D7 and D28) indicate healthy cardiac
electrical signal propagation with no arrhythmias. (B) Ejection fraction and (C) fractional
shortening as quantitative analysis for cardiac function for spheroids injection do not
show deleterious effects of nanowired spheroid injection. Error bars represent standard
deviation (N=4). (D) H&E staining of single cell injection sites (identified by Matrigel
dense area – asterisk) and nanowired spheroids (WC1k) on D1 post transplantation.
Dotted line encircles spheroid intramyocardial location. (E) Immunofluorescent staining
of Matrigel dense regions of single cell and nanowired spheroids transplantation in
myocardium on D1 indicate presence of troponin I (red) contractile protein in spheroid
groups and minimal presence with HNA-positive cells (arrow) for single cell injection.
Green-human nucleolar antigen (HNA); red-troponin I (TnI); blue-DAPI. (F) TUNEL
staining (green) with high magnification inset of single cell injection sites (marked by
Matrigel – asterisk) and nanowired spheroids on D1 post transplantation show a
significantly reduced number of apoptotic cells in nanowired spheroid transplantation.
Dotted line encircles spheroid intramyocardial location. Yellow-light scattered signal of
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e-SiNWs, blue – DAPI nuclear stain. Scale bars: (D) top=50 µm, bottom= 100 µm; (E)=
50 µm; (F)= 50 µm.
The hearts were harvested on 1 day post-transplantation for histological analysis
to examine spheroid retention and survival. Intramyocardial injections of dissociated
hiPSC-CMs in Matrigel were used as a control [104]. As shown in Figure 5.10 D-E, the
nanowired spheroids, identified by human nucleolar antigen (HNA) staining, did not
dissociate upon injection and maintained their spherical shaped microtissue configuration
after transplantation into beating hearts, which gave rise to excellent cell retention. In
contrast, very few HNA-positive hiPSC-CMs were found in the myocardium, when
single hiPSC-CMs were injected with Matrigel (Figure 5.10 D-E; Figure 5.11). In
addition, all of these HNA-positive cells showed negative TnI staining. Further, an
increase in TUNEL positive cells was found at the dissociated hiPSC-CM injection sites
located by Matrigel dense regions, while few TUNEL positive cells were found within
and around the transplanted spheroids (Figure 5.10 F). Scarcity of viable hiPSC-CMs
after injection of dissociated hiPSC-CMs is consistent with the literature and was
attributed to injection-induced and/or anoikis-mediated cell death pathways [173]. The
improved cell retention and survival of the nanowired spheroid injection was attributed to
the enhanced 3D cell-cell adhesion and stable microtissue configuration to better resist
redistribution caused by the mechanical stress of the beating heart.
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Figure 5.11: Limited cell retention using single hiPSC-CMs injection with Matrigel.
Immunofluorescent staining of single cell injection on D1 post-transplantation in
myocardium indicate presence of a small amount of human nucleolar antigen-positive
cells that lack troponin I (red) contractile protein expression. Green-human nucleolar
antigen (HNA); red-myocardium marker (troponin I); blue-DAPI. Scale bar = 50 µm

By 7 days post-transplantation, the injected nanowired spheroids showed
excellent cellular engraftment (Figure 5.12). Compared with day 1 grafts, the day 7 grafts
showed strong evidence of alignment with the host myocardium (Figure 5.12 A-B) and
development of sarcomere structures (Figure 5.12A, C). The graft alignment with the
host myocardium indicated that the grafts adapted to the local electrical/mechanical
stimuli after transplantation. Alignment also serves as a structural foundation for the
mechanical graft-host integration, supported by the improved expression and organization
of contractile proteins in day 7 grafts. Together with no detection of arrhythmia (Figure
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5.10 A), these results suggest the possibility of contractile integration of the transplanted
spheroids with host myocardium.
A
e-SiNWs
TnI
HNA
DAPI

Inset

e-SiNWs
TnI
HNA
DAPI

D

2.5

Average number of
located grafts per heart

WC1k D7

*

2
1.5
1
0.5
0

WC1k D7

NC1kD7

C
Inset

TnI
HNA
DAPI

WC1k D7

E

e-SiNWs
αSA
DAPI

*

3.5
3
2.5
2
1.5
1
0.5
0
NC1kD7

F
NC1k D7

WC1kD7

4

Inset

Average graft size
(x104µm2)

B

WC1kD7

G
TnI
HNA
DAPI

TnI
HNA
DAPI

Inset

NC1k D7

Inset

αSA
HNA
DAPI

Figure 5.12: Nanowired spheroid transplantation improves the cell alignment and
structural maturation. (A) Confocal images of the engraftment in rat myocardium on D7
for nanowired spheroids (WC1k) transplantation. Insets (right) reveal improved
contractile development in nanowired spheroid grafts. Green-human nucleolar antigen
(HNA); red-troponin I (TnI); yellow-e-SiNWs; blue-DAPI. (B) WC1k graft sections
displayed aligned single cells from nanowired spheroids with host myocardium. GreenHNA; red-TnI; blue-DAPI. (C) WC1k spheroid grafts stained with alpha sarcomeric
actinin (αSA) staining reveal sarcomere development by D7. (D) Average grafts per heart
for unwired spheroids (NC1k) and nanowired spheroids (WC1k) transplantation
calculated as number of slides per heart (observed using 30-40 total slides per heart) with
visible grafts (N=5 rats, total of ~150 observed slides). (E) Average size of grafts in heart
for NC1k and WC1k spheroids transplantation reveal increased graft size in WC1k
treatment. (N=5 rats). Confocal imaging showed that NC1k grafts with poorly developed
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contractile structure identified by TnI (F) and αSA (G) staining. Green-HNA; blue-DAPI.
Scale bars: (A-C)= 50 µm; (F-G) = 50 µm. Asterisks (*) represent statistical significance
with p<0.05; error bars represent standard deviation.

Notably, significantly less (Figure 5.12 D) and smaller (Figure 5.12 E) grafts have
been found after the transplantation of unwired spheroids. Compared to the nanowired
spheroids, the transplantation of the unwired spheroids led to the less developed
contractile proteins (Figure 5.12F-G). In some cases, no detectable expression of
contractile proteins was found for the unwired spheroid grafts (Figure 5.13). This
difference strongly suggests the e-SiNWs in the spheroids can facilitate the
electromechanical integration with the host myocardium. It is worth to note that we can
reliably detect hiPSC-CM grafts with the nanowired spheroid injection of ~30k hiPSCCMs/rat, whereas the literature uses ~5 million dissociated hESC-CMs/rat to detect
hESC-CM engraftment in healthy myocardium [173]. This highlights the remarkable
potential of using nanowired hiPSC cardiac spheroids as a cell delivery system for heart
repair.
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Figure 5.13: The unwired spheroids lose the cardiac phenotype identified by negative
staining for troponin I by D7 post-transplantation. Confocal imaging showed that some
NC1k grafts show no troponin I contractile protein staining. Green-human nucleolar
antigen (HNA); red-troponin I; blue-DAPI. Scale bars: 50 µm.

By 28 days post-transplantation, nanowired hiPSC cardiac spheroids showed
strong evidence of functional integration with host myocardium. As shown in Figure 5.14
A-C, nanowired spheroids have shifted from the original spherical shape on day 1 postinjection to a cardiac muscle bundle-like structure on day 28 post-injection. This
indicates that the spherical configuration of nanowired hiPSC spheroid microtissues does
not prevent alignment with the host myocardium after transplantation and suggests
functional integration. This was further supported by histological analysis showing the

153

formation of electrical cellular junctions, Cx-43 (Figure 5.14 D), and mechanical cellular
junctions, N-cad (Figure 5.14 E), between the transplanted spheroids and host
myocardium. In addition, Isolectin B4 staining revealed capillary-like lumen structures
that contained blood cells within the day 28 spheroids grafts (Figure 5.14 F). As the
transplanted spheroids do not contain endothelial cells, this demonstrated the infiltration
of the host vasculature into the transplanted spheroid grafts. Together, these results
provided strong evidence that the electromechanical stimuli of host myocardium can
effectively condition transplanted nanowired spheroids and facilitate electrical,
mechanical, and vascular integration of the injected nanowired spheroids with the host
myocardium by 28 days after transplantation.
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Figure 5.14: Nanowired spheroid transplantation improves functional integration with rat
host myocardium. (A-C) Confocal images of nanowired spheroid grafts in rat
myocardium at D1, D7 and D28 post-transplantation display adaptation and alignment of
spherical microtissue over time. Green-human nucleolar antigen (HNA); red-troponin I
(TnI); blue-DAPI. (D-F) Nanowired spheroid grafts integrate with host myocardium. The
D28 post transplantation sample shows the presence of connexin-43 (Cx-43) staining (D)
for graft-host gap junctions formation and N-cadherin staining (E) for mechanical
integration between graft and host myocardium. Isolectin B4 (IB4) staining (F) shows
capillary-like structures (arrow) with blood cells within the nanowired spheroid graft.
Blood cells are identified by unspecific staining with TnI and IB4 (orange). Scale bars:
(A-C)= 100 µm; (D-F) =100 µm, inset = 25µm.
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As recent research has shown that chronic fibrosis can prevent electrical
integration between the transplanted hiPSC-CMs epicardial patches and the host
myocardium [182], we examined the fibrosis around the transplanted nanowired
spheroids. As shown in the Figure 5.15, we observed minimal fibrosis on day 1, high
fibrosis on day 7 and decreased fibrosis on day 28 post-injection. We reasoned that the
reduced fibrosis around the day 28 grafts allowed for the formation of electrical and
contractile integration of the grafts with host myocardium shown in the Figure 7.
Notably, few e-SiNWs were found in the nanowired spheroid graft 28 days postinjection, which is consistent with the results from the e-SiNW intramyocardial injection
experiments (Figure 5.7 A-B). The e-SiNWs in the day 28 grafts (Figure 5.14 D inset)
are significantly smaller than the e-SiNWs in the day 1 graft (Figure 10 F inset), which
has been attributed to the biodegradation of e-SiNWs [246].

Figure 5.15: The fibrosis decreases on day 28 post nanowired spheroids transplantation.
Collagen I staining (red) of human engraftment in rat myocardium with nanowired
spheroids transplantation on D1, D7 and D28 post-transplantation indicated typical short
term increase in fibrotic response that decreases by D28 for improved integration. Scale
bars: 100 μm.
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5. Discussion
In this study, we examined the cardiac biocompatibility of the e-SiNWs and cell
retention, engraftment and integration after the injection of the nanowired hiPSC cardiac
spheroids into adult rat hearts. The absence of major cell death or chronic
inflammation/fibrosis from the e-SiNW intramyocardial injection indicated their high
cardiac biocompatibility and is consistent with recent work by Zimmerman and
coworkers demonstrating the biological interactions with SiNWs [196]. The observed
cardiac functional biocompatibility of e-SiNWs seen by healthy ECG and
echocardiogram characteristics was in line with previous studies using conductive
nanomaterials in the heart [146]. The high cardiac compatibility of e-SiNWs supports the
in vivo use of nanowired hiPSC cardiac spheroids for transplantation.
To this end, nanowired spheroids were then injected into rat hearts that led to the
enhanced electrical/mechanical/vascular integration with the host tissue in contrast with
single hiPSC-CM and unwired spheroid injections. We reasoned that the improvements
seen in the nanowired spheroids treatment are partially due to the enhanced microtissue
formation and maturation prior to transplantation [148]. Microtissue formation and
maturation over 7 days in an in vitro spheroid culture allows for the development of cellcell and cell-matrix interactions, which improved the cellular delivery, retention, and
engraftment of spheroid injection. Although Matrigel provides a matrix/growth factor
enriched microenvironment for dissociated hiPSC-CMs to reduce anoikis-related
apoptosis and shear force-induced cell death from intramyocardial injection, our study
has shown that the nanowired spheroids can better support cell viability and significantly
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reduce the risk of these common cellular injection challenges [181]. Notably, even with
the formation and maturation of spherical cardiac microtissues prior to transplantation,
the nanowired spheroids did not inhibit adaptation and alignment with the host
myocardium after transplantation. This directly addresses concerns over the suitability of
the nanowired hiPSC spheroids based on the pre-alignment criteria.
In addition to alignment, nanowired spheroids showed significantly improved
cellular integration and contractile development than single cell hiPSC-CM injections and
unwired cardiac spheroid injections. The high electrical conductivity of e-SiNWs (150 500 µS/µm) in cardiac spheroids may lead to an enhanced ability to receive exogenous
electromechanical pacing signals to initiate simultaneous contraction with the host
myocardium. This was supported by the banded sarcomeric structures in the nanowired
spheroid grafts. In comparison, the unwired spheroid grafts showed significantly less
sarcomere development. Further, our recent report showed that e-SiNWs are essential for
the use of electrical stimulation to promote contractile development of hiPSC cardiac
spheroids [190]. In addition, previous studies have shown that the addition of electrically
conductive gold nanowires to electrically insulating alginate hydrogels improves the
range of the electrical propagation under exogenous electrical stimulation [147]. This
may indicate that the presence of electrically conductive nanowires in the spheroids may
enhance graft-host electrical coupling for improved contractile mechanics throughout
integration. In addition, our results showed the e-SiNWs in the nanowired spheroids
degrades over 28 days after transplantation. As non-biodegradable electrical
nanomaterials (e.g., carbon tubes) can permanently stay in the myocardium after
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transplantation and pose arrhythmogenic risk by interfering with the innate electrical
conduction system [146], the biodegradability of e-SiNWs makes them an ideal
nanoscaffolding material to promote hiPSC-CMs engraftment and integration with host
myocardium.
The previous studies have clearly showed that there are diverse sets of challenges
facing cardiac cell therapy. Most notably, cell therapy approaches using hiPSC-CMs have
consistently resulted in insufficient cell retention to effectively remuscularize injured
heart models. However, the reason for low cell retention is confounded by numerous
factors, such as anoikis-mediated cell death, inflammation, ischemic microenvironment
and variation among different injured animals. In this study, we aimed to improve the
fundamental understanding of improving hiPSC-CM cellular retention and integration.
To minimize the additional injury-induced variables and to effectively evaluate our
hypothesis on the cell retention and integration of nanowired spheroids, we used a
healthy rat heart model with a stringent cell injection condition (~30k cells/rat). The
healthy rat model provides an ideal model to compare treatment-induced differences in
cell retention and integration. Our data showed the use of injectable microtissues improve
cell retention, consistent with the previous studies. Further, our data showed the
nanowired spheroids improvements in graft-host integration after transplantation over
unwired spheroids or single cell injections due to the presence of e-SiNWs in the
nanowired spheroids. Notably, injectable nanowired spheroids provide a minimally
invasive approach to deliver tissue constructs and induce mild fibrosis as opposed to
surgically transplanted epicardial patches [175, 182]. Further, the effective engraftment
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and integration of the nanowired hiPSC cardiac spheroids with ~30k hiPSC-CMs/rat
hearts clearly demonstrated its potential to cost-effectively deliver the large number of
hiPSC-CMs needed to treat injured human hearts [170]. While future studies will focus
on injecting nanowired spheroids into injured rat hearts to examine their
therapeutic/functional efficacy, it should be noted that these nanowired hiPSC spheroids
may still pose an arrhythmogenic risk after transplantation due to their spontaneous
contractions (~0.5Hz) [153]. While this cannot be directly addressed in the rat model due
to the anti-arrhythmogenic nature of rat heart [182], we plan to use extended conditioning
strategies (e.g., exogenous electrical stimulation) to decrease the spontaneous beating of
the nanowired spheroids with the goal of preparing electrically quiescent hiPSC cardiac
spheroids for transplantation [180, 190].
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CHAPTER SIX
OVERALL CONCLUSIONS AND FUTURE DIRECTIONS
1. Summary of my research
MI causes a significant amount (around 25%) of irreversible cardiac cells death
within the LV myocardium. So far, current clinical interventions have shown to slow
down the progression of heart failure, none of them can reverse this deleterious process
and regenerate new myocardium to replace the necrotic regions of the LV. Recent
researches on MI treatment are focusing on cell therapies aiming to reverse heart
remodeling and reduce scar formation with transplantation of various stem/ progenitor/
terminally differentiated cells. Among all the cell types of cell therapies for MI treatment,
hiPSCs have emerged as a more promising cell resource for heart repair due to their
proven capacity to produce patient-specific functional hiPSC-CMs. In addition, recent
progress in cardiac differentiation of hiPSCs allows for the derivation of a large number
of hiPSC-CMs (>109 cells/patient) needed for cardiac repair.
1.1 Accelerate structural and contractile maturation of hiPSC-CMs in
nanowired spheroids system
The immature phenotypes of hiPSC-CMs pose a potential

risk for

arrhythmogenicity in vivo, which could hamper host conducting system and functional
integration of transplanted cardiomyocytes with the host myocardium. In the past decade,
physical stimuli (e.g. electrical and mechanical stimulation) has been applied to advance
the immature cardiomyocytes towards more matured phenotypes with more organized
sarcomere structures (width, length and alignment) and unregulated expression level of
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gap junction protein (Connexin-43). In order to mimic the electrically conductive
properties of native myocardium, conductive nanomaterials (gold nanowires, carbon
tubes) have been used as scaffolding materials to fabricate engineered cardiac tissue with
stronger contractile and electrical properties for promoting cardiomyocyte maturation in
vitro and in vivo. However, above mentioned gold or carbon based conductive
nanomaterials are non-biodegradable, which may hold potential risk of arrhythmogenicity
and chronic immune response induce by these permanently resident foreign materials in
the heart.
For the first time, we incorporated a trace amount of e-SiNWs into rat-neonatal
and hiPSC cardiac spheroids to create electrically conducting microenvironments and
induce synchronized and enhanced contraction, which was shown to promote structural
and contractile maturation. e-SiNWs were selected because of their controllable electrical
conductivity, tunable dimensions, and convenient surface tailorability. Further, the recent
research showed SiNWs are biodegradable, and their degradation products are found
mainly in the form of Si(OH)4 and are metabolically tolerant in vivo. This makes them
advantageous over other non-biodegradable, electrically conductive nanomaterials (e.g.,
gold nanowires, carbon nanotubes and nanofibers), especially for potential in vivo
applications. We demonstated that e-SiNWs could facilitate the self-assembly of hiPSCCMs to form nanowired hiPSC cardiac spheroids and improve the functions of the
microtissues, which lead to

significantly more advanced cellular structural and

contractile maturation of hiPSC-CMs in nanowired spheroids system.
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1.2 Optimize the size of nanowired spheroids and confirm the critical role of
electrical conductivity of e-SiNWs in improving the function of cardiac spheroids
We demonstrated that addition of e-SiNWs into the human cardiac spheroids
creates an electrically conductive microenvironment and improves tissue function and
cellular maturation of hiPSC cardiac spheroids. In addition, recent research has shown
that cellular spheroids/aggregates improve cell retention and survival after transplantation
due to their 3D microtissue configuration. In my research, we try to examine two major
factors that can affect the functions of the nanowired human cardiac spheroids: (1) the
number of cells per spheroid (i.e., size of the spheroids), and (2) the role of the electrical
conductivity of the e-SiNWs in improving tissue functions of the spheroids.
The optimal cell number in the spheroids is affected by two competing factors: 1)
the improved 3D cell-cell adhesion, and 2) the reduced oxygen supply to the center of
spheroids with the increase of cell number. Firstly, we experimentally identified the
optimal cell number in the spheroids and developed a semi-quantitative theory to explain
the finding. The functional analysis of contraction amplitude, IHC analysis of contractile
and conductive proteins, and metabolic investigation demonstrated that spheroids with 3k
cells per spheroids maximize the beneficial effects of the 3D spheroid microenvironment.
In our previous report, we showed the addition of e-SiNWs in the human cardiac
spheroids improved cellular maturation and tissue function. However, the role of
electrical conductivity of the e-SiNWs has not been examined. Secondly, we prepared
three types of the spheroids: spheroids without the addition of nanowires, spheroids with
the addition of phosphorus doped silicon nanowires (electrically conductive), and
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undoped silicon nanowires (none electrically conductive). We studied the functions of
these three different types of spheroids and confirmed the critical role of electrical
conductivity of e-SiNWs in improving tissue functions of the hiPSC cardiac spheroids.
Additionally, the electrical conductivity of silicon nanowires was confirmed to contribute
to accelerate structural and functional development of hiPSC-CMs in spheroids.
1.3 Injected nanowired spheroids improve cell retention, survival,
maturation, long term engraftment and functional integration with rat hearts
While most of research utilized direct injection of the dissociated hiPSC-CMs into
the injured myocardium, the success of this single cell delivery is limited by low cell
retention and survival after cell transplantation. Additionally, lack of cell-to-cell adhesion
amongst single cells leads to cell death caused by anoikis and/or ischemia. To improve
the efficiency of cell delivery, significant efforts have been devoted to the development
of tissue-engineered epicardial patches. The cardiac patch provides a better method to
deliver cardiac cells to the injured myocardium to achieve better outcomes such as higher
cell retention and survival, larger and more controlled infarction area coverage, reduced
LV remodeling post MI. However, regarding this invasive surgical procedure as patches
transplantation, recent research has shown there is limited electrical integration between
the transplanted patches and host myocardium, largely attributed to the chronic fibrotic
response that occurs after transplantation. In addition, the human engraftment formed
from transplanted patch is totally isolated from host tissue by fibrosis and it does not
contribute to functional improvements in MI model. This highlights an urgent need to
develop a less invasive delivery approach to improve the retention, engraftment and
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integration of the transplanted hiPSC-CMs with the host myocardium upon
transplantation.
hiPSC cardiac spheroids have been proposed as an attractive cell delivery system
for heart repair, given the recent literature showing spheroid/aggregate delivery improves
cellular retention and post transplantation survival as less invasive approach (injectable).
To this end, we recently utilized e-SiNWs to facilitate the self-assembly of hiPSC-CMs to
form nanowired hiPSC cardiac spheroids and improve the functions of the microtissues,
resulting in significantly more advanced cellular structural and contractile maturation of
hiPSC-CMs. Here we reasoned that the presence of the e-SiNWs in the injectable
spheroids improves their ability to receive exogenous electromechanical pacing from the
host myocardium and enhances their integration with host tissues post-transplantation.
This theory was inspired by our recent finding that the addition of e-SiNWs in hiPSC-CM
spheroids are essential for exogenous electrical stimulation/pacing to promote hiPSC-CM
development and maturation. Furthermore, recent reports showed the presence of
electrical nanomaterials (e.g., gold nanowires) in cardiac tissue engineering constructs
synergizes with exogenous electrical pacing to improve the function of the constructs.
Compared to other electrical nanomaterials (e.g. gold nanowires, carbon nanotubes), eSiNWs have distinct advantages, including their controllable electrical conductivity,
tunable dimensions, and convenient surface tailorability. Additionally, both in vitro and
in vivo biocompatibility studies have shown no significant cytotoxic effects for either
undoped or n-type e-SiNWs. Notably, the absence of a pre-aligned structure within the
nanowired hiPSC cardiac spheroids has raised concerns over their suitability for
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transplantation.
We examined the cardiac biocompatibility of the e-SiNWs and cell retention,
engraftment and integration after the injection of the nanowired hiPSC cardiac spheroids
into adult rat hearts. The absence of major cell death or chronic inflammation/fibrosis
from the e-SiNW intramyocardial injection indicated their high cardiac biocompatibility,
which supports the in vivo use of nanowired hiPSC cardiac spheroids for transplantation.
More importantly, our research showed the injected nanowired spheroids improve cell
retention, survival, maturation, long term engraftment and functional integration with the
host tissue compared with single cell and unwired spheroid transplantation.
2. Challenges and limitations
Past literatures indicates that mammalian heart consists of 30% cardiomyocytes
and 70% non-cardiomyocytes (cardiac fibroblasts, endothelial cells, smooth muscle cells)
[281]. Cardiac fibroblasts (CFs) play a critical role in maintaining normal heart function
and LV remodeling post MI. In addition, CFs significantly contribute to the synthesis and
deposition of ECM, cell–cell communication affecting the electrophysiological
properties, secretion of growth factors and cytokines, and angiogenesis in the heart [282].
The extra vascular cells (endothelial cells, smooth muscle cells) could provide necessary
components for new blood vessels formation in vivo. However, there is only
cardiomyocytes in our nanowired cardiac spheroids system, which may be not the
optimal cell resource for transplantation. We plan to add non-cardiomyocytes (cardiac
fibroblasts, endothelial cells, smooth muscle cells) in our nanowired cardiac spheroids
system to achieve better therapeutic outcomes upon transplantation in MI models.
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It should be noted that nanowired hiPSC spheroids may still pose an
arrhythmogenic risk after transplantation due to their spontaneous contractions (~0.5Hz).
While this cannot be directly addressed in the rat model due to the anti-arrhythmogenic
nature of rat heart, we plan to use extended conditioning strategies (e.g., exogenous
electrical stimulation) to decrease the spontaneous beating of the nanowired spheroids
with the goal of preparing electrically quiescent hiPSC cardiac spheroids for
transplantation.
3. Future directions
3.1 Application of cardiac regenerative medicine
The future studies will focus on injecting nanowired spheroids into injured rat
hearts to examine their therapeutic/functional efficacy. We will create a MI model on
athymic adult rats, and delivery the injectable nanowires cardiac spheroids into the
infarcted rat heart to investigate 1) whether these cardiac spheroids can survive and form
engraftment in the ischemic environment in rat MI model; 2) whether these cardiac
spheroids can reduce the fibrosis in MI site and form functional integration with host
myocardium to replace the damaged heart tissue; 3) whether these cardiac spheroids can
improve the heart function evaluated by echo measurement. If we could reach our
experiment goals, this will be the great advance in the cardiac regenerative medicine by
combined application of nanomaterials (electrically conductive silicon based nanowires),
stem cells (hiPSCs derived cardiomyocytes) and engineering methods (non-invasive 3D
scaffold-free spheroid delivery).
3.2 Potential application in brain tissue regeneration
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Persistent cell dysfunction and poor neural regenerative capabilities at the lesion
site after ischemic stroke lead to the formation of a cavity that is associated with
prolonged neurological impairment. Transplantation of stem cells represents a promising
strategy to reconstruct the lesion cavity and promote tissue regeneration after ischemic
stroke. Despite the advances in deriving hiPSCs into neurons and specific functional
subtypes, the progress in demonstrating cell engraftment, improving angiogenesis and
promoting the integration of the differentiated neurons with the host tissue is limited.
We have established nanowired hiPSC-derived cardiac spheroids as a lessinvassive injectable appoach to deliver cardiomyocytes with enhanced cell retention,
engraftment, and functional integration with rat host myocardium. Since stem cell
therapies for the treatment of MI and ischemic stroke have similar issues need to be
addressed, such as low cell survival, lack control of cell differentiation, and low cell
maturation and integration with host tissue, I propose to develop a nanowired
prevascularized neural spheroid (NPNS) system based on hiPSC-derived neural stem
cells and endothelial cells and to deliver this NPNS for brain tissue regeneration after
ischemic stroke. This project will establish a framework to support the survival,
maturation, and integration of transplanted cells to treat stroke-damaged brain tissue.
The overall objective of this project is to develop NPNS as a unique cell delivery
system to transplant hiPSC-derived neural/progenitor stem cells (NSCs) at the lesion site
following ischemic stroke for neural regeneration. We will examine whether the hiPSCderived neurons can display specific patterns of axonal projections and dendritic
outgrowth, and whether they integrate functionally with the host synaptic circuitry. We
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will optimize the ratio of e-SiNWs, hiPSC NSCs and hiPSC ECs in vitro. We will
examine the survival, organization, differentiation, maturation, and integration of
transplanted NPNS, and demonstrate advantages of NPNS in promoting structural repair
and functional recovery of stroke-injured brain.
We hypothesize that the NPNS system consisting three key elements to maximize
regeneration outcomes after transplantation in the animal model of middle cerebral artery
occlusion (MCAO). The first element in NPNS is e-SiNWs, which offer distinct
advantages as nanoscaffolding materials for conductive tissue engineering (heart and
brain), including their controllable electrical conductivity, tunable dimensions, and
convenient surface tailorability. The e-SiNWs in the NPVS is capable of receiving the
host electrical signal to stimulate the differentiated cells from the transplanted hiPSC
NSCs at the lesion site of MCAO and enhance the electrically integration of the
regenerated neurons with the host tissue. The second element in NPNS is 3D spheroid
mainly consist of hiPSC NSCs, which have capability to differentiate to neurons,
astrocytes and oligodendrocytes for in vivo regeneration. The spheroids act as a bridge
between traditional 2D cell culture and in vivo tissue because they mimic in vivo
microenvironment with enhanced cell-cell and cell-ECM interaction, which lead to
spheroid‟s resistance to anoikis-mediate cell death pathways after transplantation in vivo.
The last element in NPNS is hiPSC derived endothelial cells, which could form vascular
structures in vitro and in vivo to improve nutrients and oxygen supply to maintain the
survival of hiPSC NSCs in long term in vivo.
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